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ABSTRACT 
A number of conditions related to X-linked intellectual disabilities (XLID) are in 
part due to microduplications that are not visible cytogenetically. With the focus on Rho, 
Ras and Rab genes, a family of genes known to be associated with intellectual 
disabilities, were screened for dosage aberrations (Leeuwen, F. N. 1997), (Ng, E. L. 
2008), (Gissen, P. 2007), (Gurkan, C. 2005). Cohorts of intellectually disabled ID 
individuals were explored with new technologies.  These new technologies include 
comparative genomic hybridization (CGH), multiplex ligation dependent probe 
amplification (MLPA) and quantitative PCR (qPCR) (Madrigal, I. 2007), (Hermsen, M. 
A. 2005), (Morey, J. S. 2006).   
The first screening was of two groups of individuals, one group with hypotonia 
and varying degrees of ID and the other of individuals with nonsyndromic ID and a 
suspected X-linked etiology. These cohorts were screened using the Mental Retardation 
on the X chromosome (MRX) kit, which focuses on genes that cause intellectual 
disability and are located on the X chromosome. The second screening consisted of the 
two former groups and 5 additional cohorts totaling 1152 patients, using a synthetic probe 
kit that was designed to target primarily Ras, Rab and Rho X-linked genes that were not 
covered by the MRX kit. The 5 additional cohorts were individuals that had normal 
sequencing results for one of the following X-linked genes XNP, L1CAM, UBE3A, 
FGD1, and STK9.  
 The MRX screening produced a GDI1 duplication, deletion in FACL4 and an 
FMR2 missense mutation (c.474C>T).   The synthetic MLPA screening found a partial 
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XNP duplication (248kb), a 1p36 duplication/deletion complex rearrangement and a 
greater than 3Mb 1p36 deletion. It has been concluded from this study that duplications 
in these genes are rare, appearing in less than 1% in these chosen populations. 
Another section of this project is the characterization of a 275kb Xq25 duplication 
found during routine MLPA testing for MECP2. An Xq25 control peak on the MRC 
Holland MECP2 MLPA revealed a duplication in a female that presented with a MECP2 
phenotype (Chahrour, M. 2007).  This duplication spanned four genes (AIF, ELF4, 
BCORL1 and RAB33A) and of these four, two were over-expressed (AIF and RAB33A). 
Using qPCR to look for the link that may cause the similar phenotype to Rett syndrome 
in this patient, 26 Ras, Rab and Rho genes were tested in patients with Rett syndrome, 
Fragile X syndrome, ID with unknown etiology and the Xq25 patient. A similar pattern 
of expression was seen in this small cohort with ID. The CREB1 gene, the co-activator of 
MECP2, part of the transcription factor complex for 21 of the 26 genes screened, plays a 
role in all of these conditions and may be the linking factor in producing these patterns. 
The over expression of the AIF gene seemed to play a role in the mis-regulation of many 
genes, but with uncertainty on how it led to any affect on the phenotype.  
In this study duplications that play a role in the causation of ID were found using 
MLPA technology. As array CGH becomes more refined, with higher coverage and 
better software, the finding of microduplications that cause ID will increase.  
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CHAPTER ONE 
INTRODUCTION 
The focus of this study is to determine the frequency of X-linked duplications in 
specific cohorts of individuals with intellectual disability (ID). The groups to be studied 
will consist predominately of male and a small number of female patients that have 
been subsequently subdivided based on other clinical features and exhibit varying 
degrees of intellectual disability. One group will consist of males with intellectual 
disabilities that appear to be X-linked due to family history. The study will focus but 
not be restricted to the X chromosome.  A synthetic multiplex ligation-dependent probe 
amplification (MLPA) probe set will also be used to analyze several groups of patients 
that exhibit a classical phenotype for an X-linked clinical disorder, but are normal 
based on sequence-based testing. 
A genetic screen of multiple patient cohorts will determine the frequency of 
duplications that are disease causing and have been missed by other diagnostic 
methods. MLPA technology, a relatively new testing method for gene dosage will be 
used to determine if there are mechanisms other than missense and nonsense mutations 
causing these conditions. MLPA can target specific regions simultaneously for dosage 
aberrations (Schouten, J. P. 2002). MLPA has been used to reveal the genetic causation 
of specific cancers, syndromal and nonsyndromal disease, X-linked and otherwise. The 
primary screening method used in this study is two MLPA probe sets: 
• MRX MLPA Kit from MRC Holland (Commercially available) 
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• A custom synthetic MLPA kit developed as a part of this project to target X-
linked and autosomal genes of interest. 
The first screening was of two groups of individuals, one group with hypotonia and 
varying degrees of ID and the other of individuals with nonsyndromic ID and suspected 
X-linked etiology.   In the hypotonia and X-linked cohorts, which totaled 300 patients, 
the MRX MLPA found three patients that warranted further study. The genes that 
appeared to be affected were, GDI1 and PQBP1 duplication in one patient, a FACL4 
deletion in one patient and an unusual drop in signal in FMR2 in another.   
A second screening used the synthetic MLPA probe set included the two former 
groups and 5 additional cohorts totaling 1152 patients. The 5 additional cohorts were 
individuals that had normal sequencing results for one of the X-linked genes XNP, 
L1CAM, UBE3A, FGD1, and STK9. From these screening six individuals warranted 
further study. The regions or genes that appeared to be affected are, XNP duplication in 
one patient, L1CAM and NEMO duplication in one patient and four individuals with 
1p36 deletions and/or duplications.  
Further investigation by quantitative polymerase chain reaction (qPCR) of the three 
MRX individuals led to the confirmation of the GDI1 duplication, but not the PQBP1 
duplication. In later experimentation the PQBP1 probes proved to be unreliable and 
these MRX MLPA results were taken as a false positive. The FACL4 deletion was 
confirmed and this data was used to help in determining the region of the breakpoint by 
sequencing. 
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The FMR2 unusually low result was caused by a point mutation (c.474C>T) within 
the MLPA probe hybridization region. Further investigation found the mother and 
maternal grandmother to be carriers of this change. A group of normal controls were 
screened for this mutation and it appears not to be in the normal population.  
This screening with the synthetic MLPA probe set was performed one cohort at 
a time.  The screening of the hypotonia cohort identified a partial XNP duplication. The 
clinical phenotype of the proband was clearly consistent with ATRX but with sequence 
testing was found to be normal. The obligate carrier females had 100% skewed X 
inactivation, which is also consistent with the diagnosis of ATRX.  The duplication end 
point regions were determined using qPCR and this XNP duplication is 244kb and 
spans from exon 2 through exon 31. Northern blot analysis demonstrated that no full-
length transcript existed, suggesting the duplication disrupted normal transcription of 
the gene and the cause of disease was the loss of gene product. During qPCR primer 
development and using NCBI BLAST function to validate the specificity of the 
primers, there appears to be multiple Alu sequences in these regions, giving non-
homologous recombination as the probable cause of the duplication event. (Woodward, 
K. J. 2005), (Van Esch, H. 2005), (Bailey, J. A. 2003), (Vissers, L. E. 2003), (Lin, Y. 
1999), (Lundin, C. 2002).  
The L1CAM/NEMO duplication was found to span from NEMO to SLC6A8. 
This region includes the MECP2 gene and there were ongoing studies at the 
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Greenwood Genetic Center of MECP2 duplications in males. This sample was 
transferred to these studies for further evaluation.  
Four individuals had results consistent with 1p36 duplication and/or deletion. Of 
these four, two were regarded as false positives with further investigation. The two 
remaining individuals, one with a 1p36 duplication/deletion complex rearrangement 
(56560) and one with a 1p36 deletion (60175) confirmed multiple times on many 
different testing platforms. The phenotypes in both of these individual were similar to 
X-linked conditions and this explains why they were included in these cohorts.  
The second part of this study is of a female with an Xq25 duplication, born to 
normal parents, that has a similar phenotype routinely seen in females with Rett 
syndrome and MECP2 loss of function mutation  (Jordan, C. 2007), (LaSalle, J. M. 
2007), (Nikitina, T. 2007). The Xq25 duplication spans 255kb and encompasses four 
known genes and three unknown genes. Characterization of this novel duplication and 
exploration of some of the possible mechanisms causing this abnormal phenotype was 
accomplished. Duplications may increase or disrupt gene expression depending on the 
nature and span of the change (Mazzarella, R. 1998) Duplications that span over areas 
that include more than one gene may cause over- expression of those genes (Van Esch, 
H. 2005). By using real time PCR, expression levels of the genes that are duplicated 
were determined. The four known genes, BCORL1, ELF4, AIF and RAB33A were all 
tested and the results demonstrated that only two of the genes (AIF and RAB33A) 
displayed over-expression. The main question asked is what similarities are there 
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between a loss of MECP2 and over-expression of AIF and RAB33A and how is it 
possible they cause a similar phenotype.  
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CHAPTER TWO 
BACKGROUND 
Intellectual disability (ID) affects 2-3% of the population. ID is a developmental 
disability that exhibits global deficiency in cognitive abilities and is the impairment of 
learning, and processing of complex information (Levitt, P. 2004), (Johnston, M.V. 
2003). Intellectual disabilities are considered to be syndromic when associated with 
other congenital abnormalities, such as body and brain malformations that include 
neurological, neuroendocrine, psychiatric symptoms and metabolic defects. Intellectual 
disability can also stand-alone and not be associated with other functional or anatomical 
abnormalities, which is considered nonsyndromal ID (Ramakers, G. J. 2002).  Severe 
intellectual disabilities may be associated with brain malformations, such as, 
microcephaly, lissencephaly, and a deficiency in neuronal development and migration.  
There is an association of ID with abnormal dentritic spine morphology in the 
pyramidal neurons in the cerebral cortex and hippocampus of patients with Trisomy 21, 
Rett and fragile X syndromes, which appears, in part, to be due to abnormal 
development of neuronal connectivity (Ramakers, G. J. 200).  
Families of developmental genes regulating neuronal growth, which are 
associated with actin polymerization, affect the neuronal growth cone, a specialized 
structure at the distal end of a developing neurite.  Constant extension and retraction of 
filopodia and lamellipodia guide the extending neurite toward its target in a developing 
nervous system. The growth cone receives a variety of signals from molecules on the 
surface of other cells, the extracellular matrix and diffusible chemoattractants and 
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chemorepellants. These environmental cues direct the developing neurite to extend in 
the correct direction by the reorganization of the internal actin cytoskeleton (Kozma, R. 
1997). Using the mouse model, the most studied genes that are regulators of actin are 
RhoA, Rac1 and Cdc42. These genes play a large part in mammalian neuronal 
development and ID. Overall, Rho proteins are highly conserved regulators of the actin 
cytoskeleton, cell adhesion and migration, cytokinesis and gene expression. In human, 
three X-linked genes that participate directly in cellular signaling through Rho GTPases 
are oligophrenin 1 (OPHIN1), PAK3, and αPIX (ARHGEF6). Oligophrenin acts as a 
Rho-GAP (GTPase-activating protein) and stimulates the GTPase activity of RHOA, 
RAC1 and CDC42. PAK3 is a serine/threonine protein kinase that mediates effects of 
downstream RAC1 and CDC42 on the actin cytoskeleton and gene expression. αPIX 
are a guanine nucleotide exchange factor for RAC1 and CDC42. It is noted that Rho-
linked nonspecific X-linked intellectual disability (XLID) proteins interact with Rho 
GTPases at different locations in the regulatory pathway. Other Rho genes associated 
with nonsyndromic ID are FMR2, GDI1, IL1RAPL, TM4SF2 (Ramakers, G. J. 2002).  
Rho proteins play a part in the formation of dendrites, and abnormalities in 
these structures will impair information processing at the cellular and processing 
network level. Dendrite spine and function are closely linked with observed 
abnormalities in shape and abundance. Observed abnormalities are likely to impair 
synaptic transmission and plasticity. RHO and RAC1 maintain a strict balance as 
antagonistic regulators in the formation of neurite outgrowth. The activation of RHO 
reduces neurite formation, growth cone motility and dendrite branching. The activation 
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of RAC1 induces the density and length of spine necks and neurite formation. The 
dendrite spine morphology in the cerebral cortex of the normal human infant exhibits 
many short, thick spines, while the ID dendrite morphology exhibit long thin spines 
with a mushroom cap. These long, capped spines disappear as the child matures and the 
denrite has a smooth appearance (Ramakers, G. J. 2002), (Leeuwen, F. N. 1997). 
Another pathway known to be associated with ID is the mitogen activated 
protein kinase (MAPK) signaling cascade. The downstream activation of the MAPK 
cascade stimulates phosphorylation of the transcription factor CREB and may also 
stimulate CREB-Binding protein (CBP), which has histone acetyltransferase activity 
that can lead to weakening of the DNA/histone interaction. This results in an open 
chromatin structure that promotes transcription. CREB and MECP2 are known to be co-
activators and combined they activate a large number of genes that appear to be 
involved with ID (Chahrour, M. 2008). The Ribosomal S6 Kinase-2 (RSK2) gene is 
associated with Coffin-Lowry syndrome in humans and is a protein kinase that 
activates CREB through phosphorylation.  RSK2 is activated by phosphorylation by 
several membrane receptor-coupled signaling cascades, adenylate cyclase, Ras-MAPK, 
Protein Kinase C (PKC) and Ca2+/Calmodulin-dependent protein Kinase II (CaMKii) 
pathways.  MAPKs cause cognitive disorders with defects in the signaling pathways 
that facilitate Rab function including Ras effectors that serve as guanine nucleotide 
exchange factors (GEF’s) and activators of Ras family proteins, in the following 
diseases; Coffin-Lowry syndrome, Rubinstein-Taybi syndrome, Neurofibromatosis 1, 
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Tuberous sclerosis 2, X-linked α thalassemia, and Faciogenital dysplasia  (Johnston, 
M.V. 2003),  (Mitin, N. 2005).  
This research takes a closer look into the dosage of genes involved in regulating 
actin cytoskeleton, a representative number of the Rab, Ras and Rho genes and their 
counterparts that traffic proteins in a tightly linked fashion, and a known group of genes 
that are implicated in causing intellectual disability.  There are Rab, Ras and Rho genes 
expressed primarily in the brain and may be candidate genes associated with ID.  
We are primarily focusing on Rab genes. It is important to focus on these genes 
because, Rab proteins comprise the largest group within the Ras superfamily. There are 
over 60 Rab proteins identified in humans. Individual Rab subtypes characteristically 
associate with specific membrane compartments (Gurkan, C. 2005). Ras proteins on the 
other hand function as signaling hubs that are activated by convergent signaling 
pathways. Activated Ras regulates a diversity of downstream cytoplasmic signaling 
cascades. Recent observations have established a complex signaling interplay between 
Ras and other members of the family (Mitin, N. 2005). 
Understanding the regulation and organization of the exocytic and endocytic 
membrane trafficking pathways is a large undertaking. There are housekeeping Rabs, 
specialized Rabs and tissue-specific Rabs. In this study we have an Xq25 duplication 
that has been shown to cause over-expression of the RAB33A gene.  Twenty-six 
specific genes that interact with RAB33A will have their background discussed within 
the Xq25 section. The RAB33A protein is thought to facilitate endosome to Golgi 
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transport. Interestingly, expression profiles show the RAB33A gene has prominent 
expression in the brain and co-regulates other Rab genes (Zheng, J.Y. 1998), 
(Stenmark, H. 2001). Rabs have close interactions, play a role in each other’s inhibition 
and activation, and are found to cluster. One such Cluster contains RAB3A, RAB26, 
RAB33A and RAB40B, which sometimes are joined by RAB4B and RAB11B. This 
cluster is up-regulated in the brain tissue and co-cluster with the RAB3A-regulated hub. 
RAB3A is one of the most notable and best characterized of the specialized Rabs, which 
is active in the regulated secretory pathway in the neuron. RAB3A has been extensively 
studied in the neurotransmitter release given its high abundance in the brain and 
presence in synaptic vesicles. RAB3A is believed to play an important role in tethering 
and docking of synaptic vesicles in preparation for fusion. Rabs can also be regulators. 
Up-regulation of RAB40B is confined to brain tissue with an expression profile almost 
identical to RAB3A. It is possible that RAB40B may be found to be a Rab-regulated hub 
modulating a linked step in the RAB3A-dependent synaptic vesicle cycle in the brain. 
RAB33A in brain tissue may direct an unanticipated strong link between 
RAB3A/RAB40B/RAB26 function and endosome-Golgi recycling pathways (Gurkan, C. 
2005). RAB3A co-clusters with the RAB3A-interacting proteins calmodulin, GDI1, 
RIM2, RIM3, Rabphiolin-3A and synapsin. Rabs can also be effectors and can interact 
with multiple other effectors to regulate the spatiotemporal function of organelles in 
membrane traffic. These Rabs direct vesicle tethering, docking, and fusion and can 
direct dynein motors that move along the cytoskeleton. The main point to be taken, Rab 
gene family members do not function alone, cluster members appear to co-regulate one 
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another and there are still many undiscovered Rab pathways responsible for 
development and coordination of brain activity (Gurkan, C. 2005), (Grosshans, B. L. 
2006), (Sexton, T. 2007). 
The exploration of gene dosage will consist of Rab, Ras and Rho genes and 
their counterparts and how this dosage affects expression levels of other Rab and Ras 
proteins in a tightly linked fashion (Mitin, N. 2005).  First a group of known genes that 
are implicated in the cause of intellectual disability will be tested using MLPA. 
Secondly a group of genes not yet proven to be linked with ID will have expression 
levels charted using qPCR in the Xq25 duplication patient with over-expression of 
RAB33A and a small cohort of normal and affected individuals.  
Duplications in other X-linked and autosomal genes are known to cause disease. 
Some clinically significant duplications are mentioned in the following:  
X-Linked 
• Mutations in MECP2 (methyl-CpG binding protein 2) gene causes Rett 
syndrome, a severe neurological disorder usually thought to affect exclusively 
females. Its prevalence is about 1 in 10,000 female births, and it is a prominent 
cause of profound ID in females. These mutations were initially thought to be 
lethal in males.  However MECP2 mutations are now frequently identified in 
mentally retarded male patients (Villard, L. 2007). Duplication of MECP2 
causes over-expression in males. These males have severe mental retardation, 
hypotonia, recurrent respiratory infections, and absence of speech development, 
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seizures, and spasticity (Friez, M. J. 2006). In humans, not only impaired or 
abolished gene function, but also increased MECP2 dosage causes a distinct 
phenotype (Van Esch, H. 2005). 
• The X-linked PLP1 gene has been found to cause Pelizaeus-Merzbacher disease 
(PMD). This gene is located at Xq22 and duplications have been found in 70% 
of clinically diagnosed patients. Some of the patients exhibit more than three 
copies, but copy number does not seem to play a role in the severity of the 
disease (Wolf, N. I. 2005). PMD is a rare X-linked disorder affecting 
myelination of the central nervous system. The PLP1 gene is dosage sensitive 
and duplications and missense mutations both contribute to defective proteolipid 
protein (PLP) dosage (Takanashi, J. 1999), (Woodward, K. J. 2005), (Wolf, N. 
I. 2005), (Mazzarella, R. 1998). 
Autosomal 
• 3-6 MB microduplications at chromosome 22q11.2 are caused by 
misalignments of low copy repeats. Deletions in this area have been known to 
cause DiGeorge/velocardiofacial syndrome (Levitt, P. 2004). DiGeorge 
syndrome is characterized by neonatal hypocalcemia, which may present as 
tetany or seizures, due to hypoplasia of the parathyroid glands, and 
susceptibility to infection due to a deficit of T cells. A variety of cardiac 
malformations are seen in particular affecting the outflow tract  (Jawad, A. F. 
2001), (Edelmann, L. 1999), (Moerman, P. 1980). Duplication in the same 3MB 
region was described a 4-year-old girl. She presented with failure to thrive, 
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marked hypotonia, sleep apnea, and seizure-like episodes in infancy, later 
showed delay of gross motor development with poor fine motor skills, 
velopharyngeal insufficiency, and a significant delay in language skills. Her 
facial features were mildly dysmorphic, with a narrow face and down-slanting 
palpebral fissures. Hearing and vision were normal, and there were no 
detectable cardiac abnormalities. FISH analysis identified a partial interstitial 
duplication of chromosome 22q11. Duplication produces Cat Eye Syndrome in 
the same 3-Mb region that is deleted in DiGeorge syndrome (Edelmann, L. 
1999). 
• Charcot-Marie-Tooth disease type 1A (CMT1A) gene is located at 17p11.2-p12. 
CMT1A disease is a hereditary neuropathy associated with duplications of the 
1.5-Mb region on 17p11.2-p12. Deletions in this region cause Hereditary 
Neuropathy with liability to pressure palsies (HNPP). These two rearrangements 
are the reciprocal products of an unequal meiotic crossover between the two 
chromosome 17 homologues, caused by the misalignment of the CMT1A repeat 
sequences (CMT1A-REPs), the homologous sequences flanking the 1.5-Mb 
CMT1A/HNPP monomer unit (Matise, T. C. 1994),  (Schiavon, F. 1994), 
(Lopes, J. 1996).  
• Duplication in 16p13.11p13.3 causes a phenotype resembling that of X-linked α 
thalassemia/mental retardation syndrome.  The same clinical features including 
severe ID, characteristic facies and behavior are exhibited. It is proposed that 
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the HBA gene in this region may be a target of XNP (ATRX) gene regulation 
(Akahoshi, K. 2005). 
•  Duplication and triplication of APBA2 gene, located at 15q11-q13, is caused by 
high homology that facilitates mispairing and unequal recombination events in 
meiosis.  Interstitial deletion of 15q11-q13 results in Prader Willi syndrome 
when the deletion is paternally derived or Angelman syndrome when the 
deletion is maternally derived. The interstitial duplication of the same region 
has been found in cases of autism, and the data suggests a higher risk with 
maternal compared to paternal duplications. Larger duplications are typically 
associated with a more severe autistic phenotype as multiple genes may be 
duplicated. APBA2 has also been called Mint2 for Munc-interacting protein 2, 
which functions as a neuronal adapter protein and essential for synaptic vesicle 
exocytosis (Sutcliffe, J. S. 2003). 
A study where 5,380 patients were screened for dosage aberrations, with the most 
common reasons for referral were; developmental delay (DD), and/or ID, 
dysmorphic features (DF), multiple congenital anomalies (MCA), seizure disorders 
(SD), and autistic, or other behavioral abnormalities. There were pathogenic 
rearrangements found at subtelomeric regions in 236 patients (4.4%). Among these 
patients, 103 had a deletion, 58 had a duplication, 44 had an unbalanced 
translocation, and 31 had a complex rearrangement (Shao, L. 2008). With array 
technology both oligonucleotide-based and bacterial artificial chromosome (BAC)-
based arrays, the finding of micro duplications and deletions is routine. One study 
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identified 10 unique deletions and duplications ranging in size from 280 kb to 8.3 
Mb. Analysis of parental DNA samples indicated that most of the imbalances had 
occurred de novo. Moreover, seven of the 10 imbalances represented novel 
disorders, adding to an increasing number of conditions caused by large-scale 
deletions or duplications (Aradhya, S. 2007).  
 To discuss all the newly found duplications in the literature is beyond the scope 
of this study. The duplications, deletions and mutations in this study will have the 
appropriate background included in the relevant result sections. 
 
 
 
 15
CHAPTER THREE 
COLLABORATION 
Experimentation regarding expression and functional studies were done under 
the guidance of Karl J. Franek, Ph.D. staff scientist at the Center for Molecular Studies 
in the J.C. Self Research Institute at the Greenwood Genetic Center. The proper 
equipment is available to perform the needed procedures. 
  The first gene we explored was XNP. Using antibodies that target the N-
terminus of the protein, were found available from Santa Cruz Biotechnology. Dr. 
Franek has recommended that preliminary work consist of sequencing the cDNA from 
the family with the identified XNP duplication. Due to the duplication being only 
partial, a truncated transcript as well as a full transcript may be present. It needs to be 
determined if there is more than one form of the transcript as this may give insight to 
the cause of disease.    
Collaboration with the lab of Dr. Barbara DuPont, Director of the cytogenetic 
lab at the Greenwood Genetic Center concerning Fluorescent In Situ Hybridization 
(FISH) studies will be under the direction of her staff.  Array-CGH data will also be 
confirmed using FISH as necessary.  
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CHAPTER FOUR 
RESEARCH DESIGN AND METHODS 
Importance of Study 
Duplications have been under diagnosed in the past due to limitations in 
diagnostic methods. It is believed that a number of conditions related to X-linked 
Intellectual Disabilities (XLID) are, in part, due to microduplications that are not 
visible cytogenetically. With new technologies, such as: Multiplex Ligation-dependent 
Probe Amplification (MLPA), comparative genomic hybridization (CGH) and 
quantitative polymerase chain reaction (qPCR) duplications of varying sizes are now 
more readily identified.  
 Duplications may or may not exhibit the same phenotype that might be 
expected when the affected gene is distorted with mutations and other pathogenic 
rearrangements. The MECP2 gene located at Xq28 is associated with Rett syndrome in 
females, which is characterized in females by a period of normal development for the 
first 6 to 18 months followed by progressive deterioration and degenerative mental 
retardation. Duplications have now been found in males with syndromic mental 
retardation. Previously, Rett syndrome was thought to be an X-dominant condition that 
is typically lethal in hemizygous males (Van Esch, H. 2005), (Moog, U. 2005). Males 
with duplications are quite different than the female Rett counterparts. They present 
clinically with psychomotor and developmental delay very early in life. As patients 
mature other common symptoms include: spasticity, predominantly of the lower limbs, 
seizures as well as axial and facial hypotonia. Additionally, males often suffer from 
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recurrent respiratory infections, which in many cases are severe enough to cause early 
death.  MECP2 duplications in males present a different phenotype than the typical 
phenotype seen in females with missense and nonsense mutations and small deletions 
that are associated with Rett syndrome (Van Esch, H. 2005). In the PLP gene, which 
causes Pelizaeus-Merzbacher’s disease (PMD), duplications appear to be associated 
with a specific sub phenotype called connatal PMD. This is due to over-expression of 
the PLP gene, whereas, missense mutations are associated with classic PMD. Connatal 
PMD causes progressive myelination while classical PMD is the lack of myelination in 
the cerebral corticospinal tract (Takanashi, J. 1999). Unlike the PLP gene, XNP 
duplication does not appear to have two different clinical presentations.  To date there 
is only one report consisting of two cases, and both were found to have partial 
duplication of XNP.  These partial duplications, unlike full duplications that cause two-
fold higher expression, disrupt gene transcription, causing a loss of gene product, 
therefore, causing a classical ATRX phenotype (Thienpont, B. 2007). Depending on the 
role duplication plays in the expression of a specific gene determines the nature of the 
potential clinical manifestations. Therefore, this leads us to believe that we may find 
duplications in other XLID genes. The phenotypes may be similar or vary from what is 
seen with missense or nonsense mutations in that gene.  
Probands that have presumed XLID and have normal sequencing results for 
genes associated with specific clinical features of a known XLID entity are of particular 
interest in this study. These affected individuals are good candidates for an X-linked 
duplication that is small and not visible by routine cytogenetic analysis that may disrupt 
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gene transcription. Probands with suspected X-linked etiology and non-specific clinical 
findings might have larger duplications encompassing one or more genes. Contiguous 
gene duplications may lead to phenotypes involving ID due to an over-expression of 
one or more gene product. 
Duplications have been the mechanism for large genomic changes through time. 
Beginning with chromosomal evolution, it is thought to have occurred in a random 
process of breakage and rearrangement. However, there appears to be an abundance of 
primate specific segmental duplications at the breakpoints of syntenic blocks in the 
human genome. Breakpoint regions are defined as the gaps between syntenic blocks. 
Conservatively, 25% of all breakpoints contain 10 KB of duplicated sequence. This 
association is highly significant (p< .0001), and supports the non-random model of 
chromosomal evolution. These results indicate that segmental duplications are 
associated with syntenic rearrangements. Segmental duplications are comprised of 
genes or gene segments as well as common transposable elements. This implies specific 
regions having been predisposed to both recurrent small-scale duplications and large-
scale evolutionary rearrangements within specific “fragile” regions of the mammalian 
genome (Bailey, J. A. 2004).  
The mechanisms that may play a role in the formation of duplications are; repair of 
DNA damage (Bailey, J. A. 2003), (Read, L. R. 2004), homologous recombination 
(Lin, Y. 1999), (Lundin, C. 2002), non-homologous recombination (Lundin, C. 2002), 
transposition, Alu and Line mediated recombination (Bailey, J. A. 2003), low copy 
repeats causing slippage, DNA cleavage, gross chromosomal rearrangement, repair and 
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Topoisomerase 1 sites (Dai, Y. 2003). One study of 9,464 junctions within regions of 
high quality finished sequence from a genome-wide set of 2,366 duplication alignments 
observed 1Mb of Alu intervening sequence between segmental duplications.  Alu 
retroposition activity initiated Alu-Alu mediated recombination events which caused 
the expansion of gene rich segmental duplications 35-40 million years ago now have a 
role in nonallelic homologous recombination. Alu is a primate-specific 300bp 
retroposon and is the most abundant human repeat. Alu mediated rearrangement events 
have long been recognized as a common source of local deletion and duplication events 
associated with human disease (Bailey, J. A. 2003). Understanding the role of 
segmental duplication in normal variation has just begun. Using a bacterial artificial 
chromosome (BAC) microarray, consisting of 2,194 BACs assessing copy number 
variation (CNV), identified genes or other relatively rare sequences that are duplicated, 
either in tandem or at nearby locations.  There were 199 regions of copy number 
polymorphisms (CNP) identified in screening 47 normal individuals. Some clone 
duplication signals overlapped, suggesting some copy number variations extend over 
several hundred kilobases (Mazzarella, R. 1998). Some of the CNPs were in gene 
clusters, such as the previously reported β-defensin at 8p21.1 (Hollox, E. J. 2003) and 
the IGVH/SLC6A8/CDM pseudogene cluster at 15p11.2  (Barber, J. C. 1998), (Sharp, 
A. J. 2005), (Bailey, J. A. 2004). CNPs were identified in 51 of the 130 rearrangement 
hotspots that encompassed 108 genes and partially overlapped another 33 coding 
regions. Of the 130 rearrangement hotspots there were no CNPs detected in 79 of them 
in the normal population. This suggests these remaining hotspots may be associated 
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with genomic disorders  (Sharp, A. J. 2005). There are known regions on the X 
chromosome that have duplications that are clinically significant.  Some of these are, 
Xp22.3 causing ichthyosis (Weaving, L. S. 2004) the dosage sensitive sex reversal 
candidate region in Xp21.3 (Portnoi, M. F. 2000), the Pelizaeus-Merzbacher region in 
Xq22 (Wolf, N. I. 2005), (Takanashi, J. 1999), MECP2 in males at Xq28 (Friez, M. J. 
2006), (Bauters, M. 2008), regions in the Xq24-q26 region in females causing 
developmental delay and ID (Armstrong, L. 2003), the lymphoproliferative syndrome 
in Xq23 (Garcia-Heras, J. 1997) and XNP at Xq13 (Thienpont, B. 2007).   
Duplications have been a known evolutionary occurrence and source of normal 
variation documented in the human genome. We now have a better appreciation that 
duplications of various size cause disease by several mechanisms.  By screening a 
targeted set of cohorts we intend to determine the degree of ID that may be caused by 
duplications in select X-linked genes. These genes are known to cause ID by other 
mutational events, but have not had dosage aberrations identified as a recurrent cause of 
disease. First, we intend to address if they exist, and if so, to work towards explaining 
how they function in context to the diagnosis in those affected by the duplications. 
Purpose of Study 
The focus of this study is to determine the frequency of duplications, in 
different X-linked genes involved with its ID-related conditions, which in some way 
affect the normal function of a given gene and associated pathways. How duplications 
disrupt normal gene function may be different in each case. Fluorescent in situ 
hybridization (FISH) results are pending. This methodology can help in the 
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determination of the duplicated gene location and orientation, such as, if the gene is 
duplicated in tandem or on another chromosome, partially duplicated or part of a gross 
chromosomal rearrangement. Genes known to be involved with XLID will be targeted 
using MLPA, a new technology that is highly specific and capable of determining copy 
number. This research examines gene dosage aberrations and then will determine if the 
duplication is the cause of disease.  To feel confident that the duplication is disease 
causing the following must be addressed. 
1 Clarify the expression level of the duplicated genes.  
2 Determine if full length mRNA is fully transcribed. 
3.       Determine if the mRNA is functional and translated.  
4     Does the overexpression of one gene affect the expression of other genes?   
Explanation of Research Design 
The MRC Holland MLPA kit includes probes for 13 XLID genes. They include: 
RSP6KA, ARX, IL1RAPL1, TM4SF2, PQBP1, OPHIN, FACL4, DCX, PAK3, AGTR2, 
FMR2, SLC6A8 and GDI1. The commercial kit provides a starting point, but to look at 
other genes of interest (Rho, Rab, Ras and MAPK genes) not included in this 
commercial kit, led to the development of a custom synthetic MLPA probe set. The 
synthetic probe set targeted X-linked genes (XNP, STK9, FGD1, NEMO, and L1CAM) 
with SKI and UBE3A serving as autosomal controls and SRY as a sex marker gene. By 
combining the data from both MLPA probe sets; multiple XLID genes are 
simultaneously tested for duplications and deletions. This study will determine the 
frequency of duplications in these genes in the XLID population. 
 22
  
 
 
 
 
 
 
 
   
 
 
 
 
Two cohorts were studied using the MRC Holland MRX MLPA kit and they 
consisted of 95 males exhibiting hypotonia and varying degrees of intellectual disability 
(ID) and a second cohort of 205 (194 males and 11 females) individuals with 
nonsyndromic ID and suspected X-linked etiology.   The hypotonia and X-linked 
cohorts totaling 300 patients, plus five additional cohorts totaling 552 patients with 
normal sequencing results for one of the X-linked genes (XNP, L1CAM, UBE3A, FGD1 
and STK9) were included in the synthetic MLPA study (Table 1).  
RSP6KA
ARX, STK9, IL1RAPL1
TM4SF2 
PQBP1 
OPHN 
FGD1 
XNP 
FACL4 
DCX, PAK3
AGTR2 
FMR2, GDI1, LICAM, NEMO 
SLC6A8 
Figure 1. X chromosome gene 
coverage. 
 
Genes in blue are offered on the 
MRC Holland MRX MLPA. 
 
Genes in cated on the 
s
red are lo
ynthetic MLPA probe set. 
Autosomal Controls 
Sex Marker
• SKI located at 1p36 
• UBE3A located at 15q11-q13 
 
 
• SRY located on Y chromosome
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Table 1. Number of patients screened by test and cohort. 
 
COHORT             MRX             SYNTHETIC 
Hypotonia    95   95 
Suspected X-linked   205   205 
XNP-sequence normal     29 
L1CAM-sequence normal     177 
UBE3A-sequence normal     130 
FGD1-sequence normal     182 
STK9-sequence normal     34 
 
Duplications in other XLID genes may cause syndromic ID with different 
phenotypes other than what is considered the classic phenotype for abnormalities in that 
gene. It now appears clearly evident that duplications and increased dosage of the 
MECP2 gene product cause a distinct phenotype from Rett syndrome, which is 
typically caused by point mutations and small deletions in MECP2.  Loss of function 
versus over-expression in any neurologically significant gene may cause profound ID 
with phenotypes truly unique from one another (Van Esch, H. 2005). Xq28 duplications 
involving MECP2 usually include at least several of the flanking genes and typically 
range in size from 400 Kb to 800 Kb. Carrier females with MECP2 duplications are 
nearly always asymptomatic and have highly skewed X inactivation. The two fold 
increased dosage of MECP2 mRNA has been demonstrated using qPCR and is believed 
to be the key genetic cause for the features seen in these males. L1CAM, SLC6A8 and 
GDI1 are also commonly found duplicated along with MECP2, and are known to be 
involved with ID and may contribute to some extent to the phenotype (Van Esch, H. 
2005), (Wong, E. V. 1995).   
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MLPA 
The detection of duplications using MLPA opened a new means of screening 
patients for dosage dependent mutations. To date, 232 different MLPA tests are 
commercially available. MLPAs were first designed for the detection of deletions and 
duplications in BRCA1, MSH2 and MLH1 genes. This was followed by applications 
designed for the detection of trisomies and chromosomal aberrations in cell lines and 
tumor samples as well as SNP/mutation detection (Schouten, J. P. 2002). An MLPA 
(Figure 2A-C) consists of a group of probes each made a different length. Each probe 
consists of two oligonucleotides, one left and one right with a ligation site designed to 
join the two sub-probes. The probe hybridizes with genomic DNA and when each 
probe half is in place ligation can occur.  
 
 
 A 
 
B 
 
C 
     
 
 
 
Figure 2A. Hybridization of probe to DNA.  
Figure 2B. Ligation of MLPA probes.  
Figure 2C. Amplification of probe by universal primer pair. The 
amplification product of each probe has a unique length (92- 480 bp). 
(MRC Holland 2002) 
Figure 2. MLPA Probe Design  
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Figure 3. 
 
 
3A 
 
All the probes have identical M13 end sequences allowing concerted 
amplification with one primer pair.  Each probe is designed to produce an amplicon 4-
6bp different than its neighbor, and is a part of a range of probes spanning from 90-480 
bp. The ligated probe is the template for PCR amplification; therefore, the amount of 
initial intact probe dictates the amount of end PCR product. The 3’ M13 primer is FAM 
labeled and fragment analysis is accomplished using capillary electrophoresis. The 
quantity of PCR product influences the peak height and area when electrophoresed and 
analyzed on a fragment analysis program. Comparing the peak height and area of each 
sample in an Excel spreadsheet is done by first normalizing all the samples, patients 
Figure 3A. Normal BRCA1 MLPA. Each peak is the amplification product of 
a specific probe. 
Figure 3B. Difference in relative peak area indicates a copy number 
change in the target sequence. Sample peak areas are normalized and 
compared to the average of normalized control samples peak areas. In the 
electropherogram 3B, exon 13 of BRCA1  has a lower height than the normal 
sample 3A above, indicating a drop in gene dosage. 
3B 
MLPA of the BRCA1 gene. 
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and controls.  The samples are compared by dividing the patient sample by the average 
of the normalized control samples, giving a numerical value of 1.0 as normal, 0.5 as 
deleted and 1.5 and above for duplications (Schouten, J. P. 2002). One of the greatest 
advantages that MLPA affords is that it can distinguish dosage exon by exon, which 
allows highly specific analysis.  
It has been noted using a combination of FISH, CGH and MLPA that 
Subtelomere aberrations (duplications and deletions) account for approximately 5-7% 
of genetic disease in the ID population (Varga, T. 2005), (Ahn, J. W. 2007). With that 
in mind, a population of patients that have been mapped to the X-chromosome, and are 
not genetically diagnosed, were screened using MLPA. We found duplications in a 
fraction of patients that have been found to be normal by DNA sequence analysis for a 
specific gene given the suspected clinical diagnosis. Sequencing will not find large-
scale duplications and we have a number of patients that exhibit the clinical criteria to a 
mutation in a specified gene and have a normal sequencing result for the expected gene. 
One of the first ID MLPA kits offered by MRC Holland was for MECP2 and this test 
has increased the rate of diagnosis by finding the duplications and deletions not 
detected by sequencing. The following genes are not included in commercially 
available MLPA kits and have been deemed important candidates for determining 
dosage in this study; 
• XNP (Xq13.3) causing alpha thalassemia mental retardation syndrome 
(ATRX). The protein is 2492 amino acids (aa) with 3 zinc finger domains. A 
nuclear localization signal is located at 1025-1050 aa, and a coil-coil motif is at 
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1326-1347 aa, with a central domain that is an ATPase helicase. It also has a 
catalytic domain and a DNA binding region. This protein is involved with 
regulation of gene expression, chromatin structure, and is found to bind to the 
short arms of acrocentric chromosomes (Villard, L. 1997). 
• STK9 (Xp22) serine/threonine kinase 9 also known as CDKL5 (cyclin-
dependent kinase like 5) is involved with an atypical presentation of Rett 
syndrome.  The protein is 1022 aa and has an activation motif of classic MAP 
kinases. This protein has ATP binding activities and is involved in post-
translational phosphorylation (Tao, J. 2004), (Montini, E. 1998). 
• FGD1 (Xp11.21) mutations cause facial genital dysplasia, also known as 
Aarskog syndrome. This protein is a guanine nucleotide exchange factor and 
activates Rho GTPase 42.  It is a regulatory and signaling protein and is 
involved in embryonic development and the regulation of the osteoblast actin 
cytoskeleton (Pasteris, N. G. 1994).  
• NEMO (Xq28)(IKBKG) inhibitor of kappa light polypeptide gene enhancer 
in B-cells. This protein has 4 alpha helix a leucine zipper and in its c terminal 
zinc finger motif. It is involved with B-cell survival and T cell development  
(May, M. J. 2002).  
• L1CAM  (Xq28) L1 cell adhesion molecule is 1256 aa in length and has 6 
repeating immunoglobin domains, 5 repeating fibronetin type III domains on 
the extracellular surface. L1CAM protein function is involved with cell-to-cell 
adhesion and without the functioning protein hydrocephaly is the prominent 
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clinical finding. It is a glycoprotein with two isoforms, one neuronal and one 
leukocyte (Faranda, S. 1996).  
Two autosomal genes, SKI and UBE3A were added to the synthetic probe set to 
serve as autosomal controls. The UBE3A gene was chosen, as it is known to be 
associated with ID. SKI is an autosomal gene more involved with cancer, but resides in 
a region known to be unstable in chromosome 1. SRY was chosen to be the sex marker. 
Working with duplications on the X, the sample must have proper gender assigned. 
• SKI (1p36) is a transforming growth factor-beta, which inhibits growth, is 
involved in differentiation and the induction of apoptosis. It is 728 aa in length, 
with DNA binding and repressor activities (Shapira, S. K. 1997). 
• UBE3A (15q12) is involved with short lived or abnormal proteins and neural 
development. Two diseases come from this region. Instead of duplications, this 
region is coordinately regulated by an imprinting center and it makes a 
difference with which gene, paternal or maternal is being expressed. Lack of 
functional paternal copy of 15q11-q13 causes Prader Willi syndrome while 
lack of a functional maternal copy of UBE3A, a gene within this region, causes 
Angelman syndrome (Horsthemke, B. 2008). 
• SRY (Yp11.3) Sex marker and control. 
Probe sequences for the synthetic MLPA may be found in Appendix A 
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Overview of Methodological Decisions 
MLPA 
MLPA is a methodology designed to measure the dosage of selected genomic 
sequences. MLPA may target one gene (all exons) or multiple gene panels.  The data is 
normalized and the patient sample compared to at least four normalized control 
samples. Autosomal deletions are expected to generate values approaching 0.5 while 
duplications should be roughly 1.5 relative to control ratios. With X-linked data, 
deletions in males are expected to be 0 and duplications at 2.0 whereas, in females, 
deletions are 0.5 and duplications are at 1.5. The MLPA method is not capable of 
detecting balanced translocations. The MLPA shows a decreased value if there is a base 
change in the DNA that is near the probe ligation site. This phenomenon will happen if 
there is a SNP within the DNA sequence where probe hybridization occurs, producing 
false positive results consistent with a deletion. 
DNA Isolation 
DNA isolation was performed using Autopure and Flexigene DNA kits 
(Qiagen: Hilden, Germany) following manufacturer’s recommendations. DNA samples 
were diluted to 100ng/ul. RNA was isolated following manufacturer’s 
recommendations using the PAXgene Blood RNA Kit (Qiagen: Hilden, Germany) 
Selected family members were tested diagnostically by using Superscript One Step RT 
PCR with Platinum Taq   
(Invitrogen: Carisbad, CA) combined with Big Dye chemistry and an ABI 3730 
sequencer (Applied Biosystems, Foster City, California USA). 
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Northern Blot 
Northern Blot of 0.7% agarose gel was electrophoresed overnight with RNA 
from 4 controls, proband “A”, and “B” and his obligate carrier mother. This was 
transferred to a nylon membrane using a Turbo Blotter system (Whatman, GE 
Healthcare, USA). An XNP probe (Appendix B) was hybridized overnight and two 
room temperature washes with 2X SSC and four washes .05X SSC at 72°C was 
performed. The RAB33A probe (Appendix B) was hybridized overnight and two room 
temperature washes with 2X SSC and two washes at .05X SSC at 42°C and two washes 
at 60°C was performed.  The AIF probe (Appendix B) was hybridized overnight and 
two room temperature washes with 2X SSC and two washes at .05X SSC at 55°C and 
two washes at 65°C was performed.  Autoradiography was performed with various 
exposures.  
FMR2 Sequencing 
FMR2 primers were developed to alter the sequence to produce a restriction site for 
Xba1 if the sample had the c.474 C>T change restriction took place making a double 
band.  
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FMR2 polymorphism screen 
Primer sequence in red: Xba1 restriction recognition sequence (5’-TCTAGA)  
G GAT AAT ACC CAT CCT TCA GCA CCA ATG CCT CCA CCT TCT GTT GTG 
ATA CTG AAT TCA ACT CTA ATA CAC AGC AAC AGA AAA TCA AAA CCT 
GAG TGG TCA CGT GAT AGT CAT AAC CCT AGC ACT GTA CTG GCA AGC 
CA    
              c.474 C>T                    
 
Array CGH 
Array CGH was performed on two independent platforms. First, an X-specific 
array from Nimblegen was utilized to validate the original MLPA and real-time data. 
Secondly, a separate X-specific array (Oxford Gene Technologies) with multiple data 
points in the region involving XNP was used to help clarify the breakpoints for a 
selected family. Genomic DNA was isolated as previously described and subsequently 
purified using the Zymo DNA Clean & Concentrator™ kit (ZymoResearch, Orange, 
California). Reference DNA used in the comparative hybridization was obtained 
commercially (Promega Madison, Wisconsin). DNA concentration and its purity were 
determined using the 260/280 ratio with a ND-1000 Spectrophotometer (NanoDrop 
Technologies, Wilmington, Delaware). Samples were purified with YM-30 Microcon 
filters from Millipore (Bedford, Massachusetts). Hybridization and washes followed 
Oxford Gene Technology’s (OGT) CytoSure™ Chromosome X exon specific array 
protocol (Oxford, UK). Arrays were scanned with the GenePix 4000B scanner from 
Changed nucleotide (C>A) 
in primer to create a 
restriction site for XbaI 
when the c.474C>T change 
is present. 
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Molecular Devices (Sunnyvale, California). Array feature extraction was performed 
with GenePix Pro 6.1.  Copy number analysis was performed with OGT’s CytoSure™ 
Viewer software package. Agilent Analysis:  ImaGene 8.0 (Modified Circular Binary 
Segmentation (CBS) algorithm). 
RNA Isolation 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Hilden, Germany) 
via a PAX tube. Samples were reverse transcribed using Superscript III (Invitrogen 
Carlsbad, California) using random primers. Each sample was Nanodrop quantified and 
diluted to 30ng/ul for cDNA. Expression qPCR was performed for BCORL1, ELF4, 
PDCD8, Rab33A genes using RNA specific primers, spanning exon boundaries and 
compared to the housekeeping gene PGK1. The patient mRNA level was quantified by 
the relative comparison of the mRNA level of PGK1, commonly known as the ∆∆ CT 
method. 
Quantitative PCR 
Real Time PCR: Delta-delta CT (∆∆Ct) method was performed for all qPCR 
assays. Primers used (Appendix C) for all quantitative experiments, were designed for 
the gene of interest, primer efficiencies were calculated using a serial dilution across 5 
different molarities and graphed.  This serial dilution of DNA or cDNA ranging from 
stock to 1/32 determined the best primer efficiency. The primer concentration with a 
slope less than .1 was chosen and used for all subsequent gene quantification 
experiments. All patient samples were run using the appropriate primer molarity. The 
critical threshold (CT) values for the samples were subtracted from the CT value of the 
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housekeeping gene and then compared logarithmically normal controls. All RNA 
samples were DNAsed before being reverse transcribed by Invitrogen’s First Strand 
Synthesis kit (Invitrogen Carlsbad, California). All sample DNA’s were diluted to 15 
ng/ul and cDNA’s to 30 ng/ul. 
X-Inactivation 
X inactivation testing used methylation sensitive restriction enzyme HpaII. Mix; 
2ul of DNA, 1ul 10X NEB buffer 1, 1ul of HpaII enzyme and 6ul of distilled water and 
allow to digest overnight.  The PCR reaction; mix 11ul of distilled water, 2.5ul of 10X 
PCR buffer, 5ul of DNTPs, 1.0ul of FAM labeled-X-inactivation forward primer and 
1.0 X-inactivation reverse primer, 0.5ul Taq polymerase, 1.5ul of DMSO and 2.5ul of 
the digested sample DNA. PCR Conditions: 94˚C x 10.0’ initial denaturation, 94˚C x 
30 sec, 62˚C x 30 sec, 30 cycles, 72˚C x 30 sec, 4 x ∞. The PCR reaction generates 
FAM labeled fragments that are separated by capillary electrophoresis and analyzed by 
GeneMapper, an ABI fragment analysis program. The PCR reaction can take place only 
if the template remains intact. Therefore, the X chromosome with a strong PCR 
amplification signal is the inactive X as the methylation has protected the template from 
digestion. 
PCR/Sequencing 
 Per sample, a standard PCR reaction stock was made of 30.5ul 6M Betaine, 5 
ul of 10X Taq Gold buffer, 3ul of 25mM MgCl2, 8ul of .25mM dNTP, 1ul each of 
100ng/ul forward and reverse primers, 1ul (2.5 units) of Taq Gold polymerase, and 1ul 
of 100ng/ul DNA. PCR reaction product was purified using Qiaquick PCR purification 
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kit (Qiagen Hilden, Germany). 2.75ul of 6M Betaine, 2ul of One Half Big Dye 
(Genetix Limited Queensway, NH) and 2ul of Big Dye (Applied Biosystems, Foster 
City, California), 1 ul of 100ng/ul forward primer and 2ul of purified PCR product was 
set for the sequencing reaction by using 95°C for five minutes, the 27 cycles consisting 
of 95°C for 10 seconds, 60°C for 2 minutes, the to 4°C hold. These products were put 
through Dye Ex columns  
(Qiagen Hilden Germany), dried, and resuspended in 15ul of formamide and run on an 
ABI 3730 sequencer.  
Synthetic MLPA 
A Synthetic probe set was developed (Figure 4) based on guidelines from MRC 
Holland (Amsterdam, The Netherlands). Briefly, to develop a synthetic probe, choose 
2-4 exons in the gene of interest that will give a good representation of that gene. Find a 
section of sequence of desired length that has no recorded polymorphisms, is not 
repetitive and is 40-60% GC rich. Split the sequence roughly in half and have the 5’ 
side of the probe be considered the left side. The 3’ side of the probe will be labeled 
right. The right probe needs to be phosphorylated during the manufacturing process for 
the ligation reaction. These sequences are flanked on both ends by forward and reverse 
M13 tails, respectively. The left and right sides, including the M13 sequence are equal 
to one probe. The left universal M13 PCR primer is FAM labeled when manufactured. 
Each length is added up and each probe needs to be at least 5 bp longer than the former 
probe. All probes have been PAGE purified: to eliminate double peaking in some of the 
probes and also allows the probes to run closer to their expected size. To make a longer 
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probe set; a left, middle, and right probe are designed with 5’ phosphorylation on the 5’ 
end of the middle and right probe sequence set. Synthetic probe reliability testing is 
done by: running probes from two genes sets only then mix different gene sets with 
each other. Check that the probes don’t interfere with one another, and lastly, is to 
remove one probe  from the full set and make sure the correct peak is the one that has 
been intentionally deleted (Figure 4). 
 
 
 
CHAPTER FIVE 
RESULTS 
 
 
 
 
 
 
 
 
 
Figure 4. The final synthetic MLPA probe set. 1,Control peak, 2 XNP, 3 UBE3A, 
4 L1CAM, 5 ATRX, 6 UBE3A, 7 XNP, 8 NEMO, 9 L1CAM, 10 AARSKOG, 11 SRY, 
12 STK9, 13 SKI, 14 SKI, 15 AARSKOG, 16 XNP. 
 CTRL 1         2       3             4       5    6          7             8         9    10    11         12  13          14       15     16  
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CHAPTER FIVE 
RESULTS 
MRX MLPA 
Using the MRC Holland MRX kit that targets Rho and MAPK genes, a group of 
100 male college student controls were screened for validation of the kit. This group of 
intellectually normally individuals was then followed by a cohort of 206 undiagnosed 
patients with a suspected X-linked etiology and 95 ID with hypotonia probands. Some 
of the DNA samples were old and had traces of organics as contamination. This made 
the older samples more difficult to get reliable results from, as good MLPA data is 
DNA quality dependent. This led to numerous repeats as well as Qiagen column 
cleanup on problematic samples. In the end, most samples did produce a result that was 
reproducible. The net result was approximately a 1% were truly abnormal. 
Approximately 3% of the results appeared to be false positives due to DNA quality and 
all of these had to be resolved using qPCR.  The entire MRX MLPA screening 
uncovered a small group of distinct aberrations. The patients with normal results will 
require further testing to determine the causative agent of their disease. For gene dosage 
studies, Array CGH may be a good candidate as it covers the entire genome, if 
negative, it would be indicated that that missense and nonsense mutations are likely 
more causative and new genes would need to be explored. The MLPA proved to be 
fast, inexpensive and makes a good first-round screening test. 
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All of the following were found in the cohort with possible X-linked causation.     
 The summary of the patient screening:  
• One patient with a GDI1 and PQBP1 duplication. 
• One patient with a FACL4 deletion. 
• A FMR2 point mutation was identified by a low value for the exon 4 FMR2 
probe. 
Each sample was repeated with MRX at least three times to ensure 
reproducibility. Quantitative Real-time Polymerase Chain Reaction (qPCR) was used to 
confirm dosage. For all quantitative experiments, quantitative PCR (qPCR) primers 
were designed for the gene of interest, primer efficiencies were calculated using a serial 
dilution and graphed. The primer concentration with a 90% efficiency or better was 
used for all subsequent gene quantification experiments.   
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GDI1 and PQBP1 Duplication 
In one patient a GDI1 duplication was identified by two probes with a 
normalized peak area value of 1.43 and a PQBP1 duplication two probes having 
normalized values of 1.36 and 1.67 was found using the MRX MLPA (Table 2). 
Normalized MLPA data values with a change greater than .35 from 1.0 are considered 
for further investigation. Also the OPHIN1 probe shows a high value of 1.87. This 
probe appears randomly high and low in many samples and is not reproducible among 
runs. Therefore, it was considered unreliable and taken out of consideration for further 
study. The GDI1 and PQBP1 genes are on different arms of the X chromosome and 
primers were designed to target the same regions as the MLPA probes in order to 
confirm the duplication.  The GDI1 and PQBP1 duplications in sample #13805, using 
the delta-delta CT method, confirmed the GDI1 duplication with primers targeting 
GDI1 exons 1 and 5. The qPCR data is set to males with one X chromosome to be 
equal to 1.0. This data shows that the female with two X chromosomes available has a 
value around 2.0. Indicating that the gene dosage is consistent within the normal 
controls. The GDI1 sample has a value at 2.0, indicating double the dosage in this 
region.  The PQBP1 duplication did not confirm in either PQBP1 exon 1 or 4 with 
values at 1.0 (Figure5). The normal control female is high and the samples were 
compared to a normal male to give more rationale to the values observed. 
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Table 2. MRX MLPA patient #13805 
    
 
      
  
CONTROL AVE   
13805 
  
G
E
N
E
 CHROM 
OR 
EXON HEIGHT AREA   HEIGHT AREA   
synthetic 2q14 0.0262 0.0255   0.70 0.68   
UTY Y-.014.5 0.0108 0.0106   0.96 0.94   
DBY Y.014.0 0.0160 0.0165   0.77 0.86   
CNTRL Xq11.2 0.0198 0.0194   0.82 0.96   
GDI1 Xq28 0.0424 0.0408   1.56 1.43   
FMR1 Xq27.3 0.0275 0.0263   1.05 0.97   
FACL4 Xq22.3 0.0348 0.0336   1.07 0.98   
FMR2 Xq28 0.0263 0.0255   1.01 0.95   
TM4SF2 Xp11.4 0.0260 0.0250   1.04 0.95   
FMR1 Xq27.3 0.0385 0.0371   1.05 1.02   
ARHGEF6 Xq26 0.0457 0.0441   1.21 1.13   
RPS6KA3 Xp22.2 0.0441 0.0425   1.15 1.04   
FACL4 Xq22.3 0.0208 0.0202   0.97 0.89   
ARX Xp22.1 0.0279 0.0273   1.03 0.95   
ARHGEF6 Xq26 0.0293 0.0286   1.35 1.23   
DCX Xq23 0.0371 0.0363   0.77 0.71   
ARX Xp22.1 0.0323 0.0316   0.95 0.86   
IL1RAPL1 Xp22.1 0.0236 0.0232   0.98 0.91   
FMR2 Xq28 0.0218 0.0216   0.76 0.73   
FACL4 Xq22.3 0.0109 0.0108   1.03 0.97   
FMR2 Xq28 0.0160 0.0158   0.69 0.66   
TM4SF2 Xp11.4 0.0251 0.0251   1.07 1.05   
DCX Xq23 0.0287 0.0288   0.69 0.68   
FMR2 Xq28 0.0145 0.0146   0.79 0.79   
IL1RAPL1 Xp22.1 0.0231 0.0234   0.91 0.92   
SLC6A8 Xq28.1 0.0205 0.0209   1.23 1.25   
PQBP1 Xp11.23 0.0096 0.0098   1.31 1.36   
DCX Xq23 0.0166 0.0171   0.69 0.72   
IL1RAPL1 Xp22.1 0.0211 0.0216   0.83 0.85   
FMR2 Xq28 0.0173 0.0179   0.73 0.77   
ARHGEF6 Xq26 0.0249 0.0258   1.16 1.22   
AGTR2 Xq24 0.0200 0.0206   1.01 1.09   
RPS6KA3 Xp22.2 0.0231 0.0240   0.99 1.08   
OPHN1 Xq12 0.0183 0.0191   0.85 0.96   
GDI1 Xq28 0.0150 0.0156   1.28 1.43   
PAK3 Xq23 0.0130 0.0138   0.70 0.78   
PQBP1 Xp11.23 0.0119 0.0125   1.46 1.67   
PAK3 Xq23 0.0101 0.0106   0.68 0.78   
OPHN1 Xq12 0.0166 0.0177   0.71 0.81   
PAK3 Xq23 0.0097 0.0104   0.72 0.86   
IL1RAPL1 Xp22.1 0.0122 0.0130   0.79 0.93   
OPHN1 Xq12 0.0064 0.0067   1.53 1.87   
ARHGEF6 Xq26 0.0171 0.0184   1.02 1.21   
RPS6KA3 Xp22.2 0.0118 0.0126   1.24 1.50   
SLC6A8 Xq28.1 0.0139 0.0149   1.02 1.25   
OPHN1 Xq12 0.0127 0.0136   0.83 1.03   
PAK3 Xq23 0.0089 0.0095   0.80 0.98   
        0.94  
Table 2.The red 
arrows indicate the 
GDI1 and PQBP1 
data points in patient 
13805. 
OPHN1 probe was not 
reliable through out the 
testing and the data was 
disregarded. 
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GDI1 and PQBP1 qPCR
0.00
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1.00
1.50
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Normal GDI1
46203
51553
52601
13805
Normal PQBP1
46203
51553
52601
13805  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. GDI1 and PQBP1 Duplication. The black arrows show 
the patient and how the GDI1 duplication in exon 5 confirmed with 
real time PCR, but the PQBP1 at corresponding exon 4 did not. 
A. Data set to normal male, B. 46203 normal female C. 51553 
normal male D. 52601 normal male, E.13805 patient. 
         A     B     C     D     E     A     B     C     D    E 
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FACL4 Deletion 
A FACL4 exon 15 deletion was found using the MRX MLPA (Table 3.). This 
family has two males affected by a deletion in the COL4A5 and FACL4 genes. The first  
hild born to this family is case #11774 and his younger brother is #11775. Both were 
L4A5 gene. 
eletion 
was kn A narrowed the 
tion of the 
genes in the FACL4 region. The deletion is shown in red. 
 
Figure 6. Gene order and direction of expression in the FACL4 region. 
5’              3’ 
  COL4A5      IRSA>       GUCY2F>                   AMMECR1> 
ACL4   
3’                     < FACL4                           5’ 
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being treated for Alport syndrome, which is consistent with a deletion in CO
It was unknown how far the deletion went into the FACL4 gene. The FACL4 d
own in this kindred but one breakpoint was unknown. The MLP
breakpoint region to be between exons 10 and 15. Sequencing later found the 
breakpoint to be located in exon 12. Figure 6 below is the order and direc
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Table 3. Red arrow depicts 
MRX MLPA detects exon 
15 FACL4 deletion in two 
brothers. The FACL4 
deletion was known in this 
kindred but one breakpoint 
was unknown. The MLPA 
narrowed the breakpoint 
region to be between exons 10 
and 15.
Table 3. MRX MLPA FACL4 Deletion 
 
 
 
 
    #   
  CMS-11774   CMS-11775   
   HEIGHT AREA   HEIGHT AREA   
synthetic   1.27 1.19   1.22 1.12   
UTY   0.98 0.91   1.24 1.16   
DBY   0.94 1.10   1.24 1.35   
CNTRL   1.15 1.02   0.71 0.72   
GDI1   1.07 0.94   0.91 0.84   
FMR1   1.15 1.06   0.92 0.86   
FACL4   1.13 0.99   1.02 0.95   
FMR2   1.05 0.92   1.12 1.04   
TM4SF2   1.00 0.85   1.00 0.92   
FMR1   1.05 0.94   0.90 0.84   
ARHGEF6   1.06 0.95   0.92 0.87   
RPS6KA3   1.06 0.96   0.96 0.86   
FACL4   0.00 0.00   0.00 0.00   
ARX   1.04 0.94   1.09 0.98   
ARHGEF6   0.84 0.77   0.82 0.78   
DCX   1.04 0.96   0.98 0.90   
ARX   1.05 1.01   1.03 0.91   
IL1RAPL1   0.91 0.89   1.08 0.97   
FMR2   1.04 1.01   0.98 0.91   
FACL4   1.03 1.00   0.72 0.69   
FMR2   1.24 1.22   0.96 0.92   
TM4SF2   0.96 0.94   1.02 0.98   
DCX   1.02 1.03   0.91 0.90   
FMR2   0.98 1.00   0.86 0.84   
IL1RAPL1   1.16 1.18   1.32 1.31   
SLC6A8   0.96 1.01   1.01 1.03   
PQBP1   0.88 0.95   1.06 1.08   
DCX   0.93 1.01   1.09 1.13   
IL1RAPL1   0.96 1.01   0.92 0.95   
FMR2   1.04 1.13   1.05 1.12   
ARHGEF6   0.92 1.01   0.92 0.99   
AGTR2   0.86 0.96   1.18 1.27   
RPS6KA3   0.89 0.99   1.06 1.15   
OPHN1   0.99 1.13   0.83 0.92   
GDI1   0.96 1.11   1.00 1.08   
PAK3   1.00 1.16   1.00 1.12   
PQBP1   0.90 1.06   1.24 1.39   
PAK3   0.89 1.05   1.21 1.37   
OPHN1   1.00 1.18   0.95 1.09   
PAK3   1.04 1.27   1.05 1.20   
IL1RAPL1   1.12 1.35   1.37 1.54   
OPHN1   0.62 0.75   2.11 2.33   
ARHGEF6   0.97 1.20   0.85 1.00   
RPS6KA3   0.96 1.18   0.81 0.95   
SLC6A8   1.00 1.27   1.39 1.65   
OPHN1   0.83 1.05   1.35 1.62   
PAK3   0.88 1.09   1.20 1.42   
FACL4 exon 10 
FACL4 exon 15 
FACL4 promoter region 
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Case #11774 is a four-year-old male with significant speech delay and no definitive 
etiology. He was born at 36 weeks weighing 5 pounds 13 ounces. He had a short 
umbilical cord wrapped around his neck. He spoke three words at age 1, then, lost those 
words a few months later. He has had normal FRAXA and routine chromosomes were 
normal, MRI, MRS acylcarnitine profile, lactate, pyruvate and serum amino acids. 
Case 11775 (brother of 11774) is 2 years of age and has seizures, a worse temper than 
his older brother, is often uncooperative and weighs 40 pounds and has always been 
big.  He is mildly dysmorphic and has a wide nasal bridge, deep set eyes, well defined 
eyebrows and widely spaced teeth.  He is on carnitor and coenzyme Q for his suspected 
metabolic disorder. 
 The FACL4 gene encodes fatty acid CoA ligase 4 and is known to be associated 
with non-specific X linked intellectual disability. COL4A5 is located at Xq22.3 and 
alterations in this collagen gene causes Alport syndrome (Longo, I. 2003). Another 
investigator at Greenwood Genetic Center was studying the same COL4A5/FACL4 
deletion and knew one breakpoint of the deletion to be in exon 1 of COL4A5 gene but 
the other breakpoint was not yet known. The MRX MLPA with data points at exon 10 
and exon 15 facilitated in finding the breakpoint in exon 12 of the FACL4 gene. The 
mother was later screened on the MRX MLPA and found to be a carrier of the deletion 
as expected (Figure 7). 
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 FACL4 DELETION
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`
Figure 7. The FACL4 deletion as seen on MRX MLPA. At the MLPA FACL4 
exon 15 probe (number 13), CMS11773 (orange) is the mother showing half the 
gene dosage of normal. The male children CMS11774 (pink) and CMS11775 
(yellow) at probe number 13 show a complete loss of dosage. 
 
Again OPHN1 gave odd results and they were discarded. DNA-20000 (dark 
blue) is a normal male control.
Figure 7. 
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FMR2 Point Mutation 
The MRX MLPA for patient # 11701 had a peak with a low signal of 0.37 at 
exon 4 of FMR2 (Table 4). The other data points for the FMR2 gene were shown to be 
near 1.0, and were considered within the normal range of 0.65. to 1.35. This low value 
was reproduced numerous times which warranted further study. Primers were designed 
to flank the MRX probe of interest. A FMR2 c.474 C>T  (p.P158S) alteration was 
found by sequencing the region where the FMR2 MLPA exon 4 probe hybridized. 
Sequence data found the mother also to be a carrier of this change (Figure 7). This is an 
unreported change in the literature and SNP databases. Thus, polymorphism studies 
were undertaken to determine the likely clinical relevance of this finding. A primer set 
was designed to modify the sequence to produce an XbaI restriction site if the 
individual was positive for the c.474 C>T change.  A group of 658 normal controls, 295 
college students plus 363 newborn screening samples of unknown sex were amplified 
and digested with XbaI. The PCR product only digested if there was the same base 
change as in the patient. In males one band would be found at 138 bases if normal, and 
if abnormal a band of 114 bases would appear due to a base change and digestion.  The 
small decrease in size between bands made analysis subjective. To have greater 
confidence in interpreting the data, a female control (mother) was used, having one 
normal allele and one affected allele gave a double band. In females a double band 
would signify the change while a single larger band was normal.  In males it was easier 
to differentiate the small difference when compared to a reference of a normal and an 
abnormal allele. There were twelve positives in the restriction controls. However, when 
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they were sequenced none of the individuals in the normal cohort was found to have the 
c.474C>T alteration (Figure 8).  
 
 
 
 
 
 
 
 
 47
Table 4. MLPA data showing low FMR2 signal in exon 4. 
          
CONTROL AVE   
11701 
G
E
N
E
 CHROM 
OR 
EXON HEIGHT AREA   HEIGHT AREA 
synthetic 2q14 0.03 0.03   1.08 1.01 
UTY Y-.014.5 0.01 0.01   1.10 1.03 
DBY Y.014.0 0.02 0.02   1.00 1.13 
CNTRL Xq11.2 0.02 0.02   1.23 1.07 
GDI1 Xq28 0.04 0.04   1.06 0.93 
FMR1 Xq27.3 0.03 0.03   1.18 1.05 
FACL4 Xq22.3 0.03 0.03   1.14 1.01 
FMR2 Xq28 0.03 0.02   1.15 1.01 
TM4SF2 Xp11.4 0.03 0.03   1.00 0.88 
FMR1 Xq27.3 0.04 0.04   1.08 0.97 
ARHGEF6 Xq26 0.05 0.05   1.01 0.91 
RPS6KA3 Xp22.2 0.05 0.04   1.04 0.93 
FACL4 Xq22.3 0.02 0.02   1.13 1.05 
ARX Xp22.1 0.03 0.03   1.05 0.96 
ARHGEF6 Xq26 0.03 0.03   0.98 0.90 
DCX Xq23 0.04 0.04   0.98 0.93 
ARX Xp22.1 0.03 0.03   0.99 0.94 
IL1RAPL1 Xp22.1 0.02 0.02   0.97 0.93 
FMR2 Xq28 0.02 0.02   1.09 1.05 
FACL4 Xq22.3 0.01 0.01   1.00 0.98 
FMR2 Xq28 0.02 0.02   1.10 1.09 
TM4SF2 Xp11.4 0.03 0.03   0.93 0.92 
DCX Xq23 0.03 0.03   1.03 1.05 
FMR2 Xq28 0.01 0.01   0.36 0.37 
IL1RAPL1 Xp22.1 0.02 0.02   1.06 1.10 
SLC6A8 Xq28.1 0.02 0.02   0.99 1.05 
PQBP1 Xp11.23 0.01 0.01   0.90 0.97 
DCX Xq23 0.02 0.02   0.99 1.07 
IL1RAPL1 Xp22.1 0.02 0.02   0.98 1.07 
FMR2 Xq28 0.02 0.02   0.95 1.06 
ARHGEF6 Xq26 0.03 0.03   0.81 0.92 
AGTR2 Xq24 0.02 0.02   0.90 1.02 
RPS6KA3 Xp22.2 0.02 0.02   0.89 1.01 
OPHN1 Xq12 0.02 0.02   0.98 1.13 
GDI1 Xq28 0.01 0.02   0.94 1.08 
PAK3 Xq23 0.01 0.01   0.93 1.08 
PQBP1 Xp11.23 0.01 0.01   0.87 1.04 
PAK3 Xq23 0.01 0.01   0.91 1.08 
OPHN1 Xq12 0.02 0.02   0.96 1.15 
PAK3 Xq23 0.01 0.01   0.92 1.14 
IL1RAPL1 Xp22.1 0.01 0.01   1.04 1.26 
OPHN1 Xq12 0.00 0.00   0.84 1.06 
ARHGEF6 Xq26 0.02 0.02   0.93 1.15 
RPS6KA3 Xp22.2 0.01 0.01   0.79 0.98 
SLC6A8 Xq28.1 0.01 0.02   0.89 1.08 
OPHN1 Xq12 0.01 0.01   0.74 0.95 
PAK3 Xq23 0.01 0.01   1.06 1.36 
        0.99 
Table 4. FMR2 exon 4  
(red text and arrow) 
shows a low value of 0.37. 
Other data points for FMR2 
(blue text and blue arrows) 
appear to be in the 
normalized range near 1.0, 
depicting a normal value. 
Figure 8. FMR2 Sequencing and restriction data. 
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 PROBAND                 MOTHER 
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The proband when restricted had a 17 base difference than the full length PCR 
product of 138 bases. It was extremely difficult to see the small drop in size on an 
agarose gel. This necessitated using the mother as a control made two bands, making it 
easier to see the restriction result.  
Figure 8B. Xba1 
restriction of 658 
normal controls. 
Normal controls are 
single banded while 
the restriction site of 
XbaI in the Mother 
with FMR2 change is 
double banded. 
Figure 8A. Point 
mutation found in 
FMR2.  
Proband is 
hemizygous for the c. 
474 C> T change and 
the mother is 
heterozygous. 
NORMAL CONTROLS 
 49
Figure 9A. Patient 
with FMR2 mutation 
at age three.   
 
 
 
 
 
Case  #11701. (Figure 9A) The patient with 
the FMR2 point mutation has developmental delay, delayed speech, motor skills, 
and learning problems. He is tall, macrocephalic, with a broad forehead referred by 
(Dr. Leah Burke, Burlington, Vermont). The mother’s X inactivation study shows 
that she has random activation (52:48). Recent data shows the mother and the 
maternal grandmother both have the c.474 C>T change (Figure 9B).  
 Kindred 9225 
 
  
 
 
             
 
 
 
Figure 9B Pedigree of cases 
11701. The mother is a carrier of 
the change. The maternal 
grandmother has been found to 
carry the change as well.  
●
1   
11702
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FMR2 Background 
CGG triplet repeats that cause fragile X syndrome, are well known in the FMR1 
gene, which is closely related to FMR2.  FMR2 is distal to FMR1 and is separated only 
by LOC100128690, LOC100132556 and MIRN514-2 at Xq27.3. Expansion repeats are 
considered to be relatively rare in FMR2.  However, It has been deemed noteworthy to 
screen for FMR2 in patients that are negative for FMR1 expansions (Knight, S. J. 
1996). The prevalence of FMR2 to that of FMR1 triplet repeat expansions is small and 
for every FRAXE (FMR2) expansion detected there will be at least 25 fragile X cases 
(FMR1) found (Brown, W.T. 1996). Point mutations in the FMR2 gene have not been 
reported. The intellectual disability of the FMR2 patient is generally milder than that of 
FMR1, and accumulated data suggest no consistent dysmorphology. It appears that the 
main clinical features are speech delay, reading and writing problems, learning 
difficulties and behavior concerns (Knight, S. J. 1996). It appears that this change is 
consistent with the loss of function FMR2 phenotype and is suspected to be the cause of 
disease. 
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CHAPTER SIX 
RESULTS 
XNP Duplication Causes ATRX syndrome 
After designing the synthetic MLPA probes, working conditions were refined to 
validate the new Synthetic MLPA test. As a part of the validation process 55 normal 
males and 51 normal females were screened. All the samples gave a normal result with 
each probe value to be within the range expected with the data normalized to1.0. 
During the initial screening of the hypotonia cohort, using the synthetic MLPA, 
a duplication in XNP was identified (Figures 11A & B). . After confirming the result in 
the affected proband, the need to test other family members (K8922) was apparent in 
order to determine if the duplication segregated with the phenotype. The family 
members chosen for screening were six obligate carrier females with 100% skewed X 
inactivation, one normal father and two additionally intellectually disabled males 
(Figure 10). Each of the affected males exhibited developmental delay, alpha 
thalassemia, and dysmorphic facies consistent with the clinical diagnosis of ATRX 
syndrome.  
  .  
    
  
    
 
   
Figure 10. 
Heart Defect 
 
Affected Male 
 
Carrier Female 
A. Pedigree of K8922 with 
XNP duplication.  The carrier 
male (2) and A, plus B of the 
two affected brothers (B and C) 
were used in duplication size 
and expression status studies. 
fe
2 
       B  C 
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B. 
 
 
 
 
 
 
 
Case report: 
The family pedigree (K8922) studied (Figure 10) consists of three males in two 
generations having severe mental retardation. Obligate carriers appear normal due to 
highly skewed X-inactivation patterns.  
A,  was born to healthy parents: father age 29 years and the mother age 33 
years. An older half-sister was healthy. Delivery was by Cesarean delivery, birth weight 
was 5.9 lbs and length 21 inches. Hemoglobin inclusions were noted during infancy 
screening and throughout childhood he had chronic microcytosis and hypochromia. 
Low motor tone was present from birth and all developmental milestones were delayed. 
He walked at 30 months and said his first words at two years. He had repeated 
respiratory infections including pertussis and respiratory syncytial virus. 
At age 3.5 years, his head circumference was 47 cm (3rd centile), height of 99 
cm (50th centile) and weight of 14.8 kg (50th centile). His nasal root was broad and 
A    C B    
B. Three affected males with ATRX m 
the XNP duplication family K8922. 
 A,B,C fro
A 
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epicathal folds were present. The lips were full and mouth open. Musculoskeletal and 
genital examinations were normal.  
At age 6 years, his height was 109 cm (60th centile), head circumference was 49 
cm ( 3rd centile) and weight was 21.6 kg ( 70th centile). The nasal root was full and 
inner canthal measurement was 3.1 cm (85th centile). Facial findings were as before 
with small nose, open mouth, full lips and tented upper lip. The alveolar ridge was 
broad and teeth widely spaced. He drooled but peripheral muscle tone appeared normal. 
Neuromuscular and skeletal examinations were normal. Digital fingerprint pattern 
included two tall arches and eight ulnar loops. MRI showed bifrontal atrophy. He 
scored 27 on the Vineland adaptive behavior scale.  
B,  was delivered from breech presentation at 34-35 weeks, weighing 2.16 kg . 
He walked at age five years and never developed significant speech. He had chronic 
constipation. At age 35 years, he had a height of 155 cm (<3rd centile). The eyes were 
recessed, the midface hypoplastic, and the philtrum short, but he did not have hypotonic 
facial characteristics. He had blunting of fingers 2-5 and the palms were excessively 
wrinked. The left elbow had limited extension and toe 2 overlapped toe 3. The testes 
were small (1.5X2.5 cm). There was no spasticity. Testing with the Vineland scale gave 
a score of less than 20. Blood smear was positive for HgbH inclusion with brilliant 
cresyl blue staining. 
C,  weighed 2.95 kg at term delivery. He walked at age 19 months, developed a 
few words at an unknown age and used up to 10 words appropriately as an adult. His 
height was 170 cm (20th centile), weight was 60.9 kg (<3rd centile) and head 
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circumference 56.7 cm (50th centile). Ears and were posteriorly angulated with deficient 
lower helix formation. The right hand was held deviated to the ulnar side. The palms 
were excessively wrinkled and fingertip dermal partterns were five arches, one low 
ulnar loop, and four ulnar loops. Deep tendon relexes were normal. Genetalia was 
normal adult. IQ was <20. (Attending clinician of the K8922 is Dr. Roberta Pagan, 
Walla Walla, WA).  
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A. Synthetic MLPA normalized data depicts the XNP duplication. XNP exons 9 
and 17, shown by peaks 1 and 15 respectively, demonstrate the XNP duplication by 
giving normalized values of 1.5 and above. The normal male (CMS-2570) in this 
family, has values that do not approach 1.5 or greater, demonstrating the lack of 
duplication in this person. 
XNP Test Results 
The XNP duplication was found in all three affected males and six obligate 
carrier females, demonstrating, it segregates with the phenotype of the family members. 
The fact that the affected males and carrier females are concordant for the XNP 
duplication adds to the strength of this finding as the likely cause for the features of 
ATRX in this family (Figures 11A & B). 
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1 93 XNP EXON 9 0.0413 0.0394   1.84 2.17   1.02 1.29   1.72 2.03   1.75 2.07 
2 100 UBE EXON 6 0.1167 0.1152   0.92 0.94   0.93 0.90   0.83 0.85   0.85 0.82 
3 103 LICAM EXON 16 0.0454 0.0443   0.85 0.86   0.93 0.87   0.89 0.90   0.88 0.85 
4 110 XNP EXON 36 0.0382 0.0402   1.03 1.02   1.09 1.13   1.03 1.03   1.15 1.13 
5 115 UBE3A EXON 4 0.1899 0.1883   0.97 0.97   1.04 1.00   0.90 0.85   0.92 0.87 
6 123 XNP EXON 2 0.0752 0.0739   0.90 0.90   0.98 0.95   0.91 0.94   0.93 0.94 
7 131 NEMO EXON 2 0.0702 0.0715   0.86 0.86   1.03 1.00   0.89 0.89   0.95 0.98 
8 135 LICAM EXON 24 0.0578 0.0573   0.93 0.91   1.02 1.00   0.93 0.93   0.95 0.95 
9 138 AARSKOG EXON 18 0.0611 0.0602   0.94 0.95   1.06 1.05   0.92 0.93   0.90 0.86 
10 142 SRY EXON-1 0.0608 0.0611   0.93 0.91   1.09 1.09   0.96 0.95   1.00 0.96 
11 148 STK9 EXON 1 0.0554 0.0570   0.93 0.81   0.99 1.08   1.05 0.68   0.94 1.10 
12 150 SKI EXON 4 0.0517 0.0514   0.99 0.90   0.80 0.75   1.03 1.28   0.77 0.73 
13 158 SKI EXON 6 0.0683 0.0726   0.69 0.68   0.89 0.97   0.94 0.90   0.91 0.90 
14 162 AARSKOG EXON 2 0.0215 0.0213   1.01 1.03   1.18 1.17   1.02 1.09   1.02 1.01 
15 168 XNP EXON 17 0.0464 0.0461   1.88 1.90   1.06 1.04   1.86 1.87   1.84 1.86 
Figure 11A 
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11B XNP duplication MLPA data is depicted on a graph.  
For visualization of the duplicated exons in the males with ATRX syndrome 
the MLPA was graphed, showing the duplication in XNP exons 9 and 17, 
(peaks 1 and 15) but not in exons 2 and 36 (peaks 4 and 6).   
Figure 12. Determining the duplication breakpoints. The blue region shows the 
XNP duplication spans from exon 2 through exon 31  (exons noted in red squares). 
The white areas depict where there is only one copy of XNP. The numbering above 
the dark blue line indicates the base in the gene where primers started. The primer 
names are below the dark blue line.  
 
 
 
 
 
 
  
 
 
Figure 12. 
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Figure 11B 
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Real time PCR was performed to narrow the duplication breakpoints. FGF16 
(proximal), PGK1 and ATP7 (distal) genes flank either side of the XNP gene and were 
determined to have normal dosage. Real time primer sequences may be found in 
Appendix C.  
Testing across intron 2 produced duplicated results through to exon 3. The 
MLPA XNP exon 2 probe shows that exon 2 was not duplicated. In contrast, the real 
time results showed numerous times and with different primer sets, that exon two, is in 
fact duplicated. Later, the MLPA XNP exon 2 probe became problematic and was taken 
out of calculations. The qPCR method appeared more reliable for walking across intron 
1 and using this technique allowed for the determination of the 5’ endpoint of the 
duplication. As the breakpoint region was narrowed, repetitive Alu sequences became 
prevalent, making it very difficult to design reliable primers for real time. Primers then 
became unacceptable as the region became so repetitive that 2-3 peaks would appear on 
the disassociation curve.  With the hope of sequencing across the breakpoint 
boundaries, taking the real time primers and pairing them so they would PCR into 
amplicons of 1-2.5KB, then sequencing this PCR product proved to be fruitless due to 
the repetitive nature of the area, and the exact breakpoint was never found. Relying on 
the qPCR data, it was determined that we were within 2,699 bases, placing it between 
XNP exons1 and 2. The 3’ breakpoint was located between XNP exons 31 and 32. 
Again the sequence in the intron became riddled with Alu repeats making it impossible 
to continue qPCR. We came within 7,480 bases of the breakpoint (Figure 12). 
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 The XNP gene was sequenced in this family providing normal results. Once the 
duplication was found on MLPA the XNP transcript was sequenced looking for 
differences in splicing or breakpoints and it was found to be normal. A Northern blot 
was done to determine the relative amount of XNP expression.  Although amplification 
was possible from the XNP transcript, the Northern blot shows that the amount of XNP 
transcript was minimal and not enough to be visually seen using the exon 9 XNP probe 
(Figure 13). This gives a good indication that the partial duplication disrupts the gene 
and a viable full-length transcript is not made.  
 
 
  
 
 
 
 
 
 
A Western blot was attempted eight times with no success of protein transfer. 
The antibody was tested and found to be in working order. Due to the protein being 
very large it is felt that it may not be released from the nucleus or is not transferring out 
of the gel. The sample of the proband was also sent to Nimblegen technologies to have 
an X chromosome array confirm the duplication. Due to the XNP region being 
Figure 13. XNP Northern blot shows no transcript for the affected 
males 1 and 2. The obligate carrier 3 has transcript to the degree of the 
normal females 4, 5 and normal males 6, 7. 
             1           2           3                    4         5          6         7 
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repetitive there were a limited number of probes in the area and confirmation was 
unclear due to the limits of the array. The Nimblegen array detected a 244kb 
duplication centromeric of XNP. This duplication was in the BRACE gene region and to 
confirm this duplication two sets of qPCR primers were designed. The qPCR data did 
not confirm the BRACE duplication. Further, it was not confirmed on an OGT X array 
platform. 
Problems with the Western blot and the Nimblegen array led to testing with the 
Oxford Gene Technologies (OGT) X chromosome array CGH that had good coverage 
in the XNP region. This platform was run to confirm the XNP duplication data derived 
from MLPA and qPCR (Morey, J. S. 2006) and to narrow and/or confirm the 
duplication breakpoints (Figure 14). The OGT X chromosome array clearly 
demonstrates the duplication and confirms the breakpoint on the 3’ end, but does not 
have enough data points on the 5’ end to determine a more precise region for the 
breakpoint.       
         Figure 14A. 
         A. 
 
 
 
 
 
 
Figure 14A. The OGT Array clearly shows the XNP duplication.  
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ATRX Background 
ATRX syndrome is a rare X-linked syndrome characterized by severe to 
profound mental retardation, characteristic facial dysmorphism, genital anomalies and 
other somatic findings. Affected patients are expected to have -thalassaemia, severe 
developmental delay with little or no language and seizures, which are present in 
approximately 30% of affected individuals (Gibbons, R. 2006). The presence of -
thalassaemia is not required in order to confirm a suspected clinical diagnosis of ATRX 
syndrome.  This syndrome results from mutations in the XNP gene and carrier females 
nearly always have highly skewed X-inactivation patterns favoring their normal X 
chromosome (Muers, M. R. 2007). ATRX protein with 2492 amino acids is widely 
expressed and demonstrates alternative splicing events that generate three isoforms that 
convey tissue specificity (Villard, L. 1997). The protein contains a zinc finger motif 
14B. OGT Array shows the XNP duplication breakpoints. Blue 
and Red arrows indicate OGT array probes. The (blue arrow left) 
ACGH_69901c probe and (blue arrow right) ACGH_69936c probe 
indicate there are 33,525 bases between the probes on the 5’ end. 
The (red arrow left) ACGH_70104c probe and (red arrow right) 
ACGH_7016c probe indicates there are 68,978 bases between the 
probes on the 3’ end. The large distances between these probes are 
possible due to the repetitive nature of these regions. 
 61
and is related to the SNF2/SWI family of transcription regulators and has been 
demonstrated to have a role as a regulator of chromatin remodeling which dictates 
DNA accessibility at numerous loci including the alpha-globin cluster and other 
unknown target genes that are critical for development (Villard, L. 1997), (Argentaro, 
A. 2007).  In the mouse model, known chromatin remodeling proteins, Daxx and 
MeCP2, are that are found to interact with ATRX. (Xue,Y. 2003).  Human homologs of 
these genes are known to be associated with mental retardation. ATRX and Daxx in 
mice make an ATP-dependent chromatin remodeling complex while MeCP2 mutations 
appear to disrupt ATRX localization (Nan, X. 2007). In humans, the large majority of 
all pathogenic XNP mutations (greater than 90%) can be detected in either the zinc 
finger or helicase functional domains (Villard, L. 1997), (Xue, Y. 2003).  
A report published during the course of this study of an intragenic duplication of 
XNP was shown to cause ATRX syndrome by disrupting synthesis of XNP transcript 
(Thienpont, B. 2007). In this report, we identify a new X-linked family with an XNP 
duplication that results in loss of full-length messenger RNA that leads to a classical 
clinical presentation of ATRX syndrome. In cases such as these with normal XNP 
sequencing results, other diagnostic methodologies such as MLPA and CGH may be 
helpful in identifying the underlying etiology. 
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CHAPTER SEVEN 
RESULTS 
L1CAM and SKI Duplications 
The L1CAM/NEMO duplication (Figure 15A) was found on the synthetic 
MLPA probe kit. Confirming the duplication using the MECP2 MLPA kit from MRC 
Holland found that the MECP2 gene was also duplicated and spanned from SLC6A8 to 
NEMO. This sample was transferred to a project being conducted at the Greenwood 
Genetic Center as an additional patient exhibiting a MECP2 duplication (Friez, M. J. 
2006). 
A 
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Figure 15A The synthetic probes find duplications in L1CAM and 
1p36. The L1CAM duplication is depicted by the red arrows. The 
SKI (1p36) duplication is shown by the white arrows.  
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Table 5. 
 
 
 
 
 
 
 
 
 
 
 
 
1p36 Background 
1p36 deletions account for .15-1.2% of idiopathic developmental delay and 
intellectual disability. It is a newly recognized segmental aneusomy condition with an 
estimated incidence of 1/5000 newborns. Routine cytogenetic karyotyping and FISH 
find most 1p36 deletions.  Phenotypic features appear to correlate with the size of the 
deletion. The distal genes contribute to the general phenotypic features of the 
syndrome, while the deletions in the more proximal regions correlate with specific 
features. There are significantly more maternally derived deletions than paternally 
derived deletions with most being de novo events. There are multiple breakpoints with 
Table 5. MLPA summary sheet depicting the L1CAM and SKI 
duplications. Patient data is compared to the average of normalized 
controls, making a deletion to be near .5 with autosomal and 0 with X-
linked and a duplication to be near 1.5 with autosomal and above 1.5 
with X-linked. 
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unclear mechanisms. (Wu, Y.Q. 1999). Patients exhibit a distinct craniofacial 
appearance, with a tower skull, prominent forehead, microcephaly, deep set eyes, 
straight eyebrows, epicanthus, midface, hyoplasia, broad nasal root/bridge, long 
philtrum, pointed chin; associated with brachy/camptodactyly and short feet. 100% had 
mild to profound developmental delay and intellectual disability and 95% had 
hypotonia. 75% had eye/vision problems, 70% of the patients had central nervous 
system anomalies and heart defects and 40% had hearing impairment and skeletal 
anomalies (Battaglia, A. 2008), (D'Angelo, C. S. 2006), (Shapira, S. K. 1997). 
In the hypotonia cohort and the group of cohorts of patients with clinical 
diagnosis and normal sequencing results, duplications and deletions of SKI (1p36) were 
found. The SKI probes on the synthetic kit were the autosomal controls.  These four 
1p36 deletions and one patient with two duplications and one deletion were tested on 
the MRC Holland 1p36 MLPA kit (Figure 15B) for further evaluation. Two of the four 
patients confirmed the synthetic MLPA finding. There were problems with the other 
two non-confirming samples, one had little DNA available and the other had DNA of 
questionable quality. To determine if the DNA was of good quality in the confirming 
and non-confirming samples, they were tested on the MECP2 MLPA kit. If the sample 
looked normal with clean data and little background noise on this kit, the data was 
considered reliable.  Patients, 56560 and 60175 confirmed with the specific 1p36 
MLPA kit from MRC Holland and two platforms of Array CGH as well as by FISH. 
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 Case 56560.  This male patient has multiple 
dysmorphic features, recurrent respiratory infections and 
developmental delays (Figure 16). Medical history reveals 
that he was born at 36 weeks to a 20-year-old mother who 
was previously a drug user. Birth weight was 7 pounds 7 
ounces and a length of 21 ½ inches. His head circumference is 46.5 cm, which is the 
50th percentile. The head is tilted to the left with the ear meeting the shoulder. There is 
a broad nasal bridge and the pupils are equal, round and reactive to light. There is mild 
to moderate hypotonia.  He has a very similar face to those with ATRX with an open 
inverted V-shaped mouth, short neck and developmental delays. He has cupped fleshy 
ears lobules, short nose and repetitive behaviors. The hemoglobin and karyotype tests 
were normal. From a respiratory standpoint when the patient gets the least little cold it 
turns into pneumonia. Gastrointestinal standpoint is that he stays constipated. He has a 
normal karyotype.  
The family history indicates that the mother has frequent bronchial episodes. 
The mother’s half brother that is 19 years old is slow and lives with her. Her other half 
brother is an average learner. The maternal grandmother is 37 years old and has a 
history of psychiatric illness. The father also has bronchial episodes but is generally 
healthy. The father has a brother who is slow and another brother that is normal. There 
is a first cousin on the mother’s side that has spina bifida and another cousin with 
Figure 16. Case 56560 morphic features of 1p36 
deletion syndrome.  
 . Patient with the common dys
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congenital heart disease (The attending physician for this family is Michael Borja, M.D. 
Statesville, NC). 
1p36 Results 
This patient was first found in the hypotonia cohort in one of the initial runs 
with the synthetic MLPA. Later, under another number it appeared again in the L1CAM 
cohort. The 1p36 kit gave atypical results and further confirmation was done to resolve 
the data. The patient appeared to have two deletions and one duplication in a very short 
span on the p arm of chromosome 1. The genes shown to be duplicated are TNFRS18, 
TNFRS4, SCNN1D, DVL1, GABRD, SKI, PEX10, TNFRS14 and ARMD2. The larger 
deletion includes, DFFB, NPHP5, ICMT, CAMT1, TNSFS9 and PARK7 genes. The 
smaller deletion included genes, RIZ1, PRMD2 and CASP9.  
The Spectral Genomics Array CGH was an “in house” method used to 
determine if the duplications and deletions confirmed in this patient. The Spectral Array 
CGH not only confirmed the duplication and deletions, it also found another deletion 
on the q arm of chromosome 1 that the 1p36 MLPA was incapable of discovering 
(Figure 17.). Another array CGH platform, Agilent 4X44 array was also used to test 
this patient. This array system found the two deletions and one duplication on the p arm 
and the deletion on the q arm of chromosome 1. Fluorescent In Situ Hybridization 
(FISH) studies revealed one of the duplications (Figure 17C) and the deletion (Figure 
17B) in patient 56560. The other duplication was too small to be detected by the probes 
used.   
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Figure 17 
A.     B. 
      
    
56560 
Probe # 
CHROMO
OR 
EXON   HEIGHT AREA
CNTRL 2q14   0.52 0.51 
SPACE SPACE   0.00 0.00 
TNFRSF4 1p36.33   0.71 0.69 
CAB45 1p36.33   0.72 0.70 
CNTRL 12q23   0.52 0.50 
HES4 1p36.33   0.56 0.53 
CNTRL 11q13   0.50 0.48 
GABRD 1p36.3   0.75 0.73 
TNFRSF 1B 1p36.34   0.53 0.51 
CNTRL 9q34   0.53 0.52 
GNB1 1p36.33   0.74 0.72 
CASP9 1p36.1   0.81 0.78 
ARPM2 1p36.3   0.85 0.82 
G1P2 1p36.33   0.51 0.50 
SCNN1D 1p36.33   0.89 0.86 
CNTRL 17q21   0.58 0.56 
SHREW1 1p36.32   0.31 0.30 
KIF1B 1p36.2   0.59 0.57 
AGRN 1p36.33   0.58 0.57 
ICMT 1p36.21   0.65 0.63 
FLJ10782 1p36.33   0.93 0.91 
CNTRL 17q11.2   0.64 0.63 
DVL1 1p36.3   0.93 0.91 
FRAP1 1p36.2   0.65 0.62 
NPHP4 1p36.22   0.33 0.32 
CNTRL 9q34   0.64 0.63 
PEX10 1p36.32   1.01 0.99 
TNFRSF18 1p36.3   0.94 0.91 
DFFP 1p36.3   0.70 0.69 
TP73 1p36.3   0.69 0.67 
PLOD 1p36.22   0.67 0.65 
TNFRSF14 1p36.32   1.00 0.98 
PRMD2 1p36   1.04 1.02 
CAMTA1 1p36.31   0.70 0.68 
CNTRL 9q34.1   0.72 0.71 
RIZ1 1p36   1.14 1.13 
DNB5 1p36.2   0.40 0.39 
TNFRSF9 1p36   0.74 0.74 
MTHFR 1p36.22   0.74 0.72 
CNTRL 11q23   0.73 0.72 
MTHFR 1p36.22   0.67 0.65 
SKI 1p36.32   1.09 1.08 
EPHA8 1p36.12   0.71 0.67 
PARK7 1p36   0.74 0.73 
KIF1B 1p36.2   0.75 0.72 
PRDM16 1p36.3   0.73 0.70 
CNTRL 8p23.1   0.78 0.78 
Figure 17A 1p36 MLPA normalized 
results for 56560 shows the 
duplication in blue and the deletion in 
red. 
17B. Spectral Genomics Array CGH 
ideogram of the 1p36 region, 
confirming the MLPA data. The blue 
marker signifies the duplication and the 
red markers signify a deletions. 
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F
F 
igure 17C. The 1p36 duplication in patient 56560 is confirmed by 
ISH studies. The red signal signifies the centromeric region while the 
green signal marks the 1p36 region at the end of chromosome. The 
hite arrow shows there is a more intense green signal than at the red 
arrow, suggesting duplication. 
 
w 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17C. 
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      Figure 17D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17D. The 1p36 deletion found in 56560 is 
confirmed by FISH studies. The red signal signifies the 
centromeric region while the green signal marks the 1p36 
region at the end of chromosome. The red arrow marks the 
green signal at the end of the normal chromosome 1. The 
white arrows show there is no green signal at the end of 
chromosome 1, suggesting a deletion. 
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Case 60175: Male born in 1993 with a birth weight of 5.6 pounds, a head 
circumference of 30cm, and a body length of 44cm. This patient has severe intellectual 
disability and the sample was submitted for L1CAM testing due to hydrocephalus. 
Delayed motor skills and speech with intellectual disabilities accompanied by seizures 
were also noted in the clinical report. The patient, showing a 1p36 deletion on the 
synthetic probe set and the 1p36 MRC Holland MLPA (Figure 18.A) was tested on the 
Spectral Array CGH (Figure 18.B) This CGH reported a deletion of at least 3Mb in the 
1p36 region, validating the MLPA result.  This patient was also run on the Agilent 
Array to confirm the previous findings by the Cytogenetics Department at the 
Greenwood Genetic Center. This array platform found the 1p36 deletion, but also found 
1 Mb duplication at 2p25. The Agilent platform reported the 1p36 deletion spans 
almost 4Mb between 1p36.32 and p36.33 (Figure 18.C). The two array platforms, due 
to probe location and coverage, reported slightly different sizes when calculating the 
deletion.  FISH analysis also confirmed the 1p36 deletion (Figure 18.D). Clinical 
significance is clear even with the number of CNVs located within this deletion. The 
genes encompassed by the deletion, that are known protein coding genes, included on 
the MLPA kit are; HES4, GIP2, AGRN, TNFRSF4, TNFRSF18, CAB45, SCNN1D, 
DVL1, GNB1, GABRD, SKI, PEX10, FLJ10782, RNFRSF14, ARPM2, PRDM16, TP73 
and DFFP. 
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Figure 18A 1p36 MLPA indicates a deletion in 1p36 region in sample 4, 
60175 (yellow line). Each peak around the .5 value of the normalized data 
signifies an autosomal deletion. Samples 1-3 that are running along the 1.0 
value are normal. 
1p36 Patient 60175 Results 
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Figure 18B Spectral Genomics Array 
CGH ideogram shows at least a 3 MB 
deletion at 1p36. The CGH was performed 
to confirm the 1p36 deletion. Indicating it 
was not terminal, but was contiguous. 
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Figure 18C Agilent 4X44K Oligo Array CGH identified a 
 is approximately 4Mb in 
size. This array has better coverage, giving a tighter estimate 
on the size of the deletion.
deletion in patient 60175 that
18D.  60175 1p36 deletion confirmed by FISH studies. The green 
signal indicates the 1p36 region while the red signal indicates the 
centromeric region. The arrow shows there is a missing green signal on 
the end of chromosome 1, indictating a deletion. 
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CHAPTER EIGHT 
RESULTS 
Xq25 Duplication 
A duplication of Xq25 spanning 4 known genes (Figure 20) was found on 
routine MECP2 MLPA testing (Figure 19) in a patient with a clinical presentation 
resembling Rett syndrome. The Xq25 duplication encompasses the BORCL1, ELF4, 
PDCD8/AIF and RAB33A genes.  qPCR was used to measure if there is a 
corresponding increase in expression relative to the duplication. The size of the 
duplication and approximate breakpoints will be demonstrated on an X chromosome 
array CGH (Figure 21).  Determining the parental origins of this duplication was also 
addressed.  
Of the four known duplicated genes only two appear to be over-expressed, AIF 
(apoptosis inducing factor) and RAB33A (Figure 25.B). Our patient with an abnormal 
clinical presentation resembling Rett syndrome is normal for both MECP2 and CDKL5. 
Parents were tested on the MECP2 MLPA and were found to be normal, making the 
duplication a de novo event.  Array CGH confirmed the duplication in the Xq25 region. 
It is a speculated that two over-expressed genes, AIF and RAB33A, play a significant 
role in the phenotype of this patient.   
To determine the change in expression of these two genes and how it affects 
other pathways and expression profiles, a broad literature search was done to find 
candidate genes that might be affected. qPCR was used to find which of the candidate 
genes had their expression levels deviate from the norm.  The first set, targeting the 
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RAB33A pathway, consisted of qPCR on a group of candidate genes, primarily Rab 
genes and their associates.             
Secondly, for the AIF gene, a commercial qPCR array system (SuperArray Profiler) 
targets different genes that are associated in the apoptosis pathway.  
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Figure 19. The Xq25 duplication was found on routine MECP2 MLPA 
testing. The red arrow marks the increase that approaching 1.5 at number 
16. This is the Xq25 control peak in the MECP2 MLPA, depicted in the 
patient. The yellow, green and blue lines are normal samples while the 
purple line with decreases at numbers 8 and 10 with a value of 0.5 is a 
female with a deletion in exons 3 and 4 of MECP2.
Figure 20. Genes 
affected by Xq25 
duplication. The 
255kb duplication 
encompasses four 
known genes 
BCORL1, ELF4, 
PDCD8 and 
RAB33 and three 
unknown genes 
LOC729571, 
LOC728584 and 
LOC643986. 
Figure 19. 
 
 
 
 
 
 
 
 
 
            
Figure 20. 
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Case 1 Background. 
This family is from Ecuador and was referred to the Kennedy Krieger Institute for 
neurologic and genetic evaluation for microcephaly in their second child. The patient 
was a 5.5-pound female baby born to a 30-year-old woman following an uncomplicated 
pregnancy.  The mother was known to have uterine myoma, but there was no bleeding 
or cramping during pregnancy. It was noted that the proband did not move much in 
utero but no other difficulties were noted. She was smaller than her sibling at birth. She 
required oxygen for the first three months of life and this appears secondary to reflux. 
At 1 month of age, there were concerns about hemoglobin, however this was 
subsequently determined to be unremarkable. At 4 months of age, the parents became 
concerned with her development presuming it was no longer reflux associated. She has 
mainly motor delays, but now manifests language delays as well. At 14 months old she 
can stay seated, however, she cannot get seated on her own. She is not yet cruising. She 
has been getting physical therapy since 4 months of age. There are also concerns about 
her fine motor use of her hands. She has some oral motor difficulties. She does choke 
quite a bit, but does not appear to be in respiratory distress when this occurs. There 
have been no seizures. They feel her vision and hearing are normal. There appears to 
have been EMG nerve conduction, which was unremarkable.  
Xq25 Proband Physical Examination and Report. 
Gerald Raymond M.D. reports from the Kennedy Krieger Institute Neurology 
Clinic in July 2005 that the proband is now 14 months and has had two MRI’s which 
are unremarkable. Her weight is less than 5 percentile at 8.1 kilograms, her height at 76 
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cm is less than 50 percentile, and her head circumference is at the 50 percentile at 43.5 
cm. She is a pretty girl with no acute distress sitting in the office. She is visually 
attentive and smiling. Head shape is normal; sclerae is clear, conjunctiva pink, pupils 
equal, round and reactive to light. Extraocular movements are intact, ears are orally 
formed, and tympanic membranes were normal. Nose and mouth are unremarkable. 
Neck was supple with no masses. Abdomen was soft, non-tender without mass or 
organomegaly. Genitalia were unremarkable, back was straight and the extremities 
reveal a normal pattern. Neurologically, she is awake and alert. There was a lot of 
babbling but no words. Cranial nerves II-XII were intact. Motor exam showed her 
generally to be hypotonic with good strength and normal muscle mass. She was noted 
to have some hand wringing as well as flex her hands open and closed several times 
during the visit. At one point while she was becoming upset, she appeared to be 
breathing rapidly, almost bordered on a persistent hyperventilation. 
Xq25 Data Results 
The MECP2 MLPA indicated a duplication in the Xq25 region. To further 
investigate this finding, a DNA sample was submitted for testing on the NimbleGen X 
chromosome array system. Meanwhile, parental DNA was obtained and tested on the 
MECP2 MLPA; both parents appear normal for the duplication indicating the 
duplication was a de novo event.  
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Figure 22. Determining which 
X is inactivated. The X 296.60 is 
from mother and with a very high 
peak height indicates the mother’s 
X is methylated  and inactive. 
The 275.85 X is from the father 
with a low peak height indicating 
this paternal X in the proband is 
the active one. 
 On the NimbleGen array system the duplication was found to span from  
bases 128,889,500 to 129,165,000 on the X chromosome (Figure 21).  
 
 
 
 
 
 
 
 
 
 
 
Proband and parents were tested for X inactivation (XI). The proband has 92:8 
ratio consistent with highly skewed XI chromosome (Figure 22). XI testing uses a 
methylation sensitive enzyme, targeting the androgen receptor (AR) gene, on the X 
chromosome. This test uses the different number of triplet repeats in each allele to 
Figure 21. 
Figure 21. The 275 kb Xq25 Duplication on the NimbleGen X 
chromosome array is depicted by the raised line with the endpoints 
indicated by the arrows. 
 79
distinguish the two X chromosomes in the female. The loss of restriction on the inactive 
X is due to methylation interfering with the enzyme. If there is no methylation present, 
the restriction enzyme cuts the DNA therefore, making PCR impossible. This unique 
length of sequence is labeled and separated using capillary electrophoresis, giving a 
value to each X chromosome corresponding to the number of AR repeats. It is possible 
to determine which X chromosome came from which parent by their unique sizes. The 
degree of methylation signifies the activation status of the X chromosome.  If 
methylation is high, the peak is low, and the gene is inactivated. If methylation is low 
the peak is high and the gene is active. The maternal peak 296.60 is nearly completely 
inactivated while the father’s peak is active (Figure 22), depicting the active ratio of 8% 
maternal to 92 % paternal.  Because two genes on the X chromosome in the Xq25 
region being over-expressed, led to the interpretation that the duplication is on the 
paternally inherited X chromosome (275.85).  
In order to further confirm which parental X chromosome is preferentially 
expressed, each family member had various X-linked genes sequenced in an attempt to 
find coding region SNPs that would be informative at the RNA level. These genes were 
L1CAM, STK9, MECP2 and MED12. Sequencing of MED12 identified a SNP that 
shows quite clearly which X chromosome is expressed in the daughter when the DNA 
to the RNA transcript is analyzed (Figure 23). Many genes on the inactive X 
chromosome escape inactivation in at least a fraction of the cells. RAB33A and AIF do 
not appear to escape inactivation indicating they are likely to be dosage sensitive 
(Brown, C. J. 1197).  
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Father 
 
 
Normal 
Ctrl 
Female
Figure 23. The MED12 gene SNP reveals which X is preferentially active. 
The mother has a “C” and the father has an “A” at this nucleotide in MED12. 
The daughter and a normal control are heterozygous for the “A” and “C” in the 
DNA. In the RNA, the affected daughter has the “A” expressed at a higher 
level (92%), (red arrow), than the “C” (8%). Therefore, the preferentially 
expressed X chromosome was inherited from the father. Notice the normal 
female having a 60/40 X inactivation pattern shows almost equal expression 
for both X chromosomes (bottom right red arrow).
        DNA       
            RNA  
 
 
 
 
 
 
 
 qPCR expression studies were performed for and four known genes 
(ELF4, BCORL1, AIF and RAB33A) were encompassed by the duplication. Of these 
genes, only RAB33A and AIF exhibit over-expression. To confirm the qPCR findings, 
Northern blots were performed (Figures 24 A & B). The Northern blot probed with AIF 
did not separate the 18S (1861 bases) and AIF (1836 bases) band due to a 25 base 
difference in length between these transcripts. Due to the inability to separate the bands 
of interest, no additional AIF Northerns were attempted (Figure 24.A). The RAB33A 
blot appeared to transfer well, but low hybridization and wash temperatures (42°C & 
55°) were necessary making the results for the blot dark and messy. The 5S rRNA runs 
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around 1020bp and these bands look equal in intensity. The RAB33A mRNA is 711bp, 
just under the 1000 base and above the 500 bp ladder band.  The patient band is slightly 
more intense than the control, confirming the qPCR data of higher expression (Figure 
24.B) than normal controls. The ladder bands are on the right ranging from 500-
2000bp. 
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Figure 24B Northern blots. AIF probe. A. is a female control, B & 
E are the Xq25 duplication patient. C, D and F are male controls and 
L is the RNA ladder. The blot on the left did not separate the bands 
of the 18S at 1861bp from the AIF band of 1836bp. The RAB33A blot 
on the right shows this gene at 711bp is expressed at a slightly higher 
level than the control, while the 5S band is equal in intensity.  
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5S 
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Figure 24A 
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Figure 24B
Figure 24A Northern 
Gel equal amounts of 
RNA loaded. In the AIF 
Northern (left) and the 
RAB33A Northern (right), 
using the rRNA bands to 
monitor the calculated 
10ug of RNA loaded, 
shows the RNA samples 
are equal A. female 
control, B & E are the 
Xq25 duplication patient. 
C, D and F are male 
controls and L is the RNA 
ladder. 
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Many qPCR expression experiments took place before the criteria for reliable 
data was obtained. Finding RNA from cell lines will have different expression values, 
although not necessarily contradictory to the final conclusion, but expression is altered 
by the age of the cell line. If the cells are newly grown, RNA expression appears to be 
more robust than cells that have been growing for a longer period of time. If the cells 
are not started in unison unreliable data will be produced. To avoid this phenomenon 
RNA was taken directly from blood via PAX tubes. These samples had to be DNased 
before reverse transcription to eliminate any DNA contamination. cDNA was made, 
diluted to 30ng/ul and qPCR’d giving reproducible data that proved to be reliable. 
 The Xq25 proband expression was compared to expression in normal 
controls.   Each gene encompassed by the Xq25 duplication was qPCR’d  to look for 
any change in expression compared to normal controls.  Two of the genes, ELF4 and 
BCORL1 appear to be having normal gene expression  (Figures 25A&B).  
 25A 
 
 
 
 
 
 
Figure 25A Two genes ELF4 and BCORL1, have normal expression. NL, 
MC1, FC1, FC2, and MC2 are all normal controls. Patient is the Xq25 
proband. 
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 Two of the genes, AIF and RAB33A appear to have higher expression 
than the normal controls. RAB33A expression is over two fold higher whereas AIF is 
slightly over expressed (Figure 25B).   
25B              
 
 
 
 
 
RAB33A Global Expression Changes 
 
A small cohort of ID patients was compared to normal controls to examine 
expression changes in a group of Rab genes and/or genes affiliated with the Rab 
pathways. Due to the Rab genes working in concert to perform their normal 
function, these genes may have a dysregulated pattern of expression in individuals 
with ID. This cohort analyzed consisted of: 
Figure 25B Two of the genes AIF and RAB33A in the proband (53271A) 
had over expression compared to normal controls D (or DMC), 20000, CS, 
KF, and FC30. The RAB33A gene was expressed over two fold that of normal 
controls while the AIF gene expression was elevated by 0.45 above normal. 
• A female with a MECP2 mutation 
• A male FMR1 patient with 300 repeats  
• A female Xq25 duplication patient 
• A female suspected of having ATRX syndrome but with negative XNP 
testing 
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•  A male patient with an unknown diagnosis  
• A normal female control  
• A normal male control  
All were tested for expression level of 26 genes, primarily Rab, Ras and Rho 
genes that are known to be associated with RAB33A or its co-regulator genes. RAB33A 
is a member of the small GTPase super family, and is expressed in the brain, 
lymphocytes and normal melanocytes. In the brain, it is present throughout the cortex 
as well as the hippocampus. RAB33A is regulated by DNA methylation of a specific 
promoter region proximal to the transcription initiation site (Sexton, T. 2007). The 
MECP2 gene, (methyl CpG binding protein 2), may have influence on the RAB33A 
promoter region and therefore, inadvertently control expression for not only RAB33A, 
but its co-regulators and associates.   
The following genes are associated with RAB33A, its co-regulator RAB3A and 
genes associated with Rab hubs and pathways. The first gene, CABC1, was tested to see 
if the apoptosis pathway was altered due to a slight increase in AIF gene expression. A 
different platform was used to continue expression studies on the AIF gene. Each of the 
following Rab genes has been cited in the literature to play a part in the concerted Rab 
cycles found in brain cells: 
CABC1 is a chaperone-encoding gene located at 1q42.1 that has 14 exons 
producing a protein of 368 amino acids. It is expressed in the brain, digestive, cardio 
vascular and nervous systems. It mediates P53 inducible apoptosis through the 
mitochondrial pathway (Gene Atlas, Baylor College).  
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FXR2 is a FXA-related protein and is located at 17p13.1, has seventeen exons 
that produce a protein of 673 amino acids. It is involved with nuclear localization 
signaling, nuclear export signaling and RNA export. This protein is known to interact 
with at least 66 other proteins (BIOGRID, (Ay, N. 2007). This gene is up-regulated 
when MeCP2 is over expressed in the hypothalamus in mice (Chahrour, M. 2008). 
GDI1 is a GDP dissociation Inhibitor 1 and is located at Xq28. It has 11 exons 
and produces a protein of 447 amino acids. It is found in the CNS and brain where it 
plays a role regulating neuronal differentiation and brain development (Pylypenko, O. 
2006). A GDI1 duplication of 250 KB has been reported in a female with mild ID with 
an IQ of 58. This patient had neonatal seizures and cyanotic crisis, walked at 14 
months, and had no speech until 15 months. She shows psychomotor delay and learning 
disabilities, microcephaly, hyperkinesias and other mild dysmorphic features such as a 
medial eyebrow flare and deep palate. Significant GDI1 overexpression of 2.8-5 fold 
was found compared to controls. Mother demonstrated 100% skewed XI (Madrigal, I. 
2007). Prenylated Rab GTPases occur in the cytosol in their GDP-bound configurations 
bound to a cytosolic protein termed GDP-disassociation inhibitor (GDI). Rab GDI 
complexes represent a pool of active; recycling Rab proteins that can deliver Rabs to 
specific and distinct membrane bound compartments.  Rab delivery to cellular 
membranes involves the release of GDI; the membrane associated Rab protein then 
exchanges GDP for GTP. GDI displacement factor (GDF) caused the release of each of 
these endosomal Rabs from GDI. GDF displayed a great enhancement rate on RABS 5, 
7, 9 but cannot react with RAB1. Rab-GDI complexes localize Rabs to the correct 
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intracellular compartments (Dirac-Svejstrup, A. B. 1997). MeCP2 activates Rab7 in 
mice (Chahrour, M. 2008). Prenylation is an important modification for Rab 
interactions. RAB7 interacts with REP and GDI, only if prenylated. The non-prenylated 
to prenylated RAB7 / REP interactions increase 4 fold, while the GDI dependence on 
prenylation is more dramatic, non-prenylated to prenylated RAB7 interactions increased 
1000 fold. GDI has minimal interaction with un-prenylated RAB7 protein. 
MYO5A is located at 15q21.1 and has 40 exons and is an actin binding 
organelle motor protein myosin 5A. It is expressed primarily in the CNS, brain and 
blood. It is found in the intracellular cytoplasm and is associated with microtubules, 
nucleus and the centrosome. The protein is 1855 amino acids long.  Mutations cause 
severe developmental delay. Although the presence of all three RAB27A, MYO5A and 
Melanophilin proteins is crucial for the trafficking of melanosomes, 
neurodevelopmental abnormalities are specific for MYO5A deficiency (Gissen, P. 
2007).  
NIF3L1 is part of the NIF3 family and is located at 2q33-q34. It has seven 
exons producing a 351 amino acid protein. It is expressed in the CNS and lymphoid 
system. Its function is in neuronal differentiation and cell life (Gene Atlas, Baylor 
College). NIF3L1 interacts with at least 38 other proteins including Rab proteins 
(BIOGRID, (Ay, N. 2007). MeCP2 activates this gene in the hypothalamus in mice 
(Chahrour, M. 2008). 
 PAK1 is a part of the Rho small GTPase family, which is critically involved 
in the regulation of spine and synaptic properties. Protein kinase PAK1 is directly 
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associated with and activated by the Rho GTPases.  PAK1 knockout mice show 
changes in the actin cytoskeleton and the actin binding protein cofilin. These results 
indicate that PAK1 is critical in hippocampal synaptic plasticity via regulating cofilin 
activity and the actin cytoskeleton (Asrar, S. 2008). It is becoming apparent that the 
Rho families of small GTPases and their downstream targets have a major function in 
regulating CNS development. This emphasizes the importance of PAK1 in regulating 
neuronal polarity, morphology, migration and synaptic function (Nikitina, T. 2007). 
RABAC1 is a RAB acceptor and is located at 19q13.13. It has five exons that 
produce a 185 amino acid protein. It is expressed in the endocrine, digestive systems, 
the pituitary and brain. It is a GDI displacement factor. This protein interacts with 57 
other proteins, most of them being Rab proteins as it serves as a Rab trafficking hub. 
RAB11B: Is a RAS oncogene located at 19q12 and has five exons that produce 
a protein made of 218 amino acids. Its primary expression is unknown, but it is found 
as a GTP binding protein, one that is involved with regulating the transcription protein 
transport (Gene Atlas, Baylor College). 
RAB17 is a part of the RAS family and is located at 2q37.3. It has six exons that 
produce a 212 amino acid protein. It is expressed in the lymphoid and digestive 
systems, blood and pancreas. It is involved with protein transport (Gene Atlas, Baylor 
College). 
RAB22A is in the RAB family and is located at 20q13 and has seven exons 
producing a protein of 194 amino acids. Its primary expression is unknown but it is 
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known to play a part in cellular trafficking and transport and interacts with RABAC1 
(BIOGRID, (Ay, N. 2007), (Gene Atlas, Baylor College).  
RAB23A is a Ras oncogene located at 6p11.2-12.3 and has seven exons 
producing a protein of 237 amino acids. It is a negative regulator of hedgehog and in 
mice it has been shown to cause NTD abnormal somites, polydactyly and poorly 
developed eyes. (Gunther, T. 1994). Nonsense mutations of Rab23A in 'open brain' 
mice were found to cause recessive embryonic lethality with neural tube defects, 
suggesting a species difference in the requirement for RAB23 during early 
development. The discovery of RAB23 mutations in patients with Carpenter syndrome 
implicated hedgehog signaling in cranial suture biogenesis; this was an unexpected 
finding given that craniosynostosis is not usually associated with mutations of other HH 
pathway components. The finding also provides a new molecular target for studies of 
obesity, which is a consistent feature of Carpenter syndrome (Jenkins, D. 2007). 
RAB27A is a RAS oncogene located at 15q15-q21.1 and has six exons 
producing a protein 221 amino acids long. It is expressed in the digestive system, 
lymphoid system, reproductive system, skin and blood. It is found in immune defense, 
regulatory signaling and transport, fusion of vesicles with their appropriate membrane 
receptors. Mutations cause type II Griscilli syndrome (OMIM 607624) an autosomal 
recessive disorder characterized by hypo-pigmentation of the skin, silvery gray hair and 
large clumps of hair pigment in the hair shaft. RAB27A is high in melanocytes and cells 
of the haematopoietic system and other secretory cells (Gissen, P. 2007). Mutations in 
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RAB5A and RAB27A cause these proteins to be retained on the ER membrane and are 
not delivered to their native locations  (Wu, Y.W. 2007).  
RAB33A:  Located at Xq25, has two exons that produce a protein with 237 
amino acids and is expressed in the lymphoid immune system, CNS, brain and visual 
eye.  It is a transport/carrier protein and is associated with membrane fusion. It is a 
chaperone for nucleotide free Rabs, based on the interaction between Rab8 and MSS4 
(Itzen, A. 2006). It has a putative GDI interaction site based on the interaction between 
S. cerevisiae Ypt1 and its guanine nucleotide dissociation inhibitor (GDI) (Rak, A. 
2003). It also has an effecter interaction site based on interactions between Rab3A and 
the effector domain of Rabphilin-3A (PubMed 10025402). RAB33A is also involved 
with development and is found to play a role in the differentiation of embryonic stem 
cells to neurons. Gene expression profiles looking to determine genes involved with 
guided differentiation found up-regulated (two fold) expression from Serpini1 and 
RAB33A at E15 which decreased with embryonic age, but maintained steady expression 
throughout adulthood (Lee, M. S. 2006). In mice, changes in MeCP2 expression up-
regulate RAB3A (Chahrour, M. 2008) a co-regulator of RAB33A. 
RAB33A is localized to the medial Golgi cisternae. Together with other cisternal Rabs, 
RAB6 and RAB6A, it is believed to regulate the Golgi response to stress and is likely a 
molecular target in stress activated signaling pathways. GTPase activating proteins 
(GAPS) interact with GTP-bound Rab and regulate hydrolysis of GTP to GDP. GAPs, 
which can accelerate hydrolysis of bound GTP over 2000-fold, can accelerate both 
activation and deactivation in cells with variable inhibitory effect. The GTP bound state 
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of the Gά subunit is active and deactivation is caused by hydrolysis of bound GTP to 
GDP (Turcotte, M. 2008). Guanine nucleotide dissociation inhibitors or GDI further 
regulate Rabs, which facilitate Rab recycling by masking C-terminal lipid binding and 
promoting cytosolic localization. Most Rab GTPases contain a lipid modification site at 
the C-terminus (Dumas, J. J. 1999), (Itzen, A. 2006), (Rak, A. 2003), (Ostermeier, C. 
1999).   
RAB3A is a Ras Oncogene located at 19p13.1. It has five exons that produce a 
protein of 220 amino acids. It is located in the CNS and is most abundantly expressed 
in the brain. It is present in all synapses and it is involved in calcium dependent 
neurotransmitter release.  Mutations in two genes implicated in RAB3A regulation are 
associated with neurodevelopment defects (Gissen, P. 2007). Recessively inherited 
changes lead to defects in catalytic and non-catalytic subunits of RAB3GAP cause 
Warburg Micro syndrome (OMIM 600118) and Martsolf syndrome (OMIM 212720) 
respectively. RAB3GAP specifically converts RAB3A GTP to GDP and thus may 
determine the timing of dissociation of RAB3A from synaptic vesicles. The neuronal 
migration defects and microgenitalia may be secondary to abnormal vesicular secretion 
of neurotransmitters and of hormones produced by the hypothalamic/pituitary axis. In 
concordance with this hypothesis, rab3gap gene knockout mice accumulate the GTP- 
bound form of Rab3a in the brain, which leads to the inhibition of calcium dependent 
glutamate release from cerebrocortical synaptosomes. It is suggested that the 
abnormality in exocytosis is due to suppressed dissociation of the Rab3a from synaptic 
vesicles resulting from abnormal conversion of GTP-Rab3a to GDP-Rab3a 
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(Ostermeier, C. 1999), (Johannes, L. 1994).  RAB3A is activated by MeCP2 in the 
hypothalamus in mice and is up-regulated in mice with an increase in expression of 
MeCP2 (Chahrour, M. 2008). Rab proteins are involved with tethering and are thought 
to function upstream of the soluble N-ethylmalemide-sensitive factor attachment 
receptor proteins (SNARE). RAB3A is implicated in the fine tune control of synaptic 
vesicle release. In Rab3a deficient mice, pre-synaptic activities were quickly attenuated 
following a series of repetitive stimuli (Yamaguchi, K. 2002). It is also implicated in 
synaptic plasticity since Mossy fiber long term potential was reduced in Rab3a 
deficient mice. Rab GTPases are necessary for docking and fusion in membrane 
trafficking pathways in conjunction with the SNARE components. The GTP bound 
forms of Rab proteins recruit their effecter proteins and this exchange process is 
regulated by guanine nucleotide exchange factors (GEF).  The GEFs identified thus far 
are personalized to their specific Rab and have no similar amino acid sequence between 
them. The RAB3A GEF is a regulator of multiple pathways. This finding demonstrates 
Rab GEF is clearly a regulator of RAB3A. There is also high expression in pancreatic 
islet cells where it plays a negative role in insulin secretion. RAB3A interacts with 
RAB27A and is a co regulator of RAB7 and RAB40B. Rab3a in mice shows, behavioral 
abnormalities, including disturbance of the circadian rhythm and sleep homeostasis 
(Handley, M.T. 2007), (Dumas, J. J. 1999). 
RAB40B: Is a RAS oncogene located at 17q25.3 and has eight exons that 
produce a protein made of 278 amino acids. It is found primarily in the brain, breast 
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and lung. RAB40B is found in a vesicular trafficking pathway of secretory vesicles 
(Gene Atlas, Baylor College). 
RAB4B: Is a RAS oncogene located at 19q13.2 and has seven exons that 
produce a protein of 213 amino acids. It is found in the lymph system, pancreas, 
exocrine, female breast and bone. It is a lipid anchor of the cytoplasmic side of the cell 
membrane. (Gene Atlas, Baylor College) This gene is activated by MeCp2 in the 
hypothalamus in mice (Chahrour, M. 2008).  
RAB5C is in the RAS oncogene family. It is located at 17q21 and has six exons 
that produce a protein of 216 amino acids. It is expressed in the lymph, immune and 
reproductive systems, lung and skin (Gene Atlas, Baylor College. It is involved in 
endocytosis and protein transport. It regulates membrane traffic into and between early 
endosomes as well as vesicle transport along microtubules. RAB5C is an integrin-
associated protein and positive regulator of integrin traffic. RAB5C and its effector 
EEA1 mediate docking/fusion of early endosomes by interacting with syntaxin 13 and 
NSF (N-ethylmaleimide sensitive factor (NSF) (Pellinen, T. 2006). 
RAB6A is in the RAS oncogene family. It is located at 2q14-q21 and has eight 
exons producing a 208 amino acid protein. It is expressed in the CNS, lymphoid system 
and respiratory system. It regulates membrane trafficking from the Golgi to the 
Endoplasmic Reticulum (ER). 
RAB8A is of the RAS oncogene family and is located at 19p13.1 and has eight 
exons that produce a 207 amino acid protein. It is expressed in the CNS, lymphoid and 
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digestive systems. It is involved with neurotransmitter release (Gene Atlas, Baylor 
College).            
RAC1 is a RHO-RAS like gene located at 7p22 and has 8 exons producing a 
protein of 192 amino acids. It is found in the lymph system, brain, pancreas and 
secretory pathways. It is a GTP binding protein and is associated in the cell cycle, 
signaling, and regulation of actin cytoskeleton. It is involved with RHO A, L1CAM, 
CDC42, and PAK in axon repulsion (Gene Atlas, Baylor College). 
RAC2 is a RHO-RAS related gene located at 22q13.1. It has seven exons to 
produce a protein of 192 amino acids. It is expressed in the lymph system, blood and 
connective tissue (Gene Atlas, Baylor College).  
RHO A is part of the RAS family and is located at 3p21.2. It has five exons that 
produce a 193 amino acid protein. It is expressed in the CNS, lymphoid system and 
blood. It is found to mediate distinct actin cytoskeleton changes, cell-to-cell adhesion 
and motility (Gene Atlas, Baylor College).  
RHOU is a RHO GTPase located at 1q42.11 and has three exons that produce a 
protein of 270 amino acids. It is a CDC42 homolog and activates PAK1. RhoGDI has 
multiple functions in regulation of Rho family GTPase activities (Gene Atlas, Baylor 
College). Rho GTPases are molecular switches cycling between active GTP-bound and 
inactive GDP-bound forms. C-terminal prenylation allows them to associate with 
membranes where they can interact with, and activate their effectors. Several levels 
tightly control their activation state and accessibility. Activation through GDP_GTP is 
catalyzed by GEF Guanine exchange Factors and promotes downstream signaling. GAP 
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GTPase activating proteins accelerate the intrinsic GTPase activity to inactivate the 
protein and terminate the signal. Rho-GTPase dissociation inhibitors (Rho-GDIs), 
Extract Rho family GTPases from membranes and solubilize them in cytosol (Dovas, 
A. 2005).  
SNAP29 is a synaptosomal associated protein located at 22q11.21 and has five 
exons producing a protein consisting of 258 amino acids. It is expressed in the brain, 
lymphoid, immune and reproductive systems. In the brain it is a neurotransmitter of 
modular synaptic transmission. Mutations cause cerebral dysgenesis, neuropathy, 
ichthyosis, keratoderma, microcephaly, sensorineural deafness, optic disc hypoplasia, 
facial dysmorphism, intracranial abnormalities and death. SNARE proteins are “soluble 
N ethylmalemide-sensitive fusion attachment protein receptor protein” SNARE 
proteins become active acquiring GTP with the aid of the Rab activator molecule. 
SNAP29 is homologous to SNAP25 in that is contains two predicted coiled-coil regions 
that can participate in the formation of the core complex; however it lacks the 
palmitoylated membrane attachment domain found in SNAP25.  It was known that 
SNAP29 can associate with syntaxin 6 and may have a role in the intracellular 
trafficking of the IGF1 receptors and other proteins in neuroectodermal tissues 
(Sprecher, E. 2005).  
WASF1 is part of the WAS Protein family and is located at 6q21-q22. It has 10 
exons that produce a protein of 559 amino acids. It is expressed in the blood, neurons, 
lymphoid system and pancreas. It is a regulator of actin organization and is downstream 
of the RAC pathway (Gene Atlas, Baylor College). 
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The following chart is the schematics of the pathways involving the genes 
studied in the Xq25 project. Red and blue arrows note the MECP2 and RAB33A gene 
interactions, while black arrows indicate trafficking control, with secondary protein 
interactions depicted as yellow ovals. RABAC1 is a central hub sorting and sending 
different proteins to their correct destination in the cell. Many times localization 
proteins, motor proteins, effectors or modifiers are added before the proteins are sent to 
their final destination. RAB33A and RAB3A are positive co-regulators of each other. 
MECP2 is regulated by CREB1 through a negative feedback loop. RAB1A regulates 
CREB1, and with CREB1 activation, comes the release of CREB repressor protein. 
Patients with mutations or dosage aberrations in these core genes are found to have 
global dys-regulation (Figure 26). 
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  Figure 28. 
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RESULTS 
Expression Screening 
qPCR was performed on each of these genes on the small cohort mentioned 
previously. The results show that there are patterns of expression in each gene among 
differently affected patients. Below is the summary of the qPCR findings showing 
under and over expression (Table 6).  
         
  GENE Xq25 ATRX FMR1 UNKN MECP2 
1 CABC1 1.45 0.84 1.30 1.09 1.85 
2 FXR2 1.73 0.85 1.06 0.90 1.57 
3 GDI1 1.09 1.30 0.96 1.01 1.80 
4 MYO5A 0.70 0.97 0.91 0.76 1.50 
5 NIF3L1 2.67 2.22 1.34 1.17 1.40 
6 PAK1 0.55 0.80 0.72 0.82 0.94 
7 RAB 1A 1.40 0.63 0.92 0.90 1.30 
8 RAB 11B 1.80 1.63 1.17 1.01 0.66 
9 RAB 17 1.87 1.65 1.68 0.95 0.67 
10 RAB 22A 1.60 1.72 1.05 1.04 1.40 
11 RAB 23A 1.40 1.05 0.42 1.12 1.97 
12 RAB 27A 0.70 1.37 0.64 0.82 1.30 
13 RAB 33A 2.75 2.75 0.70 0.41 1.50 
14 RAB 3A 2.11 1.00 1.38 1.83 2.09 
15 RAB 40B 2.73 2.13 1.52 1.50 1.14 
16 RAB 4B 1.00 1.20 1.13 0.60 0.46 
17 RAB 5C 0.78 1.02 0.77 1.14 0.93 
18 RAB 6A 0.84 1.35 0.69 0.83 0.84 
19 RAB 8A 1.14 1.15 1.05 0.96 0.73 
20 RAB AC 1 1.13 1.51 0.90 0.81 0.79 
21 RAC 1 0.84 0.91 0.68 0.71 0.86 
22 RAC 2 0.93 0.96 0.88 0.86 0.92 
23 RHO A 0.90 0.88 0.84 1.00 0.73 
24 RHOU 0.97 1.17 0.71 1.88 0.71 
25 SNAP 29 1.03 1.44 0.88 0.79 0.81 
26 WASF1 1.40 0.82 4.50 0.83 1.67 
OVER (above 1.30) 
 
UNDER (under 0.70) 
 
NORMAL (0.71-1.29)
EXPRESSION 
Table 6.  
qPCR Expression values for a 
small cohort of ID individuals. 
The samples were all derived 
from blood via a PAX tube and 
RNA isolated, DNAsed and 
reverse transcribed. The cDNA 
was diluted to 30ng/ul +/-
1ng/ul.  In each run all samples 
were compared to the same 
normal control male. 
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There were some genes that would not qPCR to an acceptable degree of quality 
satisfaction and were removed from the results. These genes are RAB26, CDC42, 
ILRAPL1, REP, H-RAS, and RAB7. A set of normal controls was first run to test the 
primers for reliable results. Differences in RNA expression between samples coming 
from cell lines and blood gave the same overall result, but with different magnitudes. 
To remove the different source variable, blood samples were used for all subsequent 
testing. Expression of each gene was run for each sample in triplicate with the 
housekeeping gene run in duplicate. The critical threshold (CT) average of the samples 
was subtracted from the CT average of the housekeeping gene. This value was 
subtracted from the normal male control CT value and multiplied by 2, commonly 
known as the delta, delta CT method. Each gene was qPCR tested twice for validation 
of the original results. 
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 1 CABC1 14 RAB 3A
2 FXR2 15 RAB 40B 
3 GDI1 16 RAB 4B 
4 MYO5A 17 RAB 5C 
5 NIF3L1 18 RAB 6A 
6 PAK1 19 RAB 8A 
7 RAB 1A 20 RAB AC 1 
8 RAB 11B 21 RAC 1 
9 RAB 17 22 RAC 2 
10 RAB 22A 23 RHO A 
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13 RAB 33A 26 WASF1 
27B
Figure 27. Similar patterns of expression among ID patients.  
27A The FMR1 positive patient is compared to the Xq25 duplication patient. 
27B The ATRX, XNP normal patient is compared to Xq25 duplication patient. 
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1 CABC1 14 RAB 3A 
2 FXR2 15 RAB 40B 
3 GDI1 16 RAB 4B 
4 MYO5A 17 RAB 5C 
5 NIF3L1 18 RAB 6A 
6 PAK1 19 RAB 8A 
7 RAB 1A 20 RAB AC 1 
8 RAB 11B 21 RAC 1 
9 RAB 17 22 RAC 2 
10 RAB 22A 23 RHO A 
11 RAB 23A 24 RHOU 
12 RAB 27A 25 SNAP 29 
13 RAB 33A 26 WASF1 
Figure 28. Similar patterns of expression.  
28A The ID patient with no known etiology is compared to the Xq25 
duplication patient.  
28B The MECP2 deletion is compared to the patient to the Xq25 
duplication patient. 
28A
28B 
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CHAPTER NINE 
 
RESULTS 
 
RT2 Profiler Super Array 
Determining what role the over-expression of AIF may play in the Xq25 
patient’s disorder is undetermined.  AIF is an apoptosis-initiating factor, but it has two 
other roles it performs in the cell, a role in the respiratory chain complex I and a potent 
redox function. The harlequin mouse mutation is a proviral insertion into the AIF gene. 
This mutation displays 80% loss of gene expression and it is mentioned that these 
mutant mice have progressive degeneration of terminally differentiated cerebellar and 
retinal neurons. (Klein, J. A. 2002). AIF is also found in the multiprotein signaling 
complexes in the postsynaptic terminal of central nervous system synapses. These 
multiprotein signaling complexes are essential for the induction of neuronal plasticity 
and cognitive processes in animals. This find makes AIF a potential target for future 
testing and resequencing of X-linked cognitive disorders (Laumonnier, F. 2007). Loss 
of AIF causes disturbances in cell cycle regulation and this dys-regulation has been 
implicated in neurodegenerative disorders. Animals in which have AIF is down 
regulated undergo unscheduled cell cycle re-entry, a molecular mechanism by which 
free radical damage can lead to neuronal death (Klein, J.A. 2002). There appears to be 
information about down-regulated AIF expression, but little information concerning up- 
regulation of the gene. Can up-regulation cause an increase of redox activity? Is the 
optimal mitochondrial respiratory function disturbed by up regulation of AIF 
(Stambolsky, P. 2006)? These are questions that need to be answered but not in this 
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project. The question asked in this project is, what does AIF over-expression in our 
Xq25 patient do to the expression of other genes in its own and other apoptosis 
pathways? To look at the expression levels of genes in a patient that may have pathway 
changes, a small array system that targets only genes known to be involved in the 
pathway of interest is commercially available. The SuperArray by Bioscience 
Corporation called the RT2 Profiler PCR Array is not as global as the array CGH or a 
large-scale expression array system. Instead these arrays are pathway focused gene 
expression of a precise and specific known pathway. RT2 Profiler PCR Array combines 
the quantitative performance of the SYBR® Green-based real time PCR with multiple 
gene profiling capabilities of a microarray (Arikawa, E. 2008). The PCR array is a 96 
well format containing 84 related genes, 5 housekeeping genes and three controls 
(Figure 29).  
 
 
 
 
 
Figure 29.  
The RT2 
Profiler TM 
PCR Array 
layout. 
 104
The genes of the apoptosis pathway were explored using RT profiler by 
comparing two normal controls to the Xq25 duplication patient with increased 
expression of AIF.  84 genes were screened, but 12 were removed due to conflicting or 
unreliable results from the analysis data. In the Xq25 duplication patient the following 
genes were found over expressed in the apoptosis pathway, BCL2, BIRC3, BNIP3, 
TNFRSF10B, TRAF3, and GAPDH. The under expressed genes in the patient are, 
BAG1, BCL2L11, BID, NAIP, BNIP3L, CARD6, CARD8, CASP1, CASP10, CASP4, 
CASP5, CASP8, CASP28, CD40LG, DAPK1, FASLG, IGF1R, LTBR, MCL1, PYCARD, 
CD27, TNFSF10, TNFSF8 and TP53BP2 (Table 7). 
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Figure 30 
Figure 30. RT2 profiler indicates numerous changes in the apoptosis 
pathways in the Xq25 patient. The overall gene expression for the 
SuperArray is automatically plotted on a dot plot graph by the software. The 
patient has 5 genes over-expressed and 24 genes under-expressed showing 
they are outside the normal range. The few genes that appear to be outside 
the range in the normal controls were also out of range to a greater degree in 
the patient. These genes were marked as unreliable results and were removed 
from the analysis.  
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Figure 30.B & C. RT2 Profiler normal controls scatter plot. This indicates 
both normal controls have the majority of the data points well within the 
normal expression range in the apoptotic pathway. 
Figure 31A  
Figure 31B 
Figures 31. A&B. The scatter plot shows that the controls have the 
majority of their genes within the normal range. 
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 Gene Gene extended name Gene Information 
RED = OVER EXPRESSION BLUE = UNDER EXPRESSION 
BCL2 B-CELL CLL/Lymphoma 2 
Antagonist of cell death located in 
Mitochondria  
BIRC3 
Baculoviral IAP repeat-
containing 2 Unknown 
BNIP3 
BCL2/adenovirus E1B 
19kDA interacting protein 3
Intracellular, cytoplasm, organelle, 
mitochondria, inner 
TNFRSF10B 
Tumor necrosis factor 
receptor superfamily  Apoptosis inducing receptor TRAIL-R2 
TRAF3 
TNF receptor-associated 
protein 
Tumor necrosis factor (TNF)-receptor 
associated factor 3 
GAPDH 
Glyceraldehyde-3-
phosphate dehydrogenase 
Triggering apoptosis when Tran located 
to the nucleus 
BAG1 
BCL2 associated 
athanogene 
Intracellular, cytoplasm, organelle, 
mitochondria, inner 
BCL2L11 
BCL2 -like 11 apoptosis 
facilitator 
Intracellular, cytoplasm, organelle, 
mitochondria, inner 
BID 
BH3 interacting domain 
death agonist Inhibits FAS mediated apoptosis 
NAIP 
NLR family, apoptosis 
inhibitory protein 
Neuronal apoptosis inhibitory protein, 
telomeric copy 
BNIP3L 
Bcl2/adenovirus e18 19kDa 
interacting protein3 
Intracellular, cytoplasm, organelle, 
mitochondria, inner 
CARD6 
Caspase recruitment domain 
family member 6 
A bundle of six antiparallel alpha helices 
consisting the caspase recruitment domain 
CARD8 
Caspase recruitment domain 
family member 8 
CARD inhibitor of NF-Kappa B-
activating ligands 
CASP1 
Caspase 1, apoptosis-related 
cysteine peptidase 
Stored in the mitochondrial 
intermembrane space and released into 
cytosol after appropriate apoptotic stimuli 
CASP10 
Caspase 10, apoptosis-
related cysteine peptidase 
Stored in the mitochondrial 
intermembrane space and released into 
cytosol after appropriate apoptotic stimuli 
CASP4 
Caspase 4, apoptosis-related 
cysteine peptidase 
Stored in the mitochondrial 
intermembrane space and released into 
cytosol after appropriate apoptotic stimuli 
CASP5 
Caspase 5, apoptosis-related 
cysteine peptidase 
Stored in the mitochondrial 
intermembrane space and released into 
cytosol after appropriate apoptotic stimuli 
Table 7. 
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CASP8 
Caspase 8, apoptosis-related 
cysteine peptidase 
Stored in the mitochondrial 
intermembrane space and released into 
cytosol after appropriate apoptotic stimuli 
CD40LG 
CD40 ligand TNF 
superfamily 
Role of sCD40L in numerous disease 
pathologies and having ability to activate 
proximal and distal immune responses 
DAPK1 
Death associated protein 
kinase 
Calcium/calmodulin-dependent 
serine/threonine kinase which acts as a 
positive regulator of apoptosis 
FASLG Fas ligand TNF superfamily
FAS ligand, a pro-apoptotic protein 
induced by DNA damage 
IGFIR 
Insulin-like growth factor 1 
receptor Unknown 
LTBR Lymphotoxin beta receptor 
Involved in lymphoid organ development 
and apoptosis through interaction with 
TRAF3 
MCL1 
Myeloid cell leukemia 
sequence 1 
Involved in programming of 
differentiation and concomitant 
maintenance of viability but not of 
proliferation: isoforms 1 inhibits 
apoptosis while isoforms 2 promotes it 
PYCARD 
PYD and CARD domain 
containing 
Moving in cells undergoing apoptosis 
from the cytoplasm to the perinuclear 
periphery 
CD27 CD27 molecule 
Preligand assembly domain (PLAD) in 
CRD1 mediating ligand-independent 
receptor assembly and signaling 
TNFSF10 
Tumor necrosis factor 
ligand superfamily Inducing apoptosis in the brain 
TNFSF8 
Tumor necrosis factor 
ligand superfamily 
Inducing cell death and reducing cell 
proliferation of other lymphoma cell lines 
TP53BP2 
Tumor protein p53 binding 
protein 2 
Enhancing p53-induced apoptosis, the 
DNA binding and transactivation function 
of TP53 
 
 
 
 
 
 
Table 7. Genes found misregulated on the RT2 profiler. 
Expression changes, red over expressed, blue under expressed, in 
the Xq25 patient when compared to normal controls in the 
apoptotic pathway. 
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This method allows for the visualization of the global changes affecting other 
apoptotic pathways due to over-expression on the AIF genes. An alternative 
explanation is that some of these genes are misregulated due to over-expression of 
RAB33A. 
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CHAPTER TEN 
DISCUSSION 
 
This study consists of a screening of Ras, Rho and Rab genes with MLPA. Of 
the 1152 patients screened from various ID cohorts, duplications as a cause of disease 
were established to be rare. In this large group only two patients with duplications were 
found, the XNP duplication in one individual and the patient having both GDI1 and 
PQBP1 duplicated. The XNP gene sequencing results were initially reported as normal 
due to some XNP transcript being present, although further study eventually 
demonstrated that full-length XNP mRNA did not exist or was present in a very low 
concentration. cDNA sequencing of the transcript was possible most likely due to very 
low copy number or large fragments of the transcript being available for amplification. 
This suggested there was at least some amount of mRNA transcribed in this patient. 
Not until the Northern blot was it shown that the mRNA transcript was at a small 
fraction of the normal concentration. Using qPCR to plot the end points of the 
duplication, it was determined to be a partial duplication spanning from exon 2 through 
31. This partial duplication disrupted the gene and prevented normal synthesis of full-
length mRNA transcript. The PQBP1 duplication portion of the GDI1 and PQBP1 did 
not confirm with qPCR, but the GDI1 duplication did. These genes are on different 
regions on the X chromosome, and are not in the same vicinity. A pseudogene or copy 
number variant (CNV) may be giving the effect of duplication in the PQBP1 gene. 
Having a smaller footprint, qPCR hybridization may possibly be more specific.  MRC 
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Holland has had probes in the past that produced unusual results, removed them from 
the kits and replaced them with a potentially better performing probe. A new MLPA 
test may clarify this contradiction.  
Later, a serendipitous find during MECP2 MLPA diagnostic testing was added 
to this project due to the interest in duplications. This duplication is in the Xq25 region 
and spans the genes BCORL1, ELF4, AIF and RAB33A. The affected female has a 
phenotype resembling Rett syndrome, but with no mutation in either MECP2 or 
CDKL5. How one or more of the duplicated genes causes a similar phenotype to Rett 
syndrome was addressed by qPCR and RT SuperArray. Looking for interactions among 
genes, dosage changes on a broader scale were explored to determine if there might be 
a pattern to the genes misregulated that cause intellectual disability.  There may be 
concerted expression directed by one or more genes in the pathway. When two genes 
control the expression of the same group of genes in the same pathway by some linking 
factor, they may give similar results in clinical findings.  
There were other X-linked duplications and deletions discovered during the 
course of this study that appear to be clinically significant. The screening of 300 
patients from two cohorts, males with ID and hypotonia and male probands with a 
suspected X-linked etiology, with the MRX MLPA kit by MRC Holland and the 
synthetic probe set discovered a FACL4 deletion and a patient with an FMR2 point 
mutation. There were also autosomal dosage aberrations detected at 1p36 in two 
patients with phenotypes similar to known X-linked conditions. 
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FACL4 Deletion 
 The FACL4 deletion was found on the MRX MLPA. At the time it was 
unknown that other work at Greenwood was being performed to determine the 
breakpoints of this previously detected deletion. The FACL4 deletion was an alteration 
that had been identified in a kindred with two affected males. The males were already 
being treated for Alport syndrome. In the literature, a patient with a deletion in three 
genes located at Xq22.3, COL4A5, FACL4 and AMMECR1, produced an Alport 
syndrome phenotype. FACL4 deletion alone is known to be associated with non-
specific X linked intellectual disability and alterations in the protein disrupt the 
pathway of lipid metabolism (Longo , I. 2003). The affected males were found to have 
a deletion from exon 1 of COL4A5 through exon 12 of FACL4. The MLPA data 
narrowed the breakpoint range to be between exon 10 and exon 15 of the FACL4 gene. 
Later, with sequencing the breakpoint was found to be in exon 12 of the FACL4 gene.  
FMR2 Missense Mutation 
 The FMR2 point mutation was found while screening the cohort of males with 
apparent X-linked intellectual disability with the MRC Holland MRX MLPA kit. The 
probe for exon 4 in the FMR2 gene had very low with a value of 0.07. Upon further 
investigation, sequencing identified an FMR2 c.474C>T  (p.P158S) alteration within 
the probe ligation site. The subsequent change was analyzed on the “Sorting Intolerant 
From Tolerant” (SIFT) (Ng, P. C. 2001) and Polyphen (prediction of functional effect 
of human nsSNPs) programs and the change was predicted to be tolerated due to 
changes in this amino acid across non-mammalian species. To pursue the finding 
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further, a primer set was designed to modify the sequence to produce an XbaI 
restriction site if the individual was positive for the c.474 C>T change. 658 normal 
controls were restricted and there were 12 positives found, but upon sequencing all 
were found to be normal.  This result assists in making a better case that this change 
may, in fact, be the cause of the features in the patient. Expansions in the triplet repeat 
associated with methylation of FMR2 are quite rare, and are reported 25 fold less 
common than FMR1 triplet repeat expansions associated with Fragile X syndrome 
(Brown, W. T. 1996), (166 Knight, S. J. 1996). The phenotype of this patient is 
compatible with an FMR2 related diagnosis, with the main clinical features being lack 
of dysmorphic features, speech delay, reading and writing problems, learning 
difficulties and behavior concerns (Knight, S. J. 1996). Most IQ tests identify them to 
be low normal or mildly retarded, with an average of 70, but the range is broad and 
some are apparently normal suggesting tissue mosaicism (Brown, W. T. 1996). FMR2 
missense mutations have not been reported in the literature, likely due to the rarity of 
trinucleotide expansions and subsequent lack of interest from a sequencing standpoint 
in this gene. An increased number of normal controls are necessary to be more 
confident about the potential pathogenicity of the point mutation detected in this case. 
The patient with the FMR2 point mutation has developmental delay, delayed speech, 
delayed motor skills, and learning problems. The unaffected mother of the child was 
sequenced and found to be a carrier. Later, the maternal grandparents were sequenced 
and the grandmother was found to have the change but is also unaffected. In the clinical 
records it was found that the X inactivation of the mother was normal. There are no 
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other family members on the maternal side exhibiting learning and developmental 
disabilities making it difficult to establish segregation of the alteration with disease. In 
the future, we hope to identify additional maternally related males that may be useful in 
determining with greater certainty, the clinical significance of this alteration. 
GDI1 and PQBP1 Duplication 
 Both GDI1 and PQBP1 appeared to be duplicated by MLPA in one affected 
patient. However, qPCR was only able to confirm duplication in the GDI1 gene, but not 
in PQBP1. Alterations in these genes are known to cause intellectual disability 
(Madrigal, I. 2007). It is unclear if this finding is the cause of disease.  Expression of 
the two genes needs to be explored to verify they are in agreement with the qPCR data. 
MRC Holland now has kits that screen other regions of both genes that may help to 
clarify the initial findings.  
Synthetic MLPA Probe Set 
The design and development of the synthetic MLPA probe set afforded the 
ability to find dosage aberrations in X-linked genes that are usually only sequenced 
during the course of diagnostic testing. The most significant finding with the synthetic 
probe set was a partial duplication in a patient from the ID with hypotonia cohort. In 
this kindred, there are three affected males in two generations that exhibit features of 
ATRX syndrome. ATRX syndrome is caused by loss of proper XNP protein function 
(Villard, L. 1997). Initial sequence-based XNP diagnostic testing was unable to confirm 
the clinical diagnosis in this family. The obligate female carriers were tested for X-
inactivation status and were highly skewed, which is consistent with the clinical 
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diagnosis in the males. Only after designing a synthetic MLPA kit that included several 
probes for the XNP gene was the partial duplication discovered. The proband in this 
family had intellectual disability, hypotonia and suspected X-linked etiology. Other 
family members were tested by MLPA with affected males and obligate carrier females 
being concordant for the XNP duplication. The breakpoints of the duplication were 
refined using qPCR, with results indicating that the duplication only affects the XNP 
gene.  The flanking genes FGF16, ATP7 and PGK1 were all found to have normal 
dosage. Using qPCR and working inward from the ends, moving across the XNP gene, 
the duplication was found to span from exon 2 through 31. Due to the highly repetitive 
nature of the introns the breakpoints were found to lie intronic between exon 1 and 2 
within a 2,699 base span and between exons 31 and 32 within a 7,480 base region. Alu 
repeats were prevalent in the breakpoint areas and this repetitive region, which made 
developing further qPCR primers to define the breakpoints at the nucleotide level 
impossible. These Alu repeats are the probable cause of the duplication. On further 
review, the MLPA probe for XNP exon 2 appeared unreliable due to giving false 
positives on large number of samples and the initial results for this single exon were 
discounted. Each XNP exon 2 positive was further studied by qPCR and determined to 
be false, giving confidence that there were no other XNP duplications overlooked by 
this study. 
 Duplications have been found in other X-linked genes causing mental 
retardation (Bauters, M. 2008), (Wang, N. J. 2008), (Ahn, J. W. 2007), (Depienne, C. 
2007), (Kirchhoff, M. 2007), (Madrigal, I. 2007), (Thienpont, B. 2007), (Torres-Juan, 
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L. 2007), (Sharp, A. J. 2005), (Woodward, K. J. 2005). The MECP2 gene located at 
Xq28 is associated with Rett syndrome in females. Mutations and loss of function of 
the gene is characterized in females by a period of normal development for the first 6 to 
18 months followed by progressive deterioration and degenerative mental retardation 
(Chahrour, M. 2007), (Villard, L. 2007), (Moretti, P. 2006). A loss of MECP2 causing 
Rett syndrome in males is typically thought to be an X-dominant condition that is 
expected to be lethal in hemizygous males (Van Esch, H. 2005) (Moog, U. 2005). 
Duplications of MECP2 causing overexpression of the gene are found in males with 
syndromic mental retardation. Males with MECP2 duplications are quite different than 
their female Rett counterparts. They clinically exhibit hypotonia at birth and develop 
symptoms with psychomotor developmental delay occurring very early in life. Later in 
life other common symptoms include hypotonia that gives way to spasticity, 
predominantly of the lower limbs seizures and recurrent infections. MECP2 profiles an 
example of the difference in the phenotype that may be derived from over-expression 
versus loss of function in genes (Bauters, M. 2008), (Van Esch, H. 2005). The XNP 
gene expression status of the K8922 family with the XNP duplication is one that is the 
same as the phenotype caused by mutations that delete, truncate or inactivate ATRX 
protein (Gibbons, R. 2006), (Villard, L. 1997). The Northern blot revealed the cause of 
disease was not due to two-fold expression of the XNP gene, but rather a nearly 
complete loss of XNP expression. Our observations are consistent with the loss of 
normal XNP transcript due to a position effect of the duplication. At this time, 
delineation of the location and orientation of the duplication is not complete. What is 
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clear is that loss of ATRX protein causes the clinical presentation in the affected males 
of this family. The Nimblegen X-Array had limited coverage in the XNP region and 
was deemed supportive but not conclusive evidence for the duplication. This array 
system also noted a 244kb duplication centromeric to the XNP gene.  CGH using the 
OGT X-Array clearly confirmed the MLPA and qPCR duplication findings. This 
platform failed to confirm the other centromeric duplication found by the Nimblegen 
array. High-resolution mapping of the XNP duplication breakpoints has proven to be 
difficult due to highly repetitive sequence found in this region, particularly in the 
intronic regions containing the suspected endpoints. It is the repetitive nature of these 
areas that may have lead to this intragenic duplication. In highly homologous segmental 
duplications, an enrichment of Alu sequences has been found in the vicinity of the end 
points and in 27% of these duplications, they terminate within an Alu repeat 
(Woodward, K. J. 2005). While designing qPCR primers for intronic XNP sequences, 
BLASTS (NCBI) many times brought up Alu sequence. DNA repair mechanisms of 
double stranded breaks (DSBs) repaired by homologous recombination and non-
homologous end joining can cause deletions and duplications. During crossing over 
mispairing between homologous segments, strand slippage and unequal sister 
chromatid exchange can also generate deletions and duplications.  
High resolution of the duplication end points cannot be resolved due to the 
repetitive nature of this area and the OGT array does not have representative data points 
in the 5’ area between exons 1 and 3, but does confirm that exon 31 is the last exon of 
the duplication. Duplications play an important role in mental retardation and under 
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expression of the XNP protein appears to be the causative agent of ATRX syndrome in 
this family (Thienpont, B. 2007). Other similar cases of novel duplications interfering 
with synthesis of normal transcript from X-linked genes will likely become apparent 
with the implementation of high-resolution dosage based methodologies. These 
duplications will likely produce a similar phenotype to nonsense mutations and 
deletions. Duplications that are responsible for a two-fold increase in expression in this 
gene may very well lead to a clinically distinct phenotype. We conclude that much is 
yet to be learned about gene duplications and their mechanisms that cause disease.  
L1CAM/NEMO Duplication 
 An L1CAM/NEMO duplication was found using the synthetic MLPA kit in the 
hypotonia cohort and was subsequently tested on the MRC Holland MECP2 MLPA kit 
for confirmation. Instead of independently doing follow up with this find, it was turned 
over to a project being conducted at the Greenwood Genetic Center on MECP2 
duplications in males. This work which resulted in two papers: Recurrent infections, 
hypotonia and mental retardation caused by duplication of MECP2 and adjacent region 
in Xq28 (Friez, M. J. 2006) and Nonrecurrent MECP2 duplications mediated by 
genomic architecture-driven DNA breaks and break induced replication repair (Bauters, 
M. 2008). Xq28 duplications that include MECP2 appear to be variable in length and 
involve different flanking genes from patient to patient. The clinical findings are all 
very similar in males with these duplications and these features are due to the MECP2 
gene being involved in each case. Therefore, it appears that MECP2 plays the largest 
role in most of the features of this syndrome. The MECP2 duplications and the XNP 
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duplication have many features in common. Included in these features are the degree of 
Alu interspersed repeats that appear to be high at each breakpoint in the XNP 
duplication. Contrary to the MECP2 GC rich region interspersed with Alu, the introns 
of XNP have long runs of As and Ts with Alu repeats interspersed. The size of the XNP 
duplication (244 kb) is slightly larger than the MECP2 duplications that range from 0.3 
to 2.3 Mb. This may be an artifact of the large size of the XNP gene. The XNP 
duplication is contiguous and does not appear to be a part of a larger complex 
rearrangement (Bauters, M. 2008). 
1p36 Duplications and Deletions 
1p36 deletions are known to cause developmental delay and intellectual 
disability (Battaglia, A. 2008), (D'Angelo, C. S. 2006), (Yu, W. 2003), (Shapira, S. K. 
1997). We considered the SKI gene a candidate gene for a Rett-like phenotype and 
using this gene located at 1p36 as an autosomal control on the synthetic MLPA kit 
allowed simultaneous dosage determination in this region. Of the accumulative results 
from all the cohorts screened, five patients were found to have a 1p36 deletion or 
duplication. Two of the five patients confirmed by array CGH and/or FISH. Of the 
three remaining, one patient had a limited amount of DNA available and the family was 
out of contact for a blood redraw and two samples were deemed to have degraded 
DNA. These samples were run on the MRC Holland MLPA MECP2 kit to address the 
DNA data integrity concerns and failed. Degraded DNA is known to give false readings 
with MLPA and these findings are now considered false positives.  
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The two male patients, #60175 (from the L1CAM sequencing negative cohort) 
and #56560 (from the ATRX sequencing negative cohort) confirmed on the MRC 
Holland 1p36 MLPA kit, which became available approximately a year after than these 
initial findings. Although his routine karyotype was normal, the #56560 patient data on 
the 1p36 kit was interpreted as a complex rearrangement with one duplication and two 
deletions. His phenotype included developmental delay along with severe intellectual 
disability and respiratory infections. His physical features of clinical interest were a 
broad nasal bridge, mild to moderate hypotonia, V-shaped mouth and a short neck. This 
phenotype is very reminiscent of ATRX syndrome except for the respiratory problems 
that appear to be similar to these seen with MECP2 duplications. With good reason, 
most of his testing to date had focused on genes on the X chromosome. This patient 
also had the Spectral Genomics Array CGH test to sort out what appeared to be noisy 
MLPA data. MLPA is normalized data and when duplications are detected other data 
points not involved drop below the normal range of 1.0. With deletions, normalized 
MLPA data points not involved in the deletion rise above the normalized value of 1.0. 
This patient having one duplication and two deletions made it very difficult to sort the 
artifacts of normalization from the real duplication and deletions.  The array CGH 
confirmed the MLPA findings plus added another deletion on the q arm of chromosome 
1. The significance of this deletion is unknown. The GGC Cytogenetic Laboratory ran 
FISH only on the p arm of chromosome 1. This confirmed the larger duplication and 
deletion, but did not find the smaller deletion due to technical limitations. The parents 
of # 56560 were found to be normal on the MRC Holland 1p36 MLPA.  It would be 
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very difficult to single out one of these deletions or duplications as the cause of the 
disease, and one must assume that the gains and losses found in these genes all 
contribute in some way to the phenotype.  
The second patient (#60175) has severe intellectual disability, hydrocephalus, 
delayed speech, delayed motor abilities and seizures. He originally came in for L1CAM 
testing. He was found positive for a 1p36 deletion with both the synthetic and the MRC 
Holland 1p36 MLPA. Unlike the former patient this deletion was singular, large and 
covered approximately 3-4 MB. The Spectral Genomics Array CGH was performed 
and confirmed the deletion found by MLPA. This patient also had a second array run, 
the Agilent 4X44K Oligo Array, to confirm the previous findings. Clinical significance 
is clear in this region because the deletion is quite large and appears to be contiguous, 
even though there are many known smaller CNVs located within the deletion. The 
FISH data confirmed the array data and a report sent to the attending physician stating 
this deletion was likely the disease-causing agent in this patient.  
The two very different presentations of disease caused by duplications and 
deletions in the 1p36 region of these two patients demonstrate how dosage aberrations 
can produce very diverse clinical conditions. Both patients were found using the 
synthetic probe set, one with duplication, and the other with a deletion of the SKI gene. 
Although each patient has a deletion(s), these deletions were in slightly different 
regions on chromosome 1 and did not include many of the same genes. The #56560 
patient’s MLPA data found the duplication included TNFRS4, TNFRS18, CAB45, 
SCNN1D, DVL1, GNB1, GABRD, SKI, PEX10, FLJ10782, and ARMD2 genes and the 
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two deletions included DFFB, NPHP5, ICMT, CAMT1, TNSFS, PARK7, and then 
RIZ1, PRMD2 and CASP9. The #60175 patient’s MLPA data shows a contiguous 
deletion with the loss of HES4, GIP2, AGRN, TNFRSF4, TNFRSF18, CAB45, 
SCNN1D, DVL1, GNB1, GABRD, SKI, PEX10, FLJ10782, ARMD2, PRDM16, TP73 
and DFFP.  One patient (#56560) had SCNN1D, DVL1, GNB1, GABRD, SKI, PEX10 
duplicated while the other (#60175) had these genes deleted. The changes in the # 
56560 patient again adds differences in gene dosage, both up and down in a small 
region. The clinical differences among these patients (#56560 and #60175) are caused 
by multiple variables. #60175 has a 1p36 deletion and which is characterized by severe 
intellectual disability, delayed growth, seizures, malformations, hearing and vision loss, 
distinct facial features, congenital heart defects and nervous system anomalies. These 
features may or may not be present, depending on the size of the deletion. Intellectual 
disability varying from mild to severe is one such feature that is dependent on the size 
of the deletion.  #56560 having one duplication and two deletions has features that are 
due to the different components of a complex rearrangement. 
Xq25 Discussion 
 
During routine diagnostic MECP2 MLPA testing, a female was discovered to 
have an Xq25 duplication based on an abnormal ratio of a control probe. Born to 
normal parents, the proband has developmental delay, hypotonia, displays hand 
wringing and when upset breathing becomes unusually rapid. She has a normal MRI. 
Her phenotype is similar to that routinely seen in females with a loss of MECP2 protein 
function (Jordan, C. 2007), (LaSalle, J. M. 2007), (Nikitina, T. 2007). By array, the 
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duplication was found to start at base 128,889,500 to 129,165,000 on the X 
chromosome, making a 275.5Kb duplication. After analysis of the breakpoints on the 
Nimblegen array, the duplication was found to encompass four known genes and three 
unknown genes. This study focused on the four known genes, BCORL1, ELF4, AIF, 
and RAB33A.  Breakpoint analysis from the array data appear to be in regions that are 
void of genes, therefore gene disruption, protein truncation or a loss is less likely to 
contribute to the phenotype.  Using qPCR it was found that two of the four known 
genes were over- expressed due to the duplication. This is interpreted to mean that 
over-expression of either and one or both may be the cause of the disease. Duplications 
in the X chromosome have been shown to cause disease in females when the affected 
chromosome is not preferentially inactivated (Muers, M. R. 2007), (Tachdjian, G. 
2004), (Armstrong, L. 2003), (Portnoi, M. F. 2000), (Monaghan, K. G. 1998), (Garcia-
Heras, J. 1997). Initial qPCR findings show normal expression in BCORL1 and ELF4 
and over-expression in AIF and RAB33A. To determine which X the proband inherited 
from each parent, the father was tested to use his androgen receptor repeat length from 
the XI assay as a marker to discriminate between the maternal vs. paternal X 
chromosome (Allen, R. C. 1992). The mother had normal X inactivation and both 
parents were normal on the MRC Holland MECP2 MLPA, which initially identified the 
duplication. This makes the Xq25 duplication appear to be a de novo rearrangement. 
The X inactivation of the proband was found to have a 92:8 ratio. The X inactivation 
studies implied that the paternal X was the one being preferentially expressed in the 
daughter. It is known that females with a duplication on one X chromosome often have 
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preferential inactivation of that chromosome and appear normal, but these findings 
more typically occur when the duplication is familial. This implies that some X 
chromosome duplications do not cause abnormal phenotypes in females and are passed 
through generations where others cause abnormalities and are more likely de novo 
events (Garcia-Heras, J. 1997), (Portnoi, M. F. 2000), (Tachdjian, G. 2004). To further 
confirm which X, (maternal vs. paternal) was being preferentially expressed, 
sequencing was performed on numerous X-linked genes looking for a heterozygous 
coding SNP that would show skewed expression in an RNA sample. A MED12 SNP 
was identified which allowed characterization of the parents and the daughter’s 
genotype. The mother’s DNA had a C nucleotide and the father’s DNA had an A 
nucleotide and the daughter was heterozygous having both the A and the C. The normal 
control was also heterozygous having both the A and the C. The RNA was then reverse 
transcribed and sequenced using cDNA as a template. This result clarified which X is 
expressed and it appears to be in agreement with the known X-Inactivation ratio 
previously discussed. The RNA sequence showed clearly that the daughter was 
expressing the father’s X at 92% and the mother’s at 8%. This leads to the belief that 
the father’s X-chromosome is the one that is preferentially active and harbors the 
duplication that has already been implicated by demonstrated over-expression of 
RAB33A and AIF. This also suggests that the over-expression of the AIF gene does not 
cause rampant premature death in the cells. Excessive apoptotic events are predicted to 
not be compatible with life because AIF is also known to play roles in the synaptal 
complex and during early development (Laumonnier, F. 2007). Both genes, RAB33A 
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and AIF are normally inactivated on the inactive X chromosome, indicating these genes 
may be dosage sensitive and cause for disease when misregulated (Brown, C. J. 1997). 
Given the expression of RAB33A and AIF two additional studies were pursued. 
One study focused on Rab and Ras gene changes in expression while the other study 
focused on AIF and explored expression in other apoptotic pathway genes.  Both 
studies used qPCR on different platforms.  The RAB33A study focused on Rab, Ras and 
Rho genes that had the potential to be associated with the MECP2 phenotype, while the 
AIF study recognized and noted the changes caused by over-expression of AIF relative 
to other factors involved in apoptosis. 
The Rab gene family is very closely linked and many of these members interact 
and have expression levels that are interdependent upon each other (Gurkan, C. 2005). 
The Rab gene family performs essential cell duties involving trafficking, recruitment 
and endo/exocytosis of proteins. They also play a part in scaffolding, membrane 
budding, vesicle release and many more cellular functions. When these genes are 
compromised in some way, causing defects in the vesicle trafficking machinery, the list 
of associated human disorders is substantial.  The Rab cycle consisting of (REP) Rab 
escort protein, (RabGGT) Rab geranylgeranyl transferase, (GDI) RabGDP dissociation 
inhibitor, (RabGEF) Rab guanine nucleotide exchange factor, and (RabGAP) 
RabGTPase activating protein must all work in concert. A deviation in one of these 
genes that is a part of a specific Rab cycle will bring about changes in other parts of the 
system. Multifactoral conditions have already been linked to abnormalities in vesicle 
trafficking, contributing to diseases such as type 2 diabetes and Alzheimer disease, 
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while Tau, a microtubule-associated protein has been found in dementia, and 
neurodegenerative disorders (Gissen, P. 2007). The effect of multiple genes being 
misregulated in the Rab family is predicted to cause some form of phenotypic 
expression with clinically significant relevance. 
In the proband, expression studies of twenty six genes (Figure 26) thought to be 
involved with RAB33A found that twelve of these genes were over-expressed and three 
under-expressed. In comparison, a MECP2 female patient had twelve genes over-
expressed and three under-expressed. Nine of the over-expressed genes in the MECP2 
patient were also over-expressed in the Xq25 patient. There were no under-expressed 
genes that coincided. Another patient referred for ATRX testing and was found to have 
normal XNP sequencing result, displayed similar results in expression changes when 
compared to the Xq25 proband. This patient had eleven genes over-expressed and one 
gene under-expressed. Six of the eleven genes that were over-expressed coincided with 
the Xq25 patient and five matched the MECP2 proband in over-expression. ATRX is 
known to interact with MECP2 (Nan, X. 2007) and this patient may have another 
mechanism impeding that interaction causing the profile seen on qPCR. The under- 
expressed gene in the pseudo-ATRX did not match the Xq25 or the MECP2 probands. 
This data is supportive that there may be a reproducible profile of certain genes that are 
affected in some intellectually disabled populations. Review: Figures 27.A&B and 
28.A&B. 
 MECP2 gene mutations with loss of protein function cause Rett syndrome a 
neurodegenerative developmental disorder in females. In males, MECP2 over-
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expression due to gene duplication causes a different developmental disorder. 
Therefore, it appears MECP2 is extremely sensitive to dosage differences with loss of 
function mutations and whole gene duplications manifesting different phenotypes. 
MECP2 has been found to be primarily an activator of over 2500 genes and secondarily 
a repressor of over 400 in the hypothalamus in mice (Chahrour, M. 2008). MECP2 
binds to the promoters of genes with CREB1. CREB1 a transcriptional activator is 
found at the promoter of genes MECP2 appears to activate. MECP2 also activates 
CREB1 by binding its promoter. This also produces a CREB1 induced microRNA 
(miR132) that represses MECP2 translation, thereby, making a negative regulatory 
loop. MECP2 repression does not involve CREB1. It is not surprising to find that 
mutations in the genes regulated by MECP2 or CREB1 produce a Rett-like phenotype 
when disrupted.  An example in mice is the ataxin 2 binding protein 1(A2bp1), a gene 
that regulates splicing of neuronal genes, is a repression target of MeCP2.  Disruption 
of A2BP1 has been identified in patients with ID and epilepsy and autism susceptibility. 
Another gene, GAMT is a target of MECP2 activation. Patients with GAMT deficiency 
suffer severe ID, absent or limited speech development, seizures and hypotonia 
(Chahrour, M. 2008).  
By searching literature and following pathways of genes that influence one 
another led to the following logic.  There will be genes in common that demonstrate 
abnormal expression levels that are due to either loss of MECP2 function or RAB33A 
over-expression. RAB33A is a co-regulator of RAB3A, which in turn is a well-
documented hub. RAB1A, which is over-expressed in the Xq25 proband, interacts with 
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CREB1 the co-activator of MECP2. MECP2 is shown to up regulate RAB3A. MECP2 
interacts with CREB1 as a co-activator but not as a repressor. Loss of MECP2 would 
lead to the loss of protein of the genes activated by both MECP2 and CREB1. Genes 
that MECP2 represses on its own would be up-regulated, while genes regulated by 
CREB1 alone may be up-regulated due to more CREB1 available due to the loss of 
MECP2 interactions.   Searching the database BIOGRID, a database that has pulled 
data of gene interactions together from major publications, making available protein 
interactions via a search is a quick and powerful tool to use for gene interactions (Ay, 
N. 2007). BIOGRID has found that CREB1 interacts with RAB1A and the Chahrour et 
al. paper has determined and validated the CREB/MECP2 relationship as well as a 
MECP2/RAB1A relationship. Another gene over-expressed in the Xq25 proband is 
RABAC1. Many genes interact with RABAC1, these are GDI1, RHOA, RAB5C, RAB7, 
RAB22A, RAB4A, RAB6A, HRAS, NIF3L1, RAB17, RAB33A, CABC1 and FRX2. 
RABAC1 does not control expression levels directly, but plays a large role in the 
synchrony of the cell trafficking of proteins. RABAC1 is a Rab acceptor hub that directs 
protein trafficking in the cell, making it a good candidate for causing disease.  All of 
these genes mentioned were chosen first from literature searches and deemed good 
candidates for abnormal expression in the Xq25 patient due to RAB33A over-
expression. Later, BIOGRID (Ay, N. 2007) confirmed the linked interactions of these 
proteins, plus added to the number of genes that may be affected due to an increase or 
decrease of interactions that may affect many other proteins downstream. The 
downstream cascade grows as a consequence of over expression in these twelve genes 
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in the Xq25 proband and the effect is magnified when looking at other genes that may 
also interact. 
The following interactions are taken directly from the BIOGRID database. In 
the results, the CABC1 gene was over expressed in the MECP2 patient and the Xq25 
patient and this gene is known to associate only with RABAC1. FXR2 is also over-
expressed in the MECP2 and Xq25 patients and interacts with 66 other known genes, 
thereby causing a potential cascade of dysregulated pathways. The MECP2 patient is 
shown to have up-regulation of the GDI1 and MYO5A genes where the Xq25 patient 
does not, but both are up regulated for NIF3L1.  NIF3L1 interacts with 38 other genes 
including an apoptosis repressor gene NOL3.  PAK1 is under-expressed and RAB27A is 
low in the Xq25 patient. RAB27A interacts with 42 other proteins, some of which are 
expressed only in the brain. Genes over-expressed in the Xq25 patient are RAB1A, 
RAB11B, RAB17, RAB22A, RAB23A, RAB33A, RAB3A WASF1 and RAB40B; whereas, 
the corresponding genes over-expressed in the MECP2 patient are RAB33A, RAB1A, 
RAB22A, RAB23A WASF1 and RAB3A.  The most important gene is likely RAB3A as it 
interacts with 35 other genes and is co-regulated with RAB33A and up regulated by 
MECP2.   
It should be noted that the expression of the NIG3L1, RAB11B, RAB17, 
RAB22A, RAB33A, RAB40B, SNP29, and RABAC1 is over-expressed in the patient that 
came in for ATRX testing and found to have normal sequencing.  In this patient, the 
only other gene over-expressed that is different from those found in the Xq25 patient is 
the SNAP29 gene. This gene interacts with 15 other proteins including some found in 
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brain, but mostly those that have vesicle-membrane-fusion properties. These aid the 
vesicle to fuse with the membrane, become one, and with this secrete the cargo of the 
vesicle to the outside of the cell. In the synaptal complex this is a crucial function for 
normal brain functioning.  
The FMR1 patient has a high level of RAB17, RAB40B, WASF1 and low levels 
of RAB23A. RAB17 interacts with chromatin remodeling protein CHMP6 and WASF1 
interacts with 11 other proteins. Little is known about RAB23A as there is no data for 
known protein interactions. The unknown patient had a very different profile than the 
others studied. The only genes over-expressed were RAB3A and RAB40B while 
RAB33A and RAB4B were under-expressed. The MECP2 patient also had RAB4B 
under-expressed. 
The RAB genes in this study and those in the Chahraur et al. paper (167 
Chahrour, M. 2008) provide more insight into genes regulated by MECP2 and how a 
similar phenotype might be generated (Table 8).   
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Table 8. 
SUMMARY OF GENES FOUND REGULATED BY MECP2 
THAT INTERACT WITH RAB FAMILY GENES 
  1 2 3 4 5 
  
# GENE
INTERACTIONS
 
 
ACTIVATED 
BY MECP2 
UP 
REGULATED 
BY MECP2 
DOWN 
REGULATED 
BY MECP2 
PERCENT 
GENE 
INTERACTIONS 
WITH MECP2 
FXR2 53 8 4 1 25% 
NIF3L1 34 3 2 0 15% 
PAK1 27 2 1 1 15% 
WASF1 6 1 0 0 17% 
RAB3A 17 1 2 0 18% 
RAB1A 16 4 0 1 31% 
RAB27A 20 3 0 2 25% 
RAB11B 1 0 0 0 0% 
RAB17 3 1 0 0 33% 
RAB22A 1 0 0 0 0% 
RAB33A 4 0 1 0 25% 
Table 8. Summary of genes regulated by MECP2 that interact with 
Rab family genes. These genes were under or over-expressed in this study 
in the Xq25 patient and have interactions with other genes. Of these genes 
in column 1, some are regulated by MECP2, columns 2, 3, and 4  
(Chahrour, M. 2008). Column 5 is the percent of the total number of gene 
interactions regulated by MECP2 that also interact with the specific Rab. 
  
 
There are eight of the genes in this Rab study that are listed in the Chahrour et 
al. paper. These regulated genes are RAB1A, FXR2, NIF3L1, SNAP29, RAB27A, 
RAB3A, PAK1 interacting protein and WASF1. The cascade continues as these genes 
have interactions with numerous other genes that are also regulated by MECP2. Each of 
the genes in this study interacts with a secondary level of genes. The number of 
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secondary interaction genes is listed in Table 4. and a percentage of these are activated, 
up-regulated or down-regulated by MECP2. The percentage is the number of genes 
regulated by MECP2 over the total number of known gene interactions for that specific 
gene. Specific genes may be seen in Appendix F. Some of these genes are recognized to 
be associated with intellectual disability diseases whereas the unknown genes may be 
good candidates for further study. The patterns of expression with the qPCR of the 
clinically different patients in their Rab and Ras genes remind us that dysregulation of 
one gene is not likely alone in causing disease. It is appreciated that many genes, acting 
in concert with the interactive pathways cause disease. This phenomenon is again seen 
in a very different gene, AIF. This gene is known to play a role in synaptic protein 
complexes and is crucial for proper development (Delettre, C. 2006), (Modjtahedi, N. 
2006), (Vahsen, N. 2006), (Ishihara, N. 2005), (Vahsen, N. 2004), (Klein, J. A. 2002). 
There is up and down regulation occurring from the over-expression of AIF in the Xq25 
patient. The RT2 Profiler TM PCR SuperArray clearly shows there are genes over and 
under-expressed in other apoptotic pathways in this patient that are not in the normal 
controls.  There were a small number of genes that were over-expressed to questionable 
degrees in one or the other control and these genes were removed from analysis as 
being false positives. Many runs would have to be done for significant statistical 
analysis, but exploring a new methodology while visualizing the expression status of 
the apoptosis pathway in the Xq25 patient was accomplished. The list from the RT 
Profiler Super array of genes found in apoptosis pathways that appear to be up-
regulated compared to two normal controls are BCL2, BIRC3, BNIP3, TNSFRSF10B, 
 133
TRAF3 and GAPDH. Surprisingly there were more genes down-regulated with AIF 
over expression. These down regulated genes are; BAG1, BCL2L11, BID, NAIP, 
BNIP3L, CARD6, CARD8, CASP1, CASP10, CASP4, CASP5, CASP8, CASP28, 
CD40LG, DAPK1, FASLG, IGF1R, LTBR, MCL1, PYCARD, CD27, TNFSF10, 
TNFSF8 and TP53BP2. It appears there are mechanisms that are in place to keep 
apoptosis pathways in check, suggesting AIF is a repression regulator of other apoptotic 
pathways. It is known that when a cell signals damage, an apoptotic cascade is set in 
motion. If one apoptosis mechanism falls short then another will initiate. Once cellular 
pathways commit to one mechanism or pathway, it will accomplish the process 
(Munoz-Pinedo, C. 2006), (Chu, C. T. 2005), (Ishihara, N. 2005), (Joza, N. 2001). It is 
speculated that with a large number of Caspase genes down regulated, that AIF has 
some repressor activity that prevents the Caspase apoptotic pathway from initiating. 
These apoptosis genes are not Rab, Ras or MAPK like those seen throughout this 
project, but it is interesting to note that there are also global changes initiated by one 
gene being misregulated. The idea of one-gene one- disease may be replaced by a 
specific set of gene expression changes that lead to one disease. As qPCR and 
expression arrays become more commonplace, the mechanisms and interactions of 
genes among and between each other will be better understood. 
Discussion of Methods Used 
 
Both the commercial MRX and the synthetic MLPA kits were cost effective means 
to screen the genes of interest. The total number of patients screened was 1152 with a 
cost in materials of approximately $10/ patient. However, this type of screening has its 
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limitations due to the relatively small number of loci actually being targeted. MLPA 
probes are designed to reveal changes in copy number in specific genes or regions and 
if changes are present, give high confidence that this is a disease causing change. 
Whereas, Array CGH has much more potential to screen a larger number of genes, 
although, copy number variations often make determining the significance of novel 
findings more difficult. At the time of this study the cost of Array CGH would have 
been 30-50 fold higher compared to MLPA. Although Array CGH pricing has 
decreased in the last year it would have been still more costly and cumbersome than the 
MLPA. The decision on choice between these methods for dosage differences should 
be carefully determined by the size of the group to be screened, if the genes to target 
are specific or unknown and how much money is available to do the screening. 
Specialized equipment is also needed for Array CGH, an ozone scrubber, and a chip 
reader with software and lab-ware for the processing of slides. MLPA on the other hand 
uses a PCR machine and a sequencer, which is common equipment in most molecular 
labs. The positive side of Array CGH is that it covers the whole genome not just 
specific areas and breakpoints can be narrowed down faster by careful inspection of the 
data point changes if the coverage is good.  Dosage differences are compared to copy 
number variants to determine if the change is possibly disease causing. Many times 
both MLPA and Array CGH need to have follow-up testing such as FISH or qPCR to 
confirm the findings. FISH may provide answers to the location and orientation of the 
copy number change and may help define breakpoints and the genes involved. 
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Whereas, qPCR can narrow the breakpoint region and can perform expression analysis 
for each gene involved and can determine which genes are probable cause of disease. 
OGT X chromosome array is a specific array for genes on the X chromosome. This 
type of array gives much more specificity and has better coverage than the whole 
genome arrays if one is looking for X-linked dosage differences. The ability to 
determine breakpoints with this array system is done more easily due to increased 
coverage. The cost is reasonable, but the array equipment is still needed. This system 
may have been the best choice if it had been available and cost was not a factor for this 
initial study. 
qPCR appears to be very reliable. It is fairly fast and effective in screening large 
numbers of samples or genes. Using this method to confirm MLPA data led us to find 
that many of the positive MLPA’s were false positives. Most were exon 2 deletions and 
duplications of XNP due to the MLPA probe not quantifying correctly. To close in on 
the breakpoints of the XNP gene, qPCR was a good method of choice. When the 
sequence became too repetitive it was easy to determine if the data was reliable or not. 
This was apparent when normal controls had odd values and differed insignificantly 
from one run to the next.  
qPCR for expression studies is reliable if certain measures are taken to limit as 
many variables as possible. Primers must have an efficiency 90% or above. All samples 
are made into cDNA, quantified and then diluted to 30ng/ul +/- 1 ng/ul. These samples 
were from the same source, meaning that RNA’s from cell lines and blood cannot be 
compared on the same run. Cells appear to have different expression levels of mRNA 
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than blood and the two should not be compared to one another in the same experiment. 
All experiments except Northern Blots where larger quantities of mRNA were needed 
used blood as the RNA source. The RNA was DNased due to having large differences 
(6 fold or more) in expression among controls. Once DNased, values were more 
uniform across controls and the sample were used with confidence of having no DNA 
contamination. qPCR is so sensitive it is obvious when something is not right with the 
experiment. qPCR should be expanded to screen moderate sized cohorts for dosage and 
expression levels. A qPCR machine is needed as extra equipment, but once this is 
acquired it is reasonable in cost to perform.  
The qPCR array system which is used to target specific areas or pathways, have 
more data points than the MLPA, but less than the Array CGH. This method may be 
more effective in increasing the gene coverage in large cohorts at a reasonable price. 
Expression studies done one gene at a time are done with a comfortable degree of 
confidence if as many variables are taken out of the experiment as possible, as 
mentioned above. Many genes may be screened at one time and by repetition statistical 
significance may be achieved. Setting up a 96-well template with primers dried in the 
wells and then stored allows for the reduction of set up time. Reproducibility should 
increase and finer mapping should be achieved by choosing specific areas of interest. 
Once a set of primers is validated and primer efficiency known, it can easily be placed 
in a group of gene primers to do a mass screening or in a group for targeted screening. 
Standard deviation differences would be eliminated as the reaction master-mix of sybr 
green, that is multi-channel pipetted into the plate at equal volumes, has the cDNA 
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already added.  This accomplishes the same amount of template being put into all the 
wells and therefore takes away another experimental variable. This can be used not 
only for expression studies, but also for gene dosage in specific regions. This array 
system can be used for diagnostic purposes or general research. More work is needed to 
develop and expand this method for later screenings.  
Discussion of Future Experimentation 
 
The diverse projects that came out of the initial research have opened up new 
questions and ideas. Some of the strengths and weaknesses will be discussed and what 
further experimentation might be done to answer some new questions that have been 
developed during the course of this study.  
The beginning of this study starting with MLPA screening, with the first screening 
of two cohorts consisting of 95 males exhibiting hypotonia and varying degrees of 
intellectual disability (ID) and another of 205 (194 males and 11 females) individuals 
with nonsyndromic ID and suspected X-linked etiology were screened by the MRX and 
synthetic MLPA.   Another five cohorts totaling 552 patients with normal sequencing 
results for one of the X-linked genes (XNP, L1CAM, UBE3A, FGD1 and STK9) were 
only screened by the synthetic MLPA. MRX MLPA was not used to test this normal 
sequencing results cohort.  In the future these five cohorts should be screened by the 
MRX MLPA to be more confident that there are no dosage aberrations in the genes 
covered by this kit.  
The findings of the initial screening, the GDI1 and PQBP1 duplications, the FACL4 
deletion, and the FMR2 missense mutation were all found on the MRX MLPA, 
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whereas, the XNP duplication and the 1p36 duplications and deletions were found using 
the synthetic kit. The GDI1 and PQBP1 duplications had significantly high values on 
the MLPA. The PQBP1 duplication would not confirm on the qPCR, whereas the GDI1 
duplication did. With no further use of this MRX MLPA kit until recently, screening of 
another cohort found that the PQBP1 duplications and now deletions appear in 20% of 
the samples.  These PQBP1 probes will be taken from further consideration. If a PAX 
tube for RNA can be acquired, expression studies will be performed to determine if the 
GDI1 duplication alters transcript dosage and may be the cause of disease. The XNP 
duplication was explored to a great extent. A Western blot would have confirmed 
further the loss of transcript but the mechanism and cause of disease was quite clear 
with the Northern blot. Due to the high degree of Alu sequences in the introns of the 
XNP gene where the duplication endpoints appear to be, this intragenic duplication 
mechanism may be of unequal crossing over or strand slippage. FISH data, which is 
forth coming will give more insight on the mechanism of this duplication event. 
The COL4A5-FACL4 deletion was the known cause of disease in the two brothers 
and no further investigation is needed.  
The FMR2 missense mutation was found to segregate in the maternal females, 
giving them carrier status, but there were no other family members screened to see if 
the mutation was in the normal males. There were circumstances that did not allow for 
additional family members to be screened at the time. Possibly in the future, and no 
other family members have the mutation, more normal controls should be screened due 
to the rarity of changes in the FMR2 gene.  
 139
The 1p36 duplications and deletions presented themselves like known X-linked 
diseases and this led to the testing of genes only on the X chromosome. For diagnostic 
consideration, patients with ATRX phenotype and found to have normal sequencing 
results should have X inactivation studies done on the mother. This may give insight to 
further testing on the X chromosome such as duplication testing or if the mother is not 
skewed, referred to 1p36 testing or Array CGH.  Patients with a MECP2 duplication 
phenotype and found normal should be screened by the MRC Holland 1p36 MLPA kit 
or Array CGH. 1p36 deletions are one of the more common aberrations in the ID 
population, occurring in 1-5/10,000 births. The following are the many features these 
three diseases have in common (Table 9). The MECP2 males may be singled more 
easily by recurrent infections and ATRX by alpha-thalassemia, but not all patients 
present these manifestations. 
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Table 9. 1p36, ATRX and MECP2 duplications in males have features in common. 
1p36 Deletion OMIM ATRX (Orphanet Jnl of Rare Disease) MECP2 Duplications (Pediatrics)
  Many have no Alpha Thalassaemia  
Mild to severe-related to deletion size Severe  
Severe developmental delay and 
ID 
Delayed growth  Growth retardation 
Hypotonia Hypotonia Hypotonia 
Difficulties in sucking and feeding   Severe feeding problems 
NL at birth head size fails to increase NL at birth head size fails to increase  Microcephaly 
Boys have underdeveloped genitals Genital abnormalities Hypoplastic genetalia 
Seizures 70% Seizures 30% Seizures 
Cleft lip jaw or palate   Narrow Palate 
Hearing and vision impairment Sensorineal deafness/optic atrphy  
Short, broad head (microcephaly) Hypotonic face, short nose Mild facial dysmorphism 
Large fontanel Large fontanel  
Prominent forehead    
Straight eyebrows and deepset eyes    
Flat nose and nasal bridge Flat face Flat midface 
Short midface and low set ears Midface hypoplasia Ears had upturned lobes 
Small mouth with down turned
corners Large mouth, open and tented upper lip Small mouth, open and drooling  
Pointed chin and asymmetry    
Congenital Heart defects 40%    
Hydrocephalus or cerebral atrophy Neurological deterioration  
    Recurrent respiratory infections 
  Spasticity 
 
The Xq25 duplication study has found patterns to the gene expression in the Ras 
and Rab families. In this patient, the over expression in RAB33A located in the Xq25 
duplication causes a similar pattern of expression that is found in a patient with a 
MECP2 deletion. The Xq25 patient has a Rett like phenotype and was sent in for Rett 
diagnostic testing.  The over expression of one Rab gene may cause similar up 
regulation in other Rab genes due to co-regulation effects among this gene family. The 
disease NF1 has up-regulated Ras activity. How a MECP2 deletion causes a similar 
pattern is linked to the interactions with CREB the cAMP response element binding 
protein transcription factor. Downstream activation of the MAKP (mitogen activated 
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kinase protein) cascade stimulates phosphorylation of the transcription factor CREB 
and may also enhance gene transcription by phosphorylating a transcription factor 
called CBP, which has histone acetyltransferase activity. Acetylation of histones 
weakens their interactions with DNA resulting in an open configuration that promotes 
transcription.  CREB1 binds directly to the DNA but has been associated with co-
activators such as CBP and MECP2 (Johnston, M. V. 2003), (Chahrour, M. 2008). 
CREB1 is a stimulus-induced transcription factor activated by a diverse array of 
extracellular signals. CREB1 activation is enhanced by MECP2, but it is not solely 
dependent on MECP2 for its expression. Once CREB1 is activated it binds to specific 
DNA sequences CRE (TGACGTCA) in their transcriptional regulatory region and their 
expression is induced by increase in the intracellular cAMP levels. This activation also 
removes the repressive action of CREB2 (Johnston, M. V. 2003). MECP2 then joins 
CREB1 to co-activate a large number of genes (Chahrour, M. 2007).   Loss of the 
CREB1 (ATF2) protein is lethal early in life in animal models (Chen, X. 2008). It is 
well known the roles the Ras and Rab gene family plays in exocytosis and neuronal 
plasticity via dendrite formation (Flint, J. 1999). One known link of the Ras and CREB1 
is RSK2 mediated CREB phosphorylation stimulated by Ras-MAPK cascade and is 
involved with cognitive development. RAB3A and CREB were both found to be 
regulated by MECP2  (Chahrour, M. 2008). RAB3A is a small GTPase protein that 
plays a role in the recruitment of synaptic vesicle exocytosis. It is the most abundant 
Rab protein in the brain (Flint, J. 1999).  
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CREB1 expression increased as MECP2 expression increased. CREB2 inhibits 
many genes at the CRE site, with increase in CREB1 expression the repressive 
regulation of these genes would be decreased. In mice Creb1 has functionally related 
mediators of camp signaling in the nucleus, Creb1, Crem and Atf1. In Creb1 deficient 
mice, Crem is up-regulated and Atf1 partial substitutes for Creb1. In humans there 
appears too many “CREB-like genes available as well and looking for mutations 
diagnostically in these genes may prove fruitless.  Looking at the genes that are 
regulated by CRE in their promoter regions or in clusters as enhancers may give a more 
specific search. Using the CREB Target Database (Salk Institute) and sorting through 
the 20,000 plus genes screened, taking only the Rab genes found the following. This 
suggests a closer look at many of the Rab genes expressed in the brain for mutations, 
transcript expression and the pathways the play a role in.  
There is little information on which transcription factors activate MECP2 except 
that MECP2 has a CRE half site and is negatively regulated by CREB1. Further 
investigation need to be done to identify the transcript regulation of MECP2. The Rab, 
Ras and Rho genes are known to play a major role in ID. The up and down-regulation 
is controlled by mechanisms and related pathways amongst themselves and those 
associated with CREB1 and MECP2. Interestingly of the genes screened in the Xq25 
study 21 out of 26 have some degree transcriptional control from CREB1. Of those 
RAB3A, RAB4B, RAB5C, RAB6A and PAK1 all have a full CRE site in their promoter 
region. Of these five genes RAB3A was up-regulated and PAK1 was down-regulated, 
the others were normal. This strongly indicates repression and expression control by 
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these factors. MECP2 is a know repressor, but is not associated when co-activating with 
CREB1. More work is needed on CREB1 and its abilities to repress transcription and to 
understand the mechanisms and pathways. Other Rab genes with full sites may be 
candidates for ID causing genes. 
 
Table 10. CRE site = Full Site/Half Site: All occurrences of full site “H” 
(TGACGTCA) or half site “h”(TGACG/CGTCA) CREs in -5Kb-1Kb region of the 
transcription start site. “F” is a full CRE site within the promoter. t= tata box present, 
T= tata box present in this species only. 
RAB10 RAB10, member RAS oncogene family ht  NM_016131 
RAB11A 
RAB11A, member RAS oncogene 
family ht  NM_004663 
RAB11B 
RAB11B, member RAS oncogene 
family ft ht  NM_004218 
Rab11-FIP2 KIAA0941 protein h  NM_014904 
Rab11-FIP3 eferin F h  NM_014700 
RAB11-FIP4 rab11-family interacting protein 4 h  NM_032932 
RAB13 RAB13, member RAS oncogene family ht  NM_002870 
RAB14 RAB14, member RAS oncogene family H ht h NM_016322 
RAB15 RAB15, member RAS onocogene familyh  NM_198686 
RAB17 RAB17, member RAS oncogene family ht h  NM_022449 
RAB18 RAB18, member RAS oncogene family ht h  NM_021252 
RAB1A RAB1A, member RAS oncogene family h  NM_004161 
RAB1B RAB1B, member RAS oncogene family h  NM_030981 
RAB2 RAB2, member RAS oncogene family ht  NM_002865 
RAB20 RAB20, member RAS oncogene family none  NM_017817 
RAB21 RAB21, member RAS oncogene family H ht  NM_014999 
RAB22A 
RAB22A, member RAS oncogene 
family h  NM_020673 
RAB23 RAB23, member RAS oncogene family h  NM_016277 
RAB23A RAB23, member RAS oncogene family h  NM_183227 
RAB24 RAB24, member RAS oncogene family h  NM_130781 
RAB25 RAB25, member RAS oncogene family F  NM_020387 
RAB27A 
RAB27A, member RAS oncogene 
family h  NM_004580 
RAB27A RAB27A, member RAS oncogene h  NM_183234 
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family 
RAB27A 
RAB27A, member RAS oncogene 
family f  NM_183235 
RAB27A 
RAB27A, member RAS oncogene 
family h  NM_183236 
RAB27B 
RAB27B, member RAS oncogene 
family h  NM_004163 
RAB28 RAB28, member RAS oncogene family h  NM_004249 
RAB2B RAB2B, member RAS oncogene family HT H h NM_032846 
RAB2L 
RAB2, member RAS oncogene family-
like ht h  NM_004761 
RAB30 RAB30, member RAS oncogene family h  NM_014488 
RAB31 RAB31, member RAS oncogene family ht  NM_006868 
RAB32 RAB32, member RAS oncogene family h  NM_006834 
RAB33A 
RAB33A, member RAS oncogene 
family none  NM_004794 
RAB33B 
RAB33B, member RAS oncogene 
family h  NM_031296 
RAB34 RAB34, member RAS oncogene family HT h  NM_031934 
RAB35 RAB35, member RAS oncogene family h  NM_006861 
RAB36 RAB36, member RAS oncogene family ht  NM_004914 
RAB37 
RAB37, member of RAS oncogene 
family h  NM_175738 
RAB38 RAB38, member RAS oncogene family none  NM_022337 
RAB39B 
RAB39B, member RAS oncogene 
family ht  NM_171998 
RAB3A RAB3A, member RAS oncogene family H ht h NM_002866 
RAB3B RAB3B, member RAS oncogene family ht  NM_002867 
RAB3C RAB3C, member RAS oncogene family h  NM_138453 
RAB3D RAB3D, member RAS oncogene family h  NM_004283 
RAB3-
GAP150 
rab3 GTPase-activating protein, non-
catalytic subunit (150kD) ht h  NM_012414 
RAB3IL1 RAB3A interacting protein (rabin3)-like 1h  NM_013401 
RAB3IP RAB3A interacting protein (rabin3) none  NM_022456 
RAB40A 
RAB40A, member RAS oncogene 
family ht  NM_080879 
RAB40B 
RAB40B, member RAS oncogene 
family h  NM_006822 
RAB40C 
RAB40C, member RAS oncogene 
family h  NM_021168 
RAB4A RAB4A, member RAS oncogene family ht h  NM_004578 
RAB4B RAB4B, member RAS oncogene family HT  NM_016154 
RAB5A RAB5A, member RAS oncogene family h  NM_004162 
RAB5B RAB5B, member RAS oncogene family ht  NM_002868 
RAB5C RAB5C, member RAS oncogene family HT h  NM_004583 
RAB6A RAB6A, member RAS oncogene family H f h  NM_002869 
RAB6B RAB6B, member RAS oncogene family ht  NM_016577 
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RAB6C RAB6C, member RAS oncogene family none  NM_032144 
RAB7 RAB7, member RAS oncogene family HT h  NM_004637 
RAB7L1 
RAB7, member RAS oncogene family-
like 1 ht h  NM_003929 
RAB9A RAB9A, member RAS oncogene family ht  NM_004251 
RAB9B RAB9B, member RAS oncogene family h  NM_016370 
RAB9P40 Rab9 effector p40 none  NM_005833 
RABAC1 Rab acceptor 1 (prenylated) h  NM_006423 
RABEP1 
rabaptin, RAB GTPase binding effector 
protein 1 H h  NM_004703 
WASF1 WAS protein family, member 1 ht h  NM_003931 
SNAP29 
synaptosomal-associated protein, 
29kDa h  NM_004782 
RAC1 
ras-related C3 botulinum toxin substrate 
1 (rho family, small GTP binding protein 
Rac1) none  NM_198829 
RAC2 
ras-related C3 botulinum toxin substrate 
2 (rho family, small GTP binding protein 
Rac2) ht h  NM_002872 
WASF1 WAS protein family, member 1 ht h  NM_003931  
SNAP29 
synaptosomal-associated protein, 
29kDa h  NM_004782 
NIF3L1 
NIF3 NGG1 interacting factor 3-like 1 
(S. pombe) ht h  NM_021824 
MYO5C myosin VC ht  NM_018728 
GDI1 GDP dissociation inhibitor 1 h  NM_001493 
CABC1 
chaperone, ABC1 activity of bc1 
complex like (S. pombe) h  NM_020247 
PAK1 
p21/Cdc42/Rac1-activated kinase 1 
(STE20 homolog, yeast) HT F h NM_002576 
MECP2 
methyl CpG binding protein 2 (Rett
syndrome) h  NM_004992 
 
 
 
 
Table 10. Rab genes with CRE binding sites in their promoter or promoter 
region. The highlighted in red genes are the genes from the Xq25 study. The CRE 
binding is signified by an “H” for a full CRE and a “h” for half a CRE binding site 
within the promoter region. The “T” is for this species only having a TATA box 
and the “t” is for TATA box found across species. The “F” is a full CRE binding 
site in the promoter. 
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The Xq25 study approached only a small portion of gene regulation amongst 
and between ID causing genes. The Rab, Ras and Rho gene families are known to play 
a major role in ID. Patterns of expression within these families may give a greater 
insight to the pathways associated ID. Continued work on Rab expression is shown by 
the gaining interest in the literature. Development of qPCR arrays will help in 
identifying these changes in expression in these genes by a fast, reliable and efficient 
method. Gene expression has proven to be complex and there is much more work to be 
done.  
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APPENDIX A 
Probes for Synthetic MLPA 
 
FAM** GGGTTCCCTAAGGGTTGGA... M13 PRIMER LEFT  
5’       GTGCCAGCAAGATCCAATCTAGA. M13 PRIMER RIGHT 
 
Probe = 121 nt’s without primers with 59% G-C 
Overall length is 163 nt’s TM= 83 0C 
FGD1 exon 2 left   
5' GGGTTCCCTAAGGGTTGGA.....CCCTTCCTGCAGGGCTGCACCAGGG 
AAACCGGATCCTGGTTAAAAGTTTGTCCCTTGACC 3’ 
FGD1 exon 2 right  
5’ P- CTGGCCAAAGCCTAGAGCCTCATCCAGAAGGTCCCCAG 
CGGCTTCGCTCAGACCCAGGTCC TCTAGATTG GATCTTGCTGGCAC 3’                                               
 
Probe = 99 nt’s without primers with 55.6 % G-C 
Overall length is 141 nt’s TM= 81.6 0C 
FGD1 exon 18 left   
5' GGGTTCCCTAAGGGTTGGA CTGACAGAAGGCATGTCTTCAAGATCA 
CCCAGAGCCACCTCAGCTGGTACTT … - 3’ 
FGD1 exon 18 right  
5’ P-CAGCCCTGAGACAGAGGAACTACAGCGACGCTGGATGGCTGTG 
CTTG. .TCTAGATTGGATCTTGCTGGCAC  3’                                           
 
 Probe = 90 nt’s without primers with 54.3% G-C 
Overall length 132 nt’s TM= 80.1 0C 
Nemo exon 2 left 
5' GGGTTCCCTAAGGGTTGGA... CCTGTGACTCCCCTGCTGCCTTTCTCTT 
TCAGCCCTTGCCCTGTTGGATG 
Nemo exon 2 right                       
                     
5’ P-AATAGGCACCTCTGGAAGAGCCAACTGTGTGAGATGGTGC. TCTA 
GATTGGATCTTGCTGGCAC  3’  
 
Probe = 63 nt’s without primers with 50% G-C 
Overall length 105 nt’s TM= 80.50C 
L1CAM exon 16 left                                 
5' GGGTTCCCTAAGGGTTGGA... GAATTTGAGGACAAGGAAATGGCGCCT 
GAAAAA  
L1CAM exon 16 right                                   
P-TGGTACAGTCTGGGCAAGGTTCCAGGGATCTAGATTGGATCTTGCTG 
GAC  3’ 
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Probe = 96 nt’s without primers with 52% G-C 
Overall length 138 nt’s TM= 800C 
 L1CAM exon 24 left                                                  
5' GGGTTCCCTAAGGGTTGGA..CTTCCCTTTCGCCACAGTATGTCAGCTA 
CAACCAGAGCTCCTACACG  
L1CAM exon 24 right                                    
5’ P-CAGTGGGACCTGCAGCCTGACACTGACTACGAGATCCACTTGTTTA 
AGTCTAGATTGGATCTTGCTGGCAC  3’                                                                                                        
 
Probe = 106 nt’s without primers with 39 % G-C 
Overall length is 148 nt’s. TM= 74 0C 
STK9 exon 1 left 
 5' GGGTTCCCTAAGGGTTGGAGCCATGTTTTGTGGCTTGCATCAAAAGA 
GGAGTTTGTCTTCATGAAGATTC 3’ 
STK9 exon 1 right 
5’ P-CTAACATTGGTAATGTGATGAATAAATTTGAGATCCTTGGGGTT 
GTAGGTGAAGGTCTAGATTG GATCTTGCTGGCAC  3’                                                                               
 
Probe = 76nt’s without primers with 45% G-C 
Overall length = 115nt’s TM= 87.6 0C 
UBE3A exon 4 left   
5' GGGTTCCCTAAGGGTTGGAGAAGACTCAG AAGCATCTTC CTCAAGGATA 
GGTGATAGCT CA         
UBE3A exon 4 right 
5’ P-CAGGGAGACA ACAATTTGCAAAAATTAGGCCCTG …. 
TCTAGATTGGATCTTGCTGGCAC  3’                                                                                                               
 
Probe = 58 nt’s without primers with 43% G-C 
Overall length is 98 nt’s.  TM= 81.79 0C 
UBE3A exon 6 left                  
5' GGGTTCCCTAAGGGTTGGACTGAGGGTCAGTTTACTCTGATTGG 3’ 
UBE3A exon 6 left                  
5’ P-CATAGTACTGGGTCTGGCTATTTACAATAACTGTCTAGATTG 
GATCTTGCTGGCAC  3’                                                                                                                                    
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Probe = 110 nt’s without primers with 63% G-C 
Overall length 152 nt’s TM=85.9 
SKI exon 4 left 
5' GGGTTCCCTAAGGGTTGGAGAAGCTGACTGTGGACACCCCAGGAGCCC 
CAGAGACGCTGGCGCCCGTGGCTGCCCCAGAG                       
SKI exon 4 right        
5’ P-GAGGACAAGGACTCGGAGGCGGAGGTGGAAGTTGAAAGCAGGGA 
GGAAT. TCTAGATTGGATCTTGCTGGCAC  3’                                                                                              
         
 
Probe = 121 nt’s without primers with 61% G-C 
Overall length 163 nt’s TM=84.1 
 SKI exon 6 left                                  
5' GGGTTCCCTAAGGGTTGGAGAAGGAGAAGCTGCGGGAGGCCACGGA 
GGCCAAGCGTAACCTGCGGAAGGA 
SKI exon 6 left                                   
                       
5’ P- GATCGAGCGTCTCCGCGCCGAGAACGAGAAGAAGATGAAA 
GAGGCCAACGAGTCACGGCTGCGCCTG TCTAGATTGGATCTTGCT 
GGCAC 3’                                                                                                                                                            
 
Probe = 80 nt’s without primers with 44.3% G-C 
Overall length is 122 nt’s.  TM= 74.90C 
ATRX exon 2 left 
5' GGGTTCCCTAAGGGTTGGACATTGCAAGTCGTGGAGGAGAACTTGTTT 
CTTCAGATTC 3’   
ATRX exon 2 right     
5’ P-TGATGAGTGTGCAAGGAAGTCATGAAGCTTCTGCACCAATGTCTAG 
ATTGGATCTTGCTGGCAC 3’                                                                                                                            
 
Probe = 126nt’s without primers with 36.7% G-C 
Overall length is 168 nt’s. TM= 74.70C 
ATRX exon 17 left 
5' GGGTTCCCTAAGGGTTGGAGATAGAAATTGAAGATGCTTCACCCACC 
AAGTGTCCAATAAC 
ATRX exon 17 middle 
5’  P-  AACCAAGTTGGTTTTAGATGAAGATGAAGAAACCAAAGAACCT- 
ATRX exon 17 right 
5’  P- TTAGTGCAGGTTCATAGAAATATGGTTATCAAATTGAAACCTCTA 
GATTGGATCTTGCTGGCAC  3’    
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Probe = 54 nt’s without primers with 46 % G-C 
Overall length is 96 nt’s. TM= 73.2 0C 
ATRX exon 9 left 
5' GGGTTCCCTAAGGGTTGGAGAAAATGATTGACCTGTTGTCCACAAGCA-3’   
ATRX exon 9 right    
5’ P-GTGCAGCTCACAATCCCATGAAGCCTCTAGATTGGATCTTGCTGG 
CAC  3’                                                                                                                                                                 
 
 Probe = 66 nt’s without primers with 50% G-C 
Overall length is 108 nt’s.  TM= 75.2 0C 
ATRX exon 36 left                  
5' GGGTTCCCTAAGGGTTGGACTCCTGGCTGGCTTGTCTACTTAATGCTA 
ACGC -3’   
5’ P-CTGTACTTAGCATTAAGTAGACAAGCCAGCCAGG ..TCTAGATTG 
GATCTTGCTGGCAC 3’                                                                 
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APPENDIX B 
XNP Study Real Time Primers 
  
 GENE ORIENTATION  NAM SEQUENCE 5' > 3' 
          
  XNP RT FORWARD 9060 TTC ATT TTG CTC ATT TGA AGT CAG 
  XNP RT REVERSE 9060 TCT ATA AGT CAA ATG TTA CCC ACC CA 
          
  XNP RT FORWARD 13080 AGA GTC TTG CTC TGT CGC CC 
  XNP RT REVERSE 13080 GAT CGC SCG TCT GCA CAC C 
          
  XNP RT FORWARD 3000 AAT GGC CAG AAG ACA AGA GGA AG 
  XNP RT REVERSE 3000 GCC AGG TCA TCG GTT TAT TTT CCT 
          
  XNP RT FORWARD 257280 TTC TCC TTT GCT TAT GAA GCT TGG TTT G 
  XNP RT REVERSE 257280 CCC ATC AGA CTA ACA GCG ACC T 
          
  XNP RT FORWARD 254440 GTT CTT TTT GCT TAG GAT TCA TTG GCT A 
  XNP RT REVERSE 254440 TGC TCA GGG AAA TCA GAG AGG A 
          
  XNP RT FORWARD 10000 TTT CAG ATA ACC TTC CTT CTA CCA CTT 
  XNP RT REVERSE 10000 AGG AAA AAT GAG GTT AGA AGC ACA AC 
          
  XNP RT FORWARD 1-2E CTC ATT GGG ACT GGT TAG GCA 
  XNP RT REVERSE 1-2E CTT CTG TCA CCC TCC ATG GG 
          
  XNP RT FORWARD 1-2D GAG AGA ATA TGG GAG GTA GAA T 
  XNP RT REVERSE 1-2D CCT GAC CCC AAC TAG CAT CCT 
          
  XNP RT FORWARD 31-32B GGG ATT GCT GGG TCA AAT GT 
  XNP RT REVERSE 31-32B GCG ATT CCT CAA AGA CCT AGA GG 
          
  XNP RT FORWARD 1-2B GGA CTG TAC TGC TGC CAT CTC 
  XNP RT REVERSE 1-2B CCA TCT CCA CCA AAA AAA TAC GAA AAC CA 
          
  XNP RT FORWARD 1-2C GTT CAA GCG ATT CTC CTG CCT CA 
  XNP RT REVERSE 1-2C GAC CAG ATC ACA AGG TCA GGA G 
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  XNP RT FORWARD 1-2A 
CAA AAA GTG GGT AAA GGA TAT GAA CAG 
ACA 
  XNP RT REVERSE 1-2A CCA AAA GTG TAA AAG TGT TCC TAT TTC TCC 
          
  XNP RT FORWARD 31-32A GGT TTG GTT TTC TGT TCC TTC ATT AGT TTG 
  XNP RT REVERSE 31-32A ACA AAA GCA AAG TCA TGG AAT CAA CCT AC 
          
  XNP RT FORWARD 31-33B CCC AGT AGT TTT CTT TCT CTC TTC TCC 
  XNP RT REVERSE 31-33B CAA AAA GAG GTA GAA GGA GAG GGA G 
          
  XNP RT FORWARD 31-33A TTT GTT TGA TTA TTT CCT GGC GGT GTT TG 
  XNP RT REVERSE 31-33A 
GAG GTA GAA CAT ATA AGA GGT AGA ATA 
AGT TC 
          
  XNP RT FORWARD 31-33C GGT TTT CCA TGT CTC TGT TTG CTT CAG 
  XNP RT REVERSE 31-33C 
TAA AAG AAC TAG AGA ACC AAG AGC AAT 
CAA ACC 
          
  XNP RT FORWARD 254800 ATC CTT TCC CCA TTG CTC GTT 
  XNP RT REVERSE 254800 ACA GCC ATC TGT TCT TTG ACA A 
          
  XNP RT FORWARD 12721 AAG TGA TGT TTT GTC CTT CAC AGC 
  XNP RT REVERSE 12721 GCA AAG GCA TTA TAC ACC TCC TG 
          
  XNP RT FORWARD 11500 AGG AGG CTG AGG CAA AAT TG 
  XNP RT REVERSE 11500 CGG AAT CTC ATT CTG TCG CC 
          
  PMM2 RT FORWARD CDG1A GGG TCA CAT CAG CAA TGG C 
  PMM2 RT REVERSE CDG1A GTA CAG ATG AAG GCT CCC CCT 
          
  XNP RT FORWARD EXON 1 GAA AAC AGT ACC GCT GAG CCC AT 
  XNP RT REVERSE EXON 1 TCT TTC GGC TAA GCA ACA CAC AGG 
          
  XNP RT FORWARD 31-33D CCT TGG TCT CTT CTG CTA TTG ATA GTT TG 
  XNP RT REVERSE 31-33D 
AGC TAA GAA TCA CGA TAA AAC AAT ACA 
GGA GC 
          
  XNP RT FORWARD EXON 34 CTT ATT TCT TGC ATT CTT CTA GGA CCT CAT T 
  XNP RT REVERSE EXON 34 TTG CTG GGT TAC GGT TTG GCA TTA TC 
          
  XNP RT FORWARD EXON 36 AGT TCT GTA TTG AGT ATC TTA AGT A 
  XNP RT REVERSE EXON 36 GAA AAT ACA ATA AAG AGC ACA ACA CA 
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  XNP RT FORWARD EXON 10 ATT GGC ACA TTT ATT TCT ATT TTG ATT C 
  XNP RT REVERSE EXON 10 GCT CAC CCT CAT CTC CTG 
          
  XNP RT FORWARD EXON 35 ACA GTA ATA AGG AGT AAA TAG AAA AT 
  XNP RT REVERSE EXON 35 TTC TTA CCA TCT GTT GTT TTG TC 
          
  XNP RT FORWARD EXON 1 B TAA GAC TCC AGT GCA TTT CTA TCG TAA CC 
  XNP RT REVERSE EXON 1 B CAA GCG AAC GCC TTC CCA AAC AC 
          
  XNP RT FORWARD EXON 31 GGG AAC CAT GGA AGA TAA GAT TTA TGA TC 
  XNP RT REVERSE EXON 31 AGTATCCCTCTTCTTCTTCTTTTCTGAATTAG 
          
  XNP RT FORWARD EXON 29 CAG CAG CAG GTG GAG CGT CAT TTT 
  XNP RT REVERSE EXON 29 AGG GTC ATC TAA TAA GTC TGG CTC AAA AG 
          
  XNP RT FORWARD EXON 9 GAACAATGTAGGTAGGTAATA AGATGAGCTAA 
  XNP RT REVERSE EXON 9 
AAGACATCA 
ATGACGATACTATGAAAGACAAAC 
          
  XNP RT FORWARD EXON 17 GAC CAT TGC TTG AAT GAT TTC TTT GAG CTT 
  XNP RT REVERSE EXON 17 TTG TTA TTG GAC ACT TGG TGG GTG AA 
          
  XNP RT FORWARD INTRON 2-3D CTT TAT GGA GCA GGC TGG AGT C 
  XNP RT REVERSE INTRON 2-3D TGC CTC AGC TTC CCT ATG TTT GTC 
          
  XNP RT FORWARD EXON 3 GGA AAA CAG CAA GGA AGA GGT AAG 
  XNP RT REVERSE EXON 3 CAC AAC AAT AAC AGA AAC AAT GAA CAC C 
          
  XNP RT FORWARD 2-3 E TCA CAG CAA CTT CCA CCT CC 
  XNP RT REVERSE 2-3 E CGC CTG TAA TCC CAG CAC TT 
          
  XNP RT FORWARD EXON 14 AAG AGG AGG AGG AAG ATG AAA ATG ATG AT 
  XNP RT REVERSE EXON 14 TCG CTC ACG CTC CCT CTC AG 
          
  XNP RT FORWARD EXON 2 GCA ATG AAT CAA AAC ACA GGT AAA T 
  XNP RT REVERSE EXON 2 CTG CTC TCT GAA TAA AAT AAA TGG 
          
  XNP RT FORWARD INTRON 2 ACC GTG CCC AGC CCC TTT G 
  XNP RT REVERSE INTRON 2 CTA GAC ATG GAT GGT GGT GGT GAA 
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  XNP RT FORWARD 255000 CTT CCA GCT TTT GCC CAT TC 
  XNP RT REVERSE 255000 TAT ACG ACA AAC CCA TGG CCA 
          
  XNP RT FORWARD 254220 CCT TTC CCC ATT GCT CGT TT 
  XNP RT REVERSE 254220 ACA GCC ATC TGC TCT TTG ACA A 
          
  XNP RT FORWARD 256500 GGG ATT GCT GGG TCA AAT GTT 
  XNP RT REVERSE 256500 TGG CGA TTC CTC AAA GAC CTA 
          
  XNP RT FORWARD 10500 AAT TGC TTG AAG CCG GGA G 
  XNP RT REVERSE 10500 GGT GGT GAT ATC TCG GCT C 
          
  XNP RT FORWARD 14400 GAC GGA TTC TTG CTG TGT TGC 
  XNP RT REVERSE 14400 CCA AGA TCA TGC CAC TGC ACT 
          
  BRACE RT FORWARD A CCA TCC TCT CAC CTT ATA CCC AGC 
  BRACE RT REVERSE A CCT TGC TGG TGA CTG ATG ATT GGG 
          
  BRACE RT FORWARD B GCT CAT TCT ATC TTA TCA TCC TTT CAG AAC C 
  BRACE RT REVERSE B ATC CCT GAG TGG TGG TAG AGT AGC 
          
  FGF-16 RT FORWARD FGF-16 CAC CCT CAC AGA AGA AAC TCA CAC 
  FGF-16 RT REVERSE FGF-16 CGT TTA GTC CTG TAT CCC TCC C 
          
  ATPA7 RT FORWARD ATPA7 ATT TCT GTT CAG GGT ATG ACT TGC  
  ATPA7 RT REVERSE ATPA7 GAG AGG AAT TAA TGG GTC AAA GAA AA 
          
  ARX RT FORWARD EXON 1 AAT CAG TAC CAG GAG GAG GG 
  ARX RT REVERSE EXON 1 GGT CAG CGG AGC AGG CA 
          
  ARX RT FORWARD EXON 4 GCC TTC CCG AGC CTA CC 
  ARX RT REVERSE EXON 4 CTG ATG AAA GCT GGG TGT CG 
          
  FACL4 RT FORWARD  EXON 10 ATG ATG CTG TCT GGA GGG G 
  FACL4 RT REVERSE  EXON 10 GTC CCA GCA CCA CAT GAT TC 
          
  FGD1 RT FORWARD  EXON 2B GAT CCT GGT TAA AAG TTT GTC CCT TGA C 
  FGD1 RT REVERSE  EXON 2B CCA CTT CTC TGC TCT TTT CCA GGA C 
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  FGD1 RT FORWARD  EXON 18B GAC AGA GCA TAT GCA AAA CCA GTT AGA AG 
  FGD1 RT REVERSE  EXON 18B GTG ATC TTG AAG ACA TGC CTT CTG TCA 
          
  FGD1 RT FORWARD  EXON 18 CGC CAG GAT GTG AAA GCC CA 
  FGD1 RT REVERSE  EXON 18 TCC TCC ATC TCC CTG TCC T 
          
  FGD1 RT FORWARD  EXON 2  CTC AGA GAA ACC CAA TAC CCC A 
  FGD1 RT REVERSE  EXON 2  GTG CCC GCT TCA GTG GTG 
          
  FGD1 RT FORWARD  EXON 3 TTC ACC ATG TTA GCC AGG CTC  
  FGD1 RT REVERSE  EXON 3 GGC CTC TCC TGA CTA TCC CTT CCT 
          
  FMR2 RT FORWARD  EXON 4 
CTA ATA CAC AGC AAC AGA AAA TCA AAA 
CCT 
  FMR2 RT REVERSE  EXON 4 GGC TTG AGA CTG GTC CTG TG 
          
  FMR2 RT FORWARD  EXON 1 CCT GGC CGC TAT GGA TCT ATT CG 
  FMR2 RT REVERSE  EXON 1 CAA CAC CTA CCA CTG CTG CTC CAA  
          
  PQBP1  RT FORWARD  EXON 1 CCC TCT GCT CCC CCA TCC C 
  PQBP1  RT REVERSE  EXON 1 CGG TAG GGA TGG ATG TCA GG 
          
  PQBP1  RT FORWARD  EXON 4 CAA GTA GAA TGA TAG TGG AT 
  PQBP1  RT REVERSE  EXON 4 CCC ACA AGA AGA AAT GAA G 
          
  PGK1 RT FORWARD PGK1 GTC TTC ATC TCT TCC TCT TCT C 
  PGK1 RT REVERSE PGK1 CCC TTC CCT TCT TCC TCC 
          
  STK9 RT FORWARD  EXON 11 GGA AAG CAG CAC ATT GTC TAA TAG G 
  STK9 RT REVERSE  EXON 11 CCA CAC AAC TCC TTA ATT GTG GTT C 
          
  STK9 RT FORWARD  EXON 16 AAC TCA AGG AAA AAG AGA AGC AAG G 
  STK9 RT REVERSE  EXON 16 
TCA GAA AGA GAC ATA ATA CAG TGC AAA 
AAT 
          
  UBE3A RT FORWARD  EXON 5 
TGA GAT AAA AAT GAA CAA GAA AGG CGC 
TAG AA 
  UBE3A RT REVERSE  EXON 5 ATG TAG TTA TTA TTC CTG TCC GTT ACC AC 
          
  UBE3A RT FORWARD EXON 6 GGA GAA GAA AGA AGA AAC AAG AAA GGT C 
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  UBE3A RT REVERSE EXON 6 CTA GCA GCC CAA CTT ACC CG 
          
  UBE3A RT FORWARD  EXON 4 ATT GCA TTT TAC AGA TCA GGA GAA CC 
  UBE3A RT REVERSE  EXON 4 TGT TCC TAT CTC CCA TTT ACT GCT A 
          
  GDI1  FORWARD EXON 5 CGATGAGAATGACCCCAAGACC 
  GDI1  REVERSE  EXON 5 CCACCCAGCTTCCCCTCAC 
          
  SLC6A8 FORWARD EXON 8 CGAGGCAGGCGTGGGCAT 
  SLC6A8 REVERSE EXON 8 TTGGAAACGGAAGTAGTAGGAGGC 
          
  SLC6A9 FORWARD EXON 12 CCTTCGCCCTGTCCTCCATGCT 
  SLC6A8 REVERSE EXON 12 GCCCAGGAGGTGCAGCGG 
          
  ATRX FORWARD EXON 14 AAGAGGAGGAGGAAGATGAAAATGATGAT 
  ATRX REVERSE EXON 14 TCGCTCACGCTCCCTCTCAG 
          
  ATRX FORWARD EXON 29 CAGCAGCAGGTGGAGCGTCATTTT 
  ATRX REVERSE EXON 29 AGGGTCATCTAATAAGTCTGGCTCAAAAG 
          
  FACL4 FORWARD EXON 10 ATGATGCTGTCTGGAGGGG 
  FACL4 REVERSE EXON 10 GTCCCAGCACCACATGATTC 
          
  ARX FORWARD EXON 1 AATCAGTACCAGGAGGAGGG 
  ARX REVERSE EXON 1 GGTCAGCGGAGCAGGCA 
          
  ARX FORWARD EXON 4 GCCTTCCCGAGCCTACC 
  ARX REVERSE EXON 4 CTGATGAAAGCTGGGTGTCG 
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APPENDIX C 
RAB Associated Gene Real Time Primers 
  GENE ORIENTATION  NAME SEQUENCE 5' > 3' 
          
  BCORL1-B FORWARD BCORL1-B-EFF GTGACCTCCTACATAATCCTCCTG 
  BCORL1-B REVERSE BCORL1-B-EFF  CCTTGGGCATGGTGGTGATTTC 
          
  CABC1 FORWARD CABC1 RT-EXP CAGATGCTGAGCATCCAGGAT 
  CABC1 REVERSE CABC1 RT-EXP TCATCTGCTTCAGTGGCATGA 
          
  CDC42 FORWARD CDC42 RT-EXP CCCAAGACCACAGTGACTACAG 
  CDC42  REVERSE CDC42 RT-EXP GATGTCCTCGCCCTCCCA 
          
  FXR2 FORWARD FXR2 RT EXP TGGAGGTTTATTCTCGAGCCA 
  FXR2 REVERSE FXR2 RT EXP GGCATCACAGGCAGCATATTC 
          
  GDI1-RT FORWARD GDI1-RT-EXP GAGACCACGGACCCTGAAAAG 
  GDI1-RT REVERSE GDI1-RT-EXP CAAAGTGTGTGGTGGCATCGTAG 
          
  MYO5A FORWARD MYO5A RT EXP CGAGGAAGGAAAGGATTTGGA 
  MYO5A REVERSE MYO5A RT EXP AGCACAGCAGGCTCATGAAGA 
          
  NIF3L1 FORWARD NIF3L1 RT EXP CATCCTTCCAAAFCTCCCAAC 
  NIF3L1 REVERSE NIF3L1 RT EXP CCGTCAATTCCTTTCACTGCA 
          
  RAB 26  FORWARD RAB 26 RT-EXP  TGTGGTGAAGAGGGAGGACG 
  RAB 26  REVERSE RAB 26 RT-EXP  CAAGGGCGGCAGCAGGA 
          
  RAB 27A FORWARD RAB 27A RT-EXP GTTATGGGACACAGCAGGGCAG 
  RAB 27A  REVERSE RAB 27A RT-EXP CCCATAGCATCTCTGAAGAACGC 
          
  RAB 7  FORWARD RAB 7 RT-EXP CCTTCTCGCTTCTGTCCTCCG 
  RAB 7  REVERSE RAB 7 RT-EXP CCTGTCATCCACCATCACCTCC 
          
  RAB11B FORWARD RAB11B EXP-RT  CAAAGTGGTGCTCATCGGGGAC 
  RAB11B REVERSE RAB11B EXP-RT  GATGCTGCGGGTGGCGAAC 
          
158
  RAB17 FORWARD RAB17 RT EXP TGCGCTTCTGGTGTACGACAT 
  RAB17 REVERSE RAB17 RT EXP TTGTTGCCCACCAGCATCA 
          
  RAB1A FORWARD RAB1A RT EXP CAGCAGGCCAGGAAAGATTT 
  RAB1A REVERSE RAB1A RT EXP TCCTGCAGCCACTGTTTAACA 
          
  RAB22A FORWARD RAB22A RT EXP GGTGAAAGAGCTTCGACAGCA 
  RAB22A REVERSE RAB22A RT EXP TCGGCGTAGTCCTTTGCATCT 
          
  RAB23 FORWARD RAB23 RT-EXP CAGGCTTGTGTGCTCGTGTTCT 
  RAB23 REVERSE RAB23 RT-EXP CAGTGCCTCAGCTTCCTCATTC 
          
  RAB3A FORWARD RAB3A EXP-RT CTTGGGTTCGAGTTCTTTGAGGC 
  RAB3A  REVERSE RAB3A EXP-RT  CGCCGTGTCCAACGACTCG 
          
  RAB33A  FORWARD RAB33A EXP-RT CCTGCCTGACCTTCCGCTTC 
  RAB33A  REVERSE RAB33A EXP-RT CCTGACCTGCTGTGTCCCAC 
          
  RAB40B FORWARD RAB40B EXP-RT  GACTACAAGACGACCACCATCCT 
  RAB40B REVERSE RAB40B EXP-RT  GGGAGTAGGAGCGGAATATGGTA 
          
  RAB4B  FORWARD RAB4B EXP-RT  GTGGGTGGGAAGACTGTGAAG 
  RAB4B   REVERSE RAB4B EXP-RT  CAGGTCCTTCTTGTTGCCACAG 
          
  RAB5C FORWARD RAB5C RT EXP AACATCGTCATTGCACTCGC 
  RAB5C REVERSE RAB5C RT EXP CAGCAAACTGTTGTCGTCTGC 
          
  RAB6A FORWARD RAB6A RT EXP CCTATCAGGCAACAATTGGCA 
  RAB6A REVERSE RAB6A RT EXP AAACGTTCCTGACCCGCAGTA 
          
  RAB8A FORWARD RAB8A RT EXP GGACGCCTTCAACTCCACTTT 
  RAB8A REVERSE RAB8A RT EXP TTGTGATCGTCCGAAACCG 
          
  RABAC1 FORWARD RAB AC1 RT EXP TGTGGTGACGTCCCCTATGTT 
  RABAC1 REVERSE RAB AC1 RT EXP TCTCGGCCAAAGAGCACAA 
          
  RHOA FORWARD RHOA RT EXP CCTGTGGAAAGACATGCTTGC 
  RHOA REVERSE RHOA RT EXP CATCCACCTCGATATCTGCCA 
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  ROU FORWARD ROU RT EXP CATCCCTACTGCCTTCGACAA 
  ROU REVERSE ROU RT EXP TGTCAAATTCATCCTGTCCGG 
          
  SNAP29 FORWARD SNAP29 RT EXP TCCAAACCAGTAGAGACCCCA 
  SNAP29 REVERSE SNAP29 RT EXP TGGCCTGGTACTTTGCTTCCT 
          
  WASF1 FORWARD WASF1 RT EXP ATTTCACGCATGCCCCCTA 
  WASF1 REVERSE WASF1 RT EXP GGCAGGACGTGAATGTTGAGA 
          
  RAB1A FORWARD RAB1A RT EXP CAGCAGGCCAGGAAAGATTT 
  RAB1A REVERSE RAB1A RT EXP TCCTGCAGCCACTGTTTAACA 
          
  RAC1 FORWARD RAC1 RT EXP CCGTGCAAAGTGGTATCCTGA 
  RAC1 REVERSE RAC1 RT EXP GGATCGCTTCGTCAAACACTG 
          
  RAC2 FORWARD RAC2 RT EXP GATGCAGGCCATCAAGTGTGT 
  RAC2 REVERSE RAC2 RT EXP GCTTGCTGTCCACCATCACAT 
          
  ELF4 FORWARD ELF4 RT EXP GGCAACCGAAGTACCTCACCTG 
  ELF4 REVERSE ELF4 RT EXP CTTAGTGCCCGCCCCATTGTC 
          
  PDCD8/AIF FORWARD AIF RT EXP  TTCTGTGTTAGTCCTTATTGTGGGCTTAT 
  PDCD8/AIF REVERSE AIF RT EXP  CCTTTTTCTGTTTCTGTTCTGGTGTCAG 
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APPENDIX D 
 
SEQUENCING PRIMERS 
 
  GENE ORIENTATION  NAME SEQUENCE 5' > 3' 
          
  CDKL5 FORWARD CDKL5 EXON 2 TAAGATTGGTTACTAGAGTACTGC 
  CDKL5 REVERSE CDKL5 EXON 2 GACACACATGTGAATTGATATAGG 
          
  CDKL5 FORWARD CDKL5 EXON 3 GAGAAGCAATGTCAGTATAGCAG 
  CDKL5 REVERSE CDKL5 EXON 3 CATGCCCACACGCAAAGACCAC 
          
  CDKL5 FORWARD CDKL5 EXON 4 CAACTGGAATCCCCAGTCGGA 
  CDKL5 REVERSE CDKL5 EXON 4 AGTGTCTGACCAGCTAGATCC 
          
  CDKL5 FORWARD CDKL5 EXON 5 GAAGTACTCAAAGCAGAAGGTGA 
  CDKL5 REVERSE CDKL5 EXON 5 TCGGGCAAATGTGCACATTGGC 
          
  CDKL5 FORWARD CDKL5 EXON 6 GCTCTGTATTGGATGAATTATTCTAG 
  CDKL5 REVERSE CDKL5 EXON 6 GACAGTAACATGTGAAATACTCTTAAC 
          
  CDKL5 FORWARD CDKL5 EXON 7 GATGCTATTACAGTGATCTAACAG 
  CDKL5 REVERSE CDKL5 EXON 7 TGTGACTCAAAAGAATGTTCCTC 
          
  CDKL5 FORWARD CDKL5 EXON 8 GCCCATGCGAGAACAGTCATTAC 
  CDKL5 REVERSE CDKL5 EXON 8 GCAAATGACAATAGAATCAGCAG 
          
  CDKL5 FORWARD CDKL5 EXON 9 AGTTGCCAAAATAATCTCTTCCTT 
  CDKL5 REVERSE CDKL5 EXON 9 GAACAATGACTCAAATACTGCAG 
          
  CDKL5 FORWARD CDKL5 EXON 10 AACACTCACAAGCACGTGCA 
  CDKL5 REVERSE CDKL5 EXON 10 TTATTTGCCATTCCACATCTCCT 
          
  CDKL5 FORWARD CDKL5 EXON 11 CTTTGTAATGTTCTTAACGATC 
  CDKL5 REVERSE CDKL5 EXON 11 CTAATTGCATCATTTAAGCAGCC 
          
  CDKL5 FORWARD CDKL5 EXON 12.1 TTGTGTGTCAGCTATTGAGGG 
  CDKL5 REVERSE CDKL5 EXON 12.1 GGTATGTTGTTGTTGGTGTGAGATC 
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  CDKL5 FORWARD CDKL5 EXON 12.2 TGCACACCAAAACCTACCAAGC 
  CDKL5 REVERSE CDKL5 EXON 12.2 GCTTTTGGCCTTGGTCCTGTAGGA 
          
  CDKL5 FORWARD CDKL5 EXON 12.3 GAGTCGGCATAGCTATATTGACAC 
  CDKL5 REVERSE CDKL5 EXON 12.3 GAATGGCTACTGTCCATGTGC 
          
  CDKL5 FORWARD CDKL5 EXON 12.4 AACGCTGGACTCACGTCGAAC 
  CDKL5 REVERSE CDKL5 EXON 12.4 CCACCAGATTCAGTCAAGGTG 
          
  CDKL5 FORWARD CDKL5 EXON 13 CTGGTTATGGTCCTAGTTCTACC 
  CDKL5 REVERSE CDKL5 EXON 13 GTGGGAGACTGGGTATTAATAC 
          
  CDKL5 FORWARD CDKL5 EXON 14 AGGCTACAGTAAGCCATGA 
  CDKL5 REVERSE CDKL5 EXON 14 GTGTAGGTGAGAAGGCCGCTG 
          
  CDKL5 FORWARD CDKL5 EXON 15 GAAAAGTCCATCAGTGACTTAC 
  CDKL5 REVERSE CDKL5 EXON 15 GGACACTAAAAAGCTCATCCAGA 
          
  CDKL5 FORWARD CDKL5 EXON 16 GTTTGATTCTTCCCGGCTATAG 
  CDKL5 REVERSE CDKL5 EXON 16 GGCTCTGTTGAGAGGATAGTTG 
          
  CDKL5 FORWARD CDKL5 EXON 17 CTCCTCTTGGGTGTGGTTGC 
  CDKL5 REVERSE CDKL5 EXON 17 GCTCAGCCTTACTGTAACATGG 
          
  CDKL5 FORWARD CDKL5 EXON 18 TCTAACTTGAATCCTGTGTGC 
  CDKL5 REVERSE CDKL5 EXON 18 CTGGTCACAGAGGACACATG 
          
  CDKL5 FORWARD CDKL5 EXON 19 GTGGGCAGAAGTGGCCAATA 
  CDKL5 REVERSE CDKL5 EXON 19 GTCTAGGGTCGTTATGGCAGC 
          
  CDKL5 FORWARD CDKL5 EXON 20 ACCTTGGCTTCAGCTGGTGTC 
  CDKL5 REVERSE CDKL5 EXON 20 GGGCAATTCCGAGGTACAGC 
          
  CDKL5 FORWARD CDKL5 EXON 21 GCCAGAGTGCACCTGCTAGC 
  CDKL5 REVERSE CDKL5 EXON 21 AAGGAAAACTCAACCTCAGCG 
          
  PDCD8 FORWARD PDCD8 EXON 1 CGCAAATCCTCTCGCCGTG 
  PDCD8 REVERSE PDCD8 EXON 1 AGGGTTCGGAGTCTGCCAAT 
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  PDCD8 FORWARD PDCD8 EXON 2 TACTCTGTTTCCTTTTGTTTCTCTCTTGG 
  PDCD8 REVERSE PDCD8 EXON 2 GCTCACCCACCCTACCCC 
          
  PDCD8 FORWARD PDCD8 EXON 3 GCACACCCAGTATTTTTTATTTCTTA 
  PDCD8 REVERSE PDCD8 EXON 3 CCATAAATCACAGCACCCAAAC 
          
  PDCD8 FORWARD PDCD8 EXON 4 CTTGCTTTTCCTCTCCCATCA 
  PDCD8 REVERSE PDCD8 EXON 4 CAATCAGTACCTTCAGACATAAAAAT 
          
  PDCD8 FORWARD PDCD8 EXON 5 TGCTTTGACATTTGCCCCTTA 
  PDCD8 REVERSE PDCD8 EXON 5 CCAAGCCATCCCTCCTAT 
          
  PDCD8 FORWARD PDCD8 EXON 6 TTCTCCCTCTCTTCTCCATACA 
  PDCD8 REVERSE PDCD8 EXON 6 CCCAGAAAGACACACTCAGC 
          
  PDCD8 FORWARD PDCD8 EXON 7 GCTAATTCATCTCTACCTCTTTTGTGT 
  PDCD8 REVERSE PDCD8 EXON 7 AGGCTGGACTCTAAAACTTGAATG 
          
  PDCD8 FORWARD PDCD8 EXON 8 GGAGTATTGTTTGGGCTGGCT 
  PDCD8 REVERSE PDCD8 EXON 8 CACAAGGAAAACACTAAAGCAGAC 
          
  PDCD8 FORWARD PDCD8 EXON 9 GTATTATTATCCTATGCCCCTTTTG 
  PDCD8 REVERSE PDCD8 EXON 9 ATCCTGCCAAACACATCTCTG 
          
  PDCD8 FORWARD PDCD8 EXON 10 GATTGACTTTTGCTTCCTGCTGT 
  PDCD8 REVERSE PDCD8 EXON 10 CAAAGGAAATAGAGTGGCAGCATA 
          
  PDCD8 FORWARD PDCD8 EXON 11 TTTTACCGTGGAGGAGACCG 
  PDCD8 REVERSE PDCD8 EXON 11 CTACTCTGGCTCTCATCATTCT 
          
  PDCD8 FORWARD PDCD8 EXON 12 GATGGGGTGGTGGAGGCT 
  PDCD8 REVERSE PDCD8 EXON 12 CCTCCAAACACTCTGACCCTA 
          
  PDCD8 FORWARD PDCD8 EXON 13 GTGTTCATGTTATGTATTTGTTTCCAC 
  PDCD8 REVERSE PDCD8 EXON 13 GCTCATAATAAAACCAAACCATAACTCT 
          
  PDCD8 FORWARD PDCD8 EXON 14 ACACCCTCTTCTCTCTTCTTA 
  PDCD8 REVERSE PDCD8 EXON 14 AAAGCACAACATGAAGAGAGG 
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  PDCD8 FORWARD PDCD8 EXON 15 GAGAGGGCTGGTGAAGG 
  PDCD8 REVERSE PDCD8 EXON 15 AGCCAAGTCCCAAGTGAAAAAGAAT 
          
  PDCD8 FORWARD PDCD8 EXON 16 TCCCACAACTCCCTCCCAG 
  PDCD8 REVERSE PDCD8 EXON 16 CCACCTTCACCCACCTGC 
          
  PDCD8 FORWARD PDCD8 EXON 2 ALT CTATTTTATTTTTGTATGTGTGTGTCTT 
  PDCD8 REVERSE PDCD8 EXON 2 ALT ACGCTGCTTTTCTACTTAC 
          
  MECP2 FORWARD MECP2 EXON 4 5' ATCCGCTCTGCCCTATCTCTGA 
  MECP2 REVERSE MECP2 EXON 4 5 TTCAGTCCTTTCCCGCTCTTCTCA 
          
  MECP2 FORWARD MECP2 EXON 4 MID GCCACCACATCCACCCAG 
  MECP2 REVERSE MECP2 EXON 4 MID ATCCCTCTGGGCATCTTCTCCTCTT 
          
  MECP2 FORWARD MECP2 EXON 4 3' TGAGAAGAGCGGGAAAGGACTGA 
  MECP2 REVERSE MECP2 EXON 4 3' CCGAGCCCTACCCATAAGGAGAAG 
          
  MECP2 FORWARD MECP2 EXON 3 CCTGCCTCTGCTCACTTGTT 
  MECP2 REVERSE MECP2 EXON 3  GTTCCCCCCGACCCCACC 
          
  MECP2 FORWARD MECP2 EXON 1 CCCGGCGTCGGCGGC 
  MECP2 REVERSE MECP2 EXON 1 TCTCGGAGAGAGGGC 
          
  ATRX FORWARD XNP RT EXON 1 GGTACAGTGATTGTACAGCCAGA 
  ATRX REVERSE XNP RT EXON 1 CTTATTTTGCTGCAACAACTGTTC 
          
  ATRX FORWARD XNP RT EXON 2 CGTATTGCTGAGAGGGAGCG 
  ATRX REVERSE XNP RT EXON 2 CATTCCTTCCTTGAGCAAGATTTC 
          
  ATRX FORWARD XNP RT EXON 3 GCAACTGTGAAACGTCCTCAG 
  ATRX REVERSE XNP RT EXON 3 TTGTTAATGCTGTATAATCTTTCCTCTG 
          
  ATRX FORWARD XNP RT EXON 4 GATTCTACCATGGTAGATGTCAGAGTG 
  ATRX REVERSE XNP RT EXON 4 TGTCACTGCCACTTCCACTTG 
          
  ATRX FORWARD XNP RT EXON 5 GATTCTGATGAAACCTCCATGAG 
  ATRX REVERSE XNP RT EXON 5 CTTCTTCCTTGACTGTGCAGTAGTG 
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  ATRX FORWARD XNP RT EXON 6 GAATTAGCTAGTAGGGAGAAGACAGAAG 
  ATRX REVERSE XNP RT EXON 6 CTTTATGTATCTGAAGGAGCTCTGC 
          
  ATRX FORWARD XNP RT EXON 7 GAGCCAGACTTATTAGATGACCC 
  ATRX REVERSE XNP RT EXON 7 GTTCATAAGTATTCGCTGAACACAGC 
          
  ATRX FORWARD XNP RT EXON 8 GCCCAGCAATCACAGAAGC 
  ATRX REVERSE XNP RT EXON 8 TTACTTCTGCTTCTAAATTCAGGCC 
          
  ATRX FORWARD XNP RT EXON 9 GGATGAAAACAACCAATGGTATTG 
  ATRX REVERSE XNP RT EXON 9 GCTTTTGTTTCAAACTTAGCATCTATG 
          
  ATRX FORWARD XNP RT EXON 10 GGAAGAAGACTTAAATTCCGAGTTTC 
  ATRX REVERSE XNP RT EXON 10 GGGGAATTAGGAAGGGAAACAG 
          
  ATRX FORWARD XNP RT EXON 11 AGCAGTGGAACTGAACAAGAAGTG 
  ATRX REVERSE XNP RT EXON 11 ACTGTGACTCATCCTGCTCACC 
          
  ATRX FORWARD XNP RT EXON 12 CTGACAGTGCTATAGATAATCCTAAGC 
  ATRX REVERSE XNP RT EXON 12 GTGTCTTTATCAACTGTGCCTTCTG 
          
  ATRX FORWARD XNP RT EXON 13 CAAGGGCACAAAAATTTGAAGAC 
  ATRX REVERSE XNP RT EXON 13 TTACTTTTCTTTTCTCCATCAGTTGTTC 
          
  ATRX FORWARD XNP RT EXON 14 CAACAGTATGAATCTTCATCTGATGG 
  ATRX REVERSE XNP RT EXON 14 TGCTTCCTTTTAGTGCTTGTTCTTAG 
          
  ATRX FORWARD ATRX RT EXON 15  GTGCTGAGAAGTCAACAGGGAAAGGAGATAG 
  ATRX REVERSE ATRX RT EXON 15 ACATTGGCAAAATCCAGTATGTGAAGACAGC 
          
  ATRX FORWARD ATRX RT EXON 16  GCACTAAAAGGAAGCAAGCTGACATTACATC 
  ATRX REVERSE ATRX RT EXON 16 ACTTTATAGCTCCGCTGATTTTCTTCCAACTC 
          
  ATRX FORWARD ATRX RT EXON 17  GAAGAAGTTAGTGAATCCGAAGATGAACAGC 
  ATRX REVERSE ATRX RT EXON 17 ACATCCCACATAAACTGAACACCATCTACTTG 
          
  ATRX FORWARD ATRX RT EXON 18  GTAATCAACAGCTGGAGGACCTCATT 
  ATRX REVERSE ATRX RT EXON 18  ACGATTGGCATTTAAGGGGACCAAACT 
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  L1CAM  FORWARD L1CAM exon 1  AACCGAGCCCGGGTGGCTGTGCTG 
  L1CAM  REVERSE L1CAM exon 1  GGCCCAACATAGCGGCGAAGGTAG 
          
  L1CAM  FORWARD L1CAM exon 11/12  GT GGT CCC AAG TCC TGC CCT GTC 
  L1CAM  REVERSE L1CAM exon 11/12  C TCC CTC CCA GAG GCA CTG CCA G 
          
  L1CAM  FORWARD L1CAM exon 13   GGT CTG GGC CTC TGG AGG AC 
  L1CAM  REVERSE L1CAM exon 13 A CTT CCA GCT TTT CCC ACT CTG C 
          
  L1CAM  FORWARD L1CAM exon 14/15 GA AGA GCC CAG ATG GCA GGA AAG 
  L1CAM  REVERSE L1CAM exon 14/15  A GGG CTG GCA GAA GTG ACG GTG G 
          
  L1CAM  FORWARD L1CAM exon 16 TC CCC CAA AGC CAC ATG CTG ATC 
  L1CAM  REVERSE L1CAM exon 16  G GAG CCC CTT CCA GGT GGC ATG G 
          
  L1CAM  FORWARD L1CAM exon 17  CC TCG TGG CTC TCC AAA AGA GGC 
  L1CAM  REVERSE L1CAM exon 17  G GGG AGC AAC AGA CAC CCA GGT C 
          
  L1CAM  FORWARD L1CAM exon 18  CG GGC CAA AGA ATG CTG GTG TTC 
  L1CAM  REVERSE L1CAM exon 18  G GAA GCA GGC GAG CTC AAC CGT G 
          
  L1CAM  FORWARD L1CAM exon 19  GG GTG AGA GCC TAT GGC TCT ATC 
  L1CAM  REVERSE L1CAM exon 19  T CAC CAT CCT GTC GCT TTA CCT C 
          
  L1CAM  FORWARD L1CAM exon 2  GG GCT GCA GGA GCT TAC TAT GTC 
  L1CAM  REVERSE L1CAM exon 2 A GCA CAT GGT GCT CAG GGA GAG C 
          
  L1CAM  FORWARD L1CAM exon 20  GT GCC TTC TGC CCC TGC GAG GTC 
  L1CAM  REVERSE L1CAM exon 20  G CAG GTA GGT CCT CGC CCA GGT C 
          
  L1CAM  FORWARD L1CAM exon 21/22  GG GCG AGG ACC TAC CTG CCA CTC 
  L1CAM  REVERSE L1CAM exon 21/22  G GCA GGT CAT TCC TCC AGC TTA C 
          
  L1CAM  FORWARD L1CAM exon 23/24  CA CTC TCC TCG TTC CCC TGC ATC 
  L1CAM  REVERSE L1CAM exon 23/24  A TGC TTC CCT GGC AGG TGA TGG C 
          
  L1CAM  FORWARD L1CAM exon 25  GG TTC TGG CTT GGG CGG CAG CAC 
  L1CAM  REVERSE L1CAM exon 25  C TCC TCT CTG CCC TCG GCT CCA C 
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  L1CAM  FORWARD L1CAM exon 26/27  TC AGG CTG GGG CGG GAG AAG AAG 
  L1CAM  REVERSE L1CAM exon 26/27  C TAT AGG GAG ACC TTG CTG TTG G 
          
  L1CAM  FORWARD L1CAM exon 28  TC GGC AGT GCT CTC ACT CGC AC 
  L1CAM  REVERSE L1CAM exon 28  T CCC AAG GCC AGG GGC ACA GCA T 
          
  L1CAM  FORWARD L1CAM exon 3  AG GCT ATG ACA CCA GCC AGG CAG  
  L1CAM  REVERSE L1CAM exon 3  C TTC TGG GCT TAG AAG TTA GGC AG 
          
  L1CAM  FORWARD L1CAM exon 4  CC GTT GGG TTC CAG GGC CTC AGG 
  L1CAM  REVERSE L1CAM exon 4  C AAT CCC ACA CGA ACT CCG GGA C 
          
  L1CAM  FORWARD L1CAM exon 5/6  AG GAG AGT GTC AGC CCG TCT GTC 
  L1CAM  REVERSE L1CAM exon 5/6  A AGG AGT CAG GGA GAG AGT GCA G 
          
  L1CAM  FORWARD L1CAM exon 7/8  GA GTC CCT CAG CCT TGC AAT TC 
  L1CAM  REVERSE L1CAM exon 7/8  T GAC AGT GGG CAT CAC AGG CCA C 
          
  L1CAM  FORWARD L1CAM exon 9/10  GC TGC TGG CTG CGG GCT CAG GGC 
  L1CAM  REVERSE L1CAM exon 9/10  C AGT GGG TGC AGG GAC AGA CTG G 
          
  GDI1  FORWARD  EXON 1 CGACTGCTGCGGTGAAGGAG 
  GDI1  REVERSE  EXON 1 GGTCATGGCAACGAGCAGAGG 
          
  GDI1  FORWARD EXON 5 CGATGAGAATGACCCCAAGACC 
  GDI1  REVERSE  EXON 5 GGAAATGGAAAGGGTGATAGGTGA 
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APPENDIX E 
Real Time PCR Primers 
  GENE ORIENTATION  NAME SEQUENCE 5' > 3' 
          
  XNP  FORWARD NORTH PROBE #1 AGG TGG TGT GCG GAA GGT GG 
  XNP  REVERSE NORTH PROBE #1 TTC CAC TGC TGC CAT CCC CTT G 
          
  XNP  FORWARD NORTH PROBE #2 TTG CCT AAC ATG CAC AAA GC 
  XNP  REVERSE NORTH PROBE #2 ATT GGC TAC GGA AAT TCA CC 
          
  XNP RT FORWARD RT EXP ATGGAATGGATGAACAATGTAGGTGGTGT 
  XNP RT REVERSE RT EXP CAGAAAGCATTATGGCAAAAGTCACAACAAATCA 
          
  18S RT FORWARD RT EXP AGT CCC TGC CCT TTG TAC ACA  
  18S RT REVERSE RT EXP GAT CCG AGG GCC TCA GTA AAC  
          
  MED12 FORWARD MED12L RT-EXP  GAGATTGCCCAGCACCAGC 
  MED12 REVERSE MED12L RT-EXP  CATATCCCAACTCGTCTTCCTCTTTC 
          
  MED12  FORWARD MED12 RT-EXP  CTCCTCTCTCTTCAGCCAGTTC 
  MED12 REVERSE MED12 RT-EXP  AATAAGGAAGAGCAAATGGAGAAAGCAC 
          
  
ANDROGEN 
R FORWARD ANDROGEN R-SEQ AGTTAGGGCTGGGAAGGGTCT 
  
ANDROGEN 
R REVERSE ANDROGEN R-SEQ GACACCGACACTGCCTTACAC 
          
  RAB33A FORWARD NORTHERN PROBE CGAGGGCGAAGAAGATCAAGGT 
  RAB33A REVERSE NORTHERN PROBE  CCTTCCCCTGCTGCCTCTC 
          
  PDCD8 FORWARD NORTHERN PROBE AAAGCAACTGCACAAGACAACCCCAAA 
  PDCD8 REVERSE NORTHERN PROBE GAGAGGAGGTCGAATGGGTAAAGG 
          
  MCT8 FORWARD MCT8 EXON 2 CCAGCAGTACCACCAGGCACTACA 
  MCT8 REVERSE MCT8 EXON 2 CATGGCCACAGGGGATTCTGC 
          
  MCT8 FORWARD MCT8 EXON 3 AAGGGCGGAGGAATGGAAGTCTCA 
  MCT8 REVERSE MCT8 EXON 3 CCCACCCCCACCCTCTGGAATCTA 
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  FMR2 FORWARD EXON 1 CCTGGCCGCTATGGATCTATTCG 
  FMR2 REVERSE EXON 1 CAACACCTACCACTGCTGCTCCAA 
          
  FMR2 FORWARD EXON 4 CTAATACACAGCAACAGAAAATCAAAACCT 
  FMR2 REVERSE EXON 4 GGCTTGAGACTGGTCCTGTG 
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APPENDIX F 
 
RAB Associated Genes Regulated by MECP2 
 
RAB 
INTERACTING  MECP2 + MECP2 -   
RAB 
INTERACTING  MECP2 + 
MECP2 
- 
FXR2       KCNRG     
FMR1 ACTIVATED     NDP52     
FXR2 UP REG     TSC224     
FXR1       FBP1     
LCMT1 UP REG     PAICS     
FLJ32855       C10 ORF 62     
RTN4       GKAP1 ACTIVATED   
ARL61P       CBS    
SNAP23       MGC2749     
AMOTL2 ACTIVATED     53 GENES TOTAL 12 1 
MCRS1 UP REG     NIF3L1     
LDOC1 ACTIVATED     COPS2     
RBBP8   
DOWN 
REG   NIF3L1 ACTIVATED   
RBMX       TRIP13     
MBIP       RABAC1     
TRIM29       EAP30     
NONO       DMRTB1     
NCK2       NOL3 UP REG   
SSSCA1 ACTIVATED     S100A1     
CYFIP2       MGC2749     
ZBTB8       XTP3TPA     
CRSP9 ACTIVATED     DCTD     
EFCBPZ       WBSCR14     
TNNT1 ACTIVATED     YWHAQ     
NT5C2       CUTC     
ZNF451       KRT15     
KIA1217       TSC22D4 ACTIVATED   
DPPA2       PCBD1 ACTIVATED   
KR720       MAPRE2     
RP1A       KCTD17     
HNRPC       DHPS     
LOC138046       C10 ORF30     
TRAF2       VIM UP REG   
PCBD1 ACTIVATED     PRTFDC1     
APZM1       NIF3L1BP1     
THAP1       DIPA     
PSME3       FLJ10094     
TRIM37       MAGEA11     
RTN3       TIFA     
KCTD4       RPIA     
RBPMS       GNMT     
RABAC1       CPSF5     
AP1M1 UP REG     ZBED1     
FLJ1730       TRAF2     
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DIPA       TRIM21     
FTH1       34 GENES TOTAL 5 0 
RAB 
INTERACTING  MECP2 + MECP2 -   
RAB 
INTERACTING  MECP2 + 
MECP2 
- 
              
RAB3A       RAB27A     
              
SYTL4       MLPH     
RABAC1       SYTL4     
CASK UP REG     SYTL5 ACTIVATED   
RAB31P       SYTL3     
RAB1F       SYTL1     
RAB3A UP REG     RPH3AL     
CHML       SYTL2   
DOWN 
REG 
RAB31L1       MYO5A     
SYTL5 ACTIVATED     STX1A ACTIVATED   
RABGGTB       COPS6     
CHML       DKFZP564O0523     
RPH3AL       RIF1   
DOWN 
REG 
RPH3A       C14 ORF1     
BSN       GDF9     
DMXL2       EEF1A1     
RIMS2       UNC13D     
RIMS1       GZMB     
17 GENES 
TOTAL 3 0   MTRIP     
      RPH3AL     
      ZBTB16 ACTIVATED   
RAB1A       20 GENES TOTAL 3 2 
              
RABAC1       RAB11B     
GOLGA2 ACTIVATED           
VDP       RAB43     
CHML       1 GENE TOTAL 0 0 
MICAL1           
GORASP2       RAB17     
GOLGA5 ACTIVATED           
TBC1D17       NUDT3 ACTIVATED   
CDKN1A       CHMP6     
RFK       RABAC1     
SLC16A8       3 GENES TOTAL 1 0 
RAB1F           
CAPNS1 ACTIVATED     RAB22A     
CREB1 ACTIVATED           
FCN1       RAB31     
HIVEP1   
DOWN 
REG   1 GENE TOTAL 0 0 
16 GENES 
TOTAL 4 1         
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RAB 
INTERACTING  MECP2 + MECP2 -   
RAB 
INTERACTING  MECP2 + 
MECP2 
- 
PAK1       WASF1     
              
NCK2       PFN1     
DLC1       CDC42 ACTIVATE   
ARHGEF7       PSTPLP1     
RAC1       SRGAP3     
CDC2L2       ARHGEF2     
LIMK1       DNMBP     
PAK1LP1       6 GENES TOTAL 1 0 
RHOJ             
ARHGEF2             
PLCG1       RAB33A     
ARPC1B             
BMX       RTN4     
RAF1       RTN3     
AKT1 UP REG     RABAC1     
PPM1F       RAB3A UP REG   
CSNK2A2       4 GENES TOTAL 1 0 
HGS             
CDC42 ACTIVATE           
NCK1 ACTIVATE           
ARHGEF6   
DOWN 
REG         
ERBB2             
MYLK             
CSNK2A1             
ABL1             
COL1A1             
PXN             
CDK5R1             
27 GENES 
TOTAL 3 1         
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